https://www.pharmadj.com/en-index Latest article updates from PharmaDJ (English) Thu, 03 Sep 2026 14:14:57 GMT en https://www.pharmadj.com/ssr/en/article/2090364151600840705 Experts Weigh In on Three Serious Adverse Events in Cell and Gene Therapy Trials Thu, 20 Aug 2026 09:03:45 GMT https://www.pharmadj.com/ssr/en/article/2090364151600840705 Donglei Feature https://www.pharmadj.com/ssr/en/article/2088158951792246786 Dr. Kerry Blanchard: A Life of Translation — From Bench to Bedside, from Academia to Industry, from Big Pharma to Biotech, from Indianapolis to Shanghai Fri, 14 Aug 2026 07:01:05 GMT https://www.pharmadj.com/ssr/en/article/2088158951792246786 Donglei Interview https://www.pharmadj.com/ssr/en/article/2086427928964431874 Thoughts and findings from two weeks in China—Growth and Instability in Biopharma's Second Superpower Sun, 09 Aug 2026 12:22:37 GMT https://www.pharmadj.com/ssr/en/article/2086427928964431874 PharmaDJ Interview https://www.pharmadj.com/ssr/en/article/2085561583519465474 Chinese biotech financing staged a strong rebound in July, with 25 private financings raising a combined $5.29 billion – a 56% jump from the $3.39 billion in June Fri, 07 Aug 2026 03:00:04 GMT https://www.pharmadj.com/ssr/en/article/2085561583519465474 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/2081618656925646850 Janet Woodcock: A True Visionary, Guardian of Public Health, and Pioneer of Regulatory Science Mon, 27 Jul 2026 05:52:17 GMT https://www.pharmadj.com/ssr/en/article/2081618656925646850 Donglei Interview https://www.pharmadj.com/ssr/en/article/2074438297616187394 In H1 2026, upfront payments and total deal value in China’s biotech sector climbed 87% and 66% year over year, respectively. In financing, Chinese biotechs raised more in the first half of 2026 than in all of 2025—a 269% surge from the year ago period. Tue, 07 Jul 2026 10:20:06 GMT https://www.pharmadj.com/ssr/en/article/2074438297616187394 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/2073966533622693889 Behind the $600 Million AI Drug Discovery Deal with a China-Based Biotech Mon, 06 Jul 2026 03:05:29 GMT https://www.pharmadj.com/ssr/en/article/2073966533622693889 Donglei Interview https://www.pharmadj.com/ssr/en/article/2062810498988048386 25 China drugmakers raised a combined $779 million in May – a month‑over‑month surge of 36% – fueled by a burst of investor enthusiasm for cell and gene therapies (CGT) and radiopharmaceuticals. Fri, 05 Jun 2026 08:15:23 GMT https://www.pharmadj.com/ssr/en/article/2062810498988048386 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/2051633176104730625 Chinese drugmakers closed 19 funding rounds totaling $574 million, compared with 30 rounds worth $1.59 billion recorded in March. Tue, 05 May 2026 12:00:41 GMT https://www.pharmadj.com/ssr/en/article/2051633176104730625 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/2049303163288223746 Witnessing Pharmaceutical Superintelligence: Interview with Alex Zhavoronkov, Founder and CEO of Insilico Medicine Wed, 29 Apr 2026 01:42:03 GMT https://www.pharmadj.com/ssr/en/article/2049303163288223746 Donglei Interview https://www.pharmadj.com/ssr/en/article/2044335106006515714 Pricing is a social science, not just math Wed, 15 Apr 2026 08:40:46 GMT https://www.pharmadj.com/ssr/en/article/2044335106006515714 Donglei Feature https://www.pharmadj.com/ssr/en/article/2041806663930937345 Chinese Drugmakers Raise $1.59B in March Financing, Topping Jan-Feb Total Wed, 08 Apr 2026 09:13:38 GMT https://www.pharmadj.com/ssr/en/article/2041806663930937345 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/2033336197381685249 Dorzagliatin's Breakthrough Approval Through Hong Kong's "1+" Regulatory Gateway Mon, 16 Mar 2026 00:15:02 GMT https://www.pharmadj.com/ssr/en/article/2033336197381685249 Donglei Interview https://www.pharmadj.com/ssr/en/article/2029025541551620097 A total of 42 financing deals were closed in January and February 2026, raising $1.36 billion — representing a 26% increase in deal count and a sharp 125% jump in financing volume compared with the same period last year. Wed, 04 Mar 2026 02:46:01 GMT https://www.pharmadj.com/ssr/en/article/2029025541551620097 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/2018969467037483010 In January 2026, 28 privately held Chinese drugmakers secured financing, with 22 disclosing total funding of $864 million. Wed, 04 Feb 2026 08:46:46 GMT https://www.pharmadj.com/ssr/en/article/2018969467037483010 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/2006353376196988929 In 2025, China’s biopharmaceutical industry witnessed a dual boom in both capital and transaction markets: total financing volume surged 39% year-on-year, upfront payments for deals jumped 82%, and Newco-model deals hit a historic high of 13. Wed, 31 Dec 2025 13:14:56 GMT https://www.pharmadj.com/ssr/en/article/2006353376196988929 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1998233818999328770 In November 2025, Chinese biotech companies recorded 22 financing deals in total. Among them, 17 firms that disclosed their funding amounts raised an aggregate of USD 367 million, marking a decrease from the USD 420 million raised in October. Tue, 09 Dec 2025 03:30:42 GMT https://www.pharmadj.com/ssr/en/article/1998233818999328770 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1991758089503731713 All slides are from Dr. Fujiwara's presentation at the 22nd DIA Japan Annual Meeting 2025, titled "Strong Ties of Japan with Asia and the World for Delivering 'Tomorrow's Normal' to Patients." Fri, 21 Nov 2025 06:38:28 GMT https://www.pharmadj.com/ssr/en/article/1991758089503731713 Donglei Interview https://www.pharmadj.com/ssr/en/article/1986687201913671681 China's biotechnology industry maintained robust momentum in October 2025, with 21 financing deals totaling $420 million. Fri, 07 Nov 2025 06:48:34 GMT https://www.pharmadj.com/ssr/en/article/1986687201913671681 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1985146072693018626 Leveraging Clinical Trials Data Extend Under ICH E17: China-Japan Collaboration Opportunities for Global Market——Insights from the 22nd DIA Japan Annual Meeting Mon, 03 Nov 2025 00:44:41 GMT https://www.pharmadj.com/ssr/en/article/1985146072693018626 Donglei Interview https://www.pharmadj.com/ssr/en/article/1980440319310786562 DIA Vice President Dr. Mitsuhiro Niimi: Insights into Global Healthcare, Pharmaceutical Innovation, and Collaborative Efforts Tue, 21 Oct 2025 01:05:42 GMT https://www.pharmadj.com/ssr/en/article/1980440319310786562 Donglei Interview https://www.pharmadj.com/ssr/en/article/1980099002068201474 At its core lies not just a commercial disagreement, but a fundamental clash over how to interpret and disclose clinical trial data. Mon, 20 Oct 2025 02:29:25 GMT https://www.pharmadj.com/ssr/en/article/1980099002068201474 PharmaDJ Feature https://www.pharmadj.com/ssr/en/article/1977994184507912194 Chinese biotechs raised more than $1.5 billion in Q3, already more than double the amount raised in Q2 2025. Tue, 14 Oct 2025 07:05:38 GMT https://www.pharmadj.com/ssr/en/article/1977994184507912194 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1972462673918554113 Transforming Healthcare: Yasuda Naoyuki and the PMDA’s Global Mission Mon, 29 Sep 2025 00:45:23 GMT https://www.pharmadj.com/ssr/en/article/1972462673918554113 Donglei Interview https://www.pharmadj.com/ssr/en/article/1968832427273089026 An Interview Marking the Second Anniversary of Kelun-Biotech’s Listing Fri, 19 Sep 2025 00:20:04 GMT https://www.pharmadj.com/ssr/en/article/1968832427273089026 Donglei Interview https://www.pharmadj.com/ssr/en/article/1962799299798536193 In August, China Biotech completed 26 fundraising rounds, raising a total of $420 million. Financing biotech companies are concentrated on RNA, TCE, in vivo gene editing and in vivo CAR-T. Tue, 02 Sep 2025 08:46:35 GMT https://www.pharmadj.com/ssr/en/article/1962799299798536193 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1954694768942436354 NRG-103 injection is a groundbreaking innovative therapy targeting glioblastoma developed by Neuregen based on its globally leading in situ trans-differentiation technology platform. Mon, 11 Aug 2025 00:02:04 GMT https://www.pharmadj.com/ssr/en/article/1954694768942436354 News https://www.pharmadj.com/ssr/en/article/1951220372839985153 In July, Chinese biotech companies have raised more capital compared to last month, with 29 funding rounds. Among these, 16 companies disclosed their financing amounts, totaling $420 million. Fri, 01 Aug 2025 09:56:03 GMT https://www.pharmadj.com/ssr/en/article/1951220372839985153 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1940318319716462593 In June, the number of China Biopharma financing rounds reached 16, an increase from 14 in the previous month. Wed, 02 Jul 2025 07:55:11 GMT https://www.pharmadj.com/ssr/en/article/1940318319716462593 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1932619382691852289 In May, China Biopharma completed 14 fundraising rounds, raising a total of $203.5 million. Wed, 11 Jun 2025 02:02:22 GMT https://www.pharmadj.com/ssr/en/article/1932619382691852289 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1930814327294652417 Mr.Shigeru Nakaji : My journey to China Fri, 06 Jun 2025 02:29:43 GMT https://www.pharmadj.com/ssr/en/article/1930814327294652417 Donglei Interview https://www.pharmadj.com/ssr/en/article/1920742002595475457 China Biopharma Tracker – April 2025 Fri, 09 May 2025 07:25:54 GMT https://www.pharmadj.com/ssr/en/article/1920742002595475457 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1913164277424906241 Dr. Mike Quigley of Sanofi: Building a Culture of Innovation That Celebrates Both Success and Failure Fri, 18 Apr 2025 09:34:43 GMT https://www.pharmadj.com/ssr/en/article/1913164277424906241 Donglei Interview https://www.pharmadj.com/ssr/en/article/1909156431167242241 March saw eight out-licensing deals in Chinese biopharma companies, with upfront payments of $735 million and a total value of 11.37 billion dollars. This marks an increase of 337% in total deal value and 332% in upfront payments compared with previous month. Mon, 07 Apr 2025 08:08:58 GMT https://www.pharmadj.com/ssr/en/article/1909156431167242241 Danni.Yin China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1899724709812043777 Dr. Kenichi Nakamura: An Innovator in Oncology at Japan’s National Cancer Center Wed, 12 Mar 2025 07:30:41 GMT https://www.pharmadj.com/ssr/en/article/1899724709812043777 Donglei Interview https://www.pharmadj.com/ssr/en/article/1898694566318505986 In a recent interview with PharmaDJ in Shanghai, Ramesh Durvasula, Lilly’s senior vice president at R&D IT, detailed the company’s AI strategies in R&D. Sun, 09 Mar 2025 11:17:15 GMT https://www.pharmadj.com/ssr/en/article/1898694566318505986 Frances Wang Interview https://www.pharmadj.com/ssr/en/article/1897456584861220866 After a strong start in January, fundraising for Chinese biopharmaceutical companies saw a significant decline in February. Only nine privately held Chinese drugmakers secured financing during the month. Thu, 06 Mar 2025 01:17:58 GMT https://www.pharmadj.com/ssr/en/article/1897456584861220866 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1894671112275558402 PharmaDJ sat down with Dr. Chris Arendt, Takeda's Chief Scientific Officer and Head of Research, to delve deeper into the company's approach to cultivating a diverse innovation ecosystem and its role in shaping the global pharmaceutical landscape. Mon, 03 Mar 2025 00:56:21 GMT https://www.pharmadj.com/ssr/en/article/1894671112275558402 Frances Wang Interview https://www.pharmadj.com/ssr/en/article/1895264199414710274 Nicolas Garnier, Servier Global Chief Patient Officer (CPO), sees his role as “conducting an orchestra,” ensuring global patient affairs teams and local patient engagement champions embedded across departments and countries together to augment clinical protocols with patient insights, educational resources, and care strategies. Mon, 03 Mar 2025 00:56:15 GMT https://www.pharmadj.com/ssr/en/article/1895264199414710274 Frances Wang Interview https://www.pharmadj.com/ssr/en/article/1894262090665885698 Dr. Yoshiaki Uyama: A Visionary Leader in Regulatory Science at Japan’s PMDA Mon, 03 Mar 2025 00:55:28 GMT https://www.pharmadj.com/ssr/en/article/1894262090665885698 Donglei Interview https://www.pharmadj.com/ssr/en/article/1889511417986424834 According to PharmaDJ data, 24 privately held Chinese drugmakers secured financing in January 2025. Wed, 12 Feb 2025 03:06:42 GMT https://www.pharmadj.com/ssr/en/article/1889511417986424834 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1878614257145294850 China Biopharma Tracker 2024 Mon, 13 Jan 2025 01:25:17 GMT https://www.pharmadj.com/ssr/en/article/1878614257145294850 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1864863303421964290 According to PharmaDJ data, 20 privately held Chinese drugmakers secured financing in November 2024. Of these, 18 disclosed funding amounts totaling $271 million. Compared to October, the number of deals increased by 25%, while the total funding raised surged by 36%. Fri, 06 Dec 2024 02:43:54 GMT https://www.pharmadj.com/ssr/en/article/1864863303421964290 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1860526922449063938 Now, the new therapy has also gained access to China's Hainan Boao Lecheng International Medical Tourism Pilot Zone (Lecheng), one step closer to being the first-in-class targeted therapy of dual inhibitor IDH to receive a New Drug Application (NDA) approval in China. Sun, 24 Nov 2024 03:32:40 GMT https://www.pharmadj.com/ssr/en/article/1860526922449063938 Frances Wang Feature https://www.pharmadj.com/ssr/en/article/1859116637003747330 The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preserving weight loss in Obesity Wed, 20 Nov 2024 06:08:42 GMT https://www.pharmadj.com/ssr/en/article/1859116637003747330 News https://www.pharmadj.com/ssr/en/article/1855775983527825409 AL01211 from AceLink Therapeutics has been granted the "Breakthrough Therapy Designation" by the CDE Mon, 11 Nov 2024 00:54:08 GMT https://www.pharmadj.com/ssr/en/article/1855775983527825409 News https://www.pharmadj.com/ssr/en/article/1854098337047834625 TenNor Therapeutics and LaNova Medicines emerged as the top recipients, each securing over $42 million. Wed, 06 Nov 2024 09:47:46 GMT https://www.pharmadj.com/ssr/en/article/1854098337047834625 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1850709720627683329 Dr. Kucherlapati talks about the many advancements being made in genome sequencing, the rise of precision medicine, and its transformative global impact. Mon, 28 Oct 2024 01:22:37 GMT https://www.pharmadj.com/ssr/en/article/1850709720627683329 Donglei Interview https://www.pharmadj.com/ssr/en/article/1845725644959342593 In Q3, 34 privately held Chinese drugmakers secured financing. Of those, 30 disclosed a total funding of $449 million—the lowest amount since 2021. Mon, 14 Oct 2024 07:17:40 GMT https://www.pharmadj.com/ssr/en/article/1845725644959342593 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1834426843460018177 “We are also actively talking to Chinese authorities in some specific areas to allow local Voranigo access before getting an official China NDA approval to meet some urgent demand,” said Servier China General Manager Manuel Ruiz at a recent media conference in Beijing. Fri, 13 Sep 2024 03:00:16 GMT https://www.pharmadj.com/ssr/en/article/1834426843460018177 Frances Wang Feature https://www.pharmadj.com/ssr/en/article/1833703658829664258 According to data from PharmaDJ, ten privately held Chinese drugmakers secured financing in August 2024. Nine of these disclosed funding, totaling $107 million. Compared to July, the number of deals and total funding raised decreased by 33% and 58%, respectively. Wed, 11 Sep 2024 03:06:35 GMT https://www.pharmadj.com/ssr/en/article/1833703658829664258 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1822856268975509505 Based on data gathered by PharmaDJ, 15 privately held Chinese drugmakers obtained financing in 2024. 12 disclosed funding worth a total of $257 million. Mon, 12 Aug 2024 04:42:56 GMT https://www.pharmadj.com/ssr/en/article/1822856268975509505 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1810201384144883714 China’s pharma financing slump continues, with 94 drugmakers raising only $1.978 billion in the first half year of 2024. Compared to the same period in 2023, total funding raised is down 31%. Mon, 08 Jul 2024 06:36:57 GMT https://www.pharmadj.com/ssr/en/article/1810201384144883714 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1801186518813925377 Based on data gathered by PharmaDJ, 13 privately held Chinese drugmakers obtained financing in May 2024. 11 disclosed funding worth a total of $107 million. Thu, 13 Jun 2024 09:35:05 GMT https://www.pharmadj.com/ssr/en/article/1801186518813925377 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1793810959146500098 Fan explains that Carvykti was developed based on Legend’s proprietary llama-derived nanobody platform, which allows the CAR-T cells to target multiple antigens simultaneously. This offers several advantages over traditional antibody-based approaches. Fri, 24 May 2024 01:07:15 GMT https://www.pharmadj.com/ssr/en/article/1793810959146500098 Minhua Chu Interview https://www.pharmadj.com/ssr/en/article/1789909672931704834 Based on data gathered by PharmaDJ, 20 privately held Chinese drugmakers obtained financing in 2024. The total value of the financings was $407 million. Mon, 13 May 2024 06:44:56 GMT https://www.pharmadj.com/ssr/en/article/1789909672931704834 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1778733809380913154 49 privately held Chinese drugmakers obtained financing in Q1. 45 disclosed funding worth a total of $1,294 million. That’s higher than Q3 and Q4 of 2023, which saw roughly lower number of deals. Fri, 12 Apr 2024 10:36:02 GMT https://www.pharmadj.com/ssr/en/article/1778733809380913154 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1765734967198949378 Based on data gathered by PharmaDJ, 14 privately held Chinese drugmakers obtained financing in 2024. 12 disclosed funding worth a total of $537 million. Thu, 07 Mar 2024 13:43:17 GMT https://www.pharmadj.com/ssr/en/article/1765734967198949378 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1760472846831767554 Based on data gathered by PharmaDJ, 22 privately held Chinese drugmakers obtained financing in January 2024. 21 disclosed funding worth a total of $519 million. Thu, 22 Feb 2024 01:13:29 GMT https://www.pharmadj.com/ssr/en/article/1760472846831767554 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1747105152426438657 China’s funding continues to peter out in 2023. Based on data gathered by PharmaDJ, Chinese biopharmaceutical companies raised a disclosed total of $4.8 billion from 203 deals, a 41% drop from $8.1 billion in 2022. 10m deals remained undisclosed. Tue, 16 Jan 2024 03:55:03 GMT https://www.pharmadj.com/ssr/en/article/1747105152426438657 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1734023980006846465 Based on data gathered by PharmaDJ, 19 privately held Chinese drugmakers obtained financing in November 2023. 15 disclosed funding worth a total of $349 million. Mon, 11 Dec 2023 01:35:08 GMT https://www.pharmadj.com/ssr/en/article/1734023980006846465 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1727559578080595970 Based on data gathered by PharmaDJ, 24 privately held Chinese drugmakers obtained financing in October 2023. 20 disclosed funding worth a total of $286 million. Thu, 23 Nov 2023 05:27:55 GMT https://www.pharmadj.com/ssr/en/article/1727559578080595970 Minhua Chu China Biopharma Tracker https://www.pharmadj.com/ssr/en/article/1721421105833525250 Last week, Hengrui Pharmaceuticals announced a licensing agreement with Merck KGaA for its next-generation potent and selective poly (ADP-ribose) polymerase 1 (PARP1) inhibitor, HRS-1167. RNAi drugmaker Argo Biopharma recently completed a Pre-A+ financing round worth $40.97 million. The key investors included China Investment, Huagai Capital, Yuanxihaihe Fund, and Trinity Fund, an existing shareholder. Mon, 06 Nov 2023 06:55:49 GMT https://www.pharmadj.com/ssr/en/article/1721421105833525250 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1720312716344770562 58 privately held Chinese drugmakers obtained financing in Q3. 48 disclosed funding worth a total of $883 million. Fri, 03 Nov 2023 05:31:28 GMT https://www.pharmadj.com/ssr/en/article/1720312716344770562 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1718956286857527298 This year’s ESMO conference saw 19 Chinese companies deliver 26 presentations reporting updated study results. Additionally, 36 Chinese drugmakers unveiled 75 posters.  Antibody-drug conjugates (ADCs) figured prominently at this year’s conference too, with Chinese researchers eight studies. Mon, 30 Oct 2023 11:41:30 GMT https://www.pharmadj.com/ssr/en/article/1718956286857527298 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1716356911450828801 Last week, Novo Nordisk agreed to buy ocedurenone from KBP Biosciences for up to $1.3 billion. The drug treats uncontrolled hypertension and has potential applications in cardiovascular and kidney disease. Sirius Therapeutics has bagged $60 million in a Series B funding round led by Hankang Capital. Delos Capital participated in the round. Mon, 23 Oct 2023 07:32:31 GMT https://www.pharmadj.com/ssr/en/article/1716356911450828801 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1713806235508162561 GSK and Zhifei Biological recently formed an exclusive partnership to jointly promote GSK's shingles vaccine, Shingrix, to healthcare professionals and vaccination centers. MediLink Therapeutics announced that it has entered into an agreement with BioNTech SE on the development of a next-generation antibody-drug conjugate candidate (ADC) against Human Epidermal Growth Factor Receptor 3 (HER3). Mon, 16 Oct 2023 06:37:02 GMT https://www.pharmadj.com/ssr/en/article/1713806235508162561 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1711347539331006466 Late last month, Adlai Nortye raised $57.5 million from its U.S. IPO on the Nasdaq and $40 million from a concurrent private placement, bringing in a total of $97.5 million. The FDA approved Tofidence (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing Actemra, on September 29. Mon, 09 Oct 2023 11:47:03 GMT https://www.pharmadj.com/ssr/en/article/1711347539331006466 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1706229987500224514 Novartis and BeiGene terminated their partnership over Tevimbra (tislelizumab) on September 19. Erenumab, a migraine drug co-developed by Amgen and Novartis, was approved in China last week. Mon, 25 Sep 2023 08:51:44 GMT https://www.pharmadj.com/ssr/en/article/1706229987500224514 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1704663494509588482 After a three-month rebound, Chinese drugmakers hit another fundraising slump last month. 16 startups raised a total of $258 million in venture capital. Amounts were not disclosed for three of these deals. This is a marked decline from 2022 figures. Last July, drugmakers raised a total of $443 million. Thu, 21 Sep 2023 01:07:03 GMT https://www.pharmadj.com/ssr/en/article/1704663494509588482 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1703669834900959234 Earlier this month, Grit Biotechnology announced that it completed a Series B financing round worth over $60. On September 12, Hasten Biopharma and LIB Therapeutics announced an agreement for LIB’s PCSK9 inhibitor lerodalcibep in Greater China. Mon, 18 Sep 2023 07:18:36 GMT https://www.pharmadj.com/ssr/en/article/1703669834900959234 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1701132107475185665 ImmuneOnco Biopharma has completed its global initial public offering and was listed on the Hong Kong Stock Exchange (HKEX) under stock code 1541 on September 5. Zenas BioPharma announced that it has entered into a license and collaboration agreement with Bristol Myers Squibb (BMS) to develop and commercialize obexelimab for autoimmune diseases. Mon, 11 Sep 2023 07:14:35 GMT https://www.pharmadj.com/ssr/en/article/1701132107475185665 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1698562266218110978 GenFleet Therapeutics a licensing deal with Verastem Oncology to cooperate on three oncology discovery programs targeting the RAS pathway.Hangzhou Zhongmei Huadong Pharmaceutical also announced last week that it would acquire exclusive licensing rights in Greater China for Wynzora cream, a topical treatment for plaque psoriasis developed by MC2 Therapeutics. Mon, 04 Sep 2023 05:02:57 GMT https://www.pharmadj.com/ssr/en/article/1698562266218110978 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1696375400270237697 Eli Lilly's dual GIP/GLP-1 receptor agonist (RA) Mounjaro is expected to be approved in China this year. Meanwhile, five Chinese-developed candidates with the same mechanism of action have already entered clinical development. Tue, 29 Aug 2023 04:13:07 GMT https://www.pharmadj.com/ssr/en/article/1696375400270237697 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1696039162480791554 Last week, China's CDE accepted Eli Lilly's supplementary marketing application for its dual GLP-1R/GIPR agonist tirzepatide for the treatment of obesity. HUTCHMED announced that the pivotal Phase 3 trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate and all secondary endpoints in adult patients with primary immune thrombocytopenia (ITP) in China. Mon, 28 Aug 2023 05:57:02 GMT https://www.pharmadj.com/ssr/en/article/1696039162480791554 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1693517027908620289 CirCode, a preclinical developer of circular RNA (cirRNA) therapies, announced it raised up to $20 million in Series A financing. Kelun-Biotech announced that its Trop2-targeted antibody-drug conjugate (ADC) candidate SKB-264, met the primary endpoint in a Phase 3 trial in patients with triple-negative breast cancer (TNBC) Mon, 21 Aug 2023 06:54:58 GMT https://www.pharmadj.com/ssr/en/article/1693517027908620289 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1692083135456579586 With the withdrawal of US dollars and the reduction of shareholdings by many listed companies, Chinese state-owned assets and Middle Eastern sovereign wealth funds are becoming increasingly important drivers in China's healthcare industry. Thu, 17 Aug 2023 07:57:12 GMT https://www.pharmadj.com/ssr/en/article/1692083135456579586 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1691362507661254657 Last month, two supplemental approvals of GLP-1 agonists, Benemae Pharmaceutical’s beinaglutide and Huadong Medicine’s liraglutide biosimilar, were separately approved to treat obesity. Tue, 15 Aug 2023 08:13:40 GMT https://www.pharmadj.com/ssr/en/article/1691362507661254657 Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1690954202308681729 Clinical-stage ion channel drug developer Leado Pharma announced last week that it raised $2.78 million in Series A financing. CanSino Biologics announced on August 7 that it signed a "contract development and manufacturing services" agreement with AstraZeneca last week. Mon, 14 Aug 2023 05:11:13 GMT https://www.pharmadj.com/ssr/en/article/1690954202308681729 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1689497495820836865 Competition in the field of antibody drug conjugates (ADCs) is heating up, with numerous new players entering the space. Lately, Duality Biologics is making a particularly impressive showing. The Shanghai-based biotech firm signed three deals with Adcendo, BioNTech and BeiGene to find partners to advance its ADCs development. Thu, 10 Aug 2023 04:42:47 GMT https://www.pharmadj.com/ssr/en/article/1689497495820836865 Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/1688831515604119553 Last month, Chinese drugmakers reported ten licensing deals, including seven out-licensing deals, one in-licensing deal and two deals between domestic companies. Tue, 08 Aug 2023 08:36:25 GMT https://www.pharmadj.com/ssr/en/article/1688831515604119553 Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/1688435154412990465 Hengrui Pharma announced that the FDA has accepted its biologics license application (BLA) for its PD-1 inhibitor camrelizumab in combination with oral VEGFR inhibitor rivoceranib. Hangzhou and New Jersey-based cancer biotechnology company Adlai Nortye filed with the U.S. Securities and Exchange Commission (SEC) to raise up to $115 million in an IPO. Mon, 07 Aug 2023 06:21:25 GMT https://www.pharmadj.com/ssr/en/article/1688435154412990465 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1686974693813350402 22 Chinese drugmakers raised a total of $443 million last month, a notable decline from June’s $539 million. Thu, 03 Aug 2023 05:38:04 GMT https://www.pharmadj.com/ssr/en/article/1686974693813350402 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1686223543375851521 Dr. Wang Zefeng, the scientific founder of CirCode Biomed, whose team was the first to demonstrate that circular RNAs (circRNAs) can be translated inside cells. Tue, 01 Aug 2023 03:53:16 GMT https://www.pharmadj.com/ssr/en/article/1686223543375851521 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1686033884465164290 Chinese drugmaker BeiGene announced that EMA's CHMP issued a positive opinion recommending approval of tislelizumab; NHSA released updated renewal rules for National Reimbursement Drug List (NRDL) drugs with market exclusivity. Mon, 31 Jul 2023 15:19:38 GMT https://www.pharmadj.com/ssr/en/article/1686033884465164290 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1684440571857448961 Earlier this month, nearly six months after filing its application, Kelun-Biotech was listed on the Hong Kong Stock Exchange (HKEX). Thu, 27 Jul 2023 05:48:22 GMT https://www.pharmadj.com/ssr/en/article/1684440571857448961 Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/1683684855068602369 China's licensing market continued to thrive in the first half of this year, with data highlighting steady growth and valuable partnerships. Tue, 25 Jul 2023 03:45:25 GMT https://www.pharmadj.com/ssr/en/article/1683684855068602369 China Deals Tracker https://www.pharmadj.com/ssr/en/article/1683368604052074497 AI-powered clinical-stage drug discovery company MindRank announced raised over $20 million to advance the company's proprietary innovative drug pipeline and to refine and commercialize its AI platform.Hengrui Pharmaceuticals published study results for SHR-1707, its anti-β-amyloid (Aβ) monoclonal antibody (mAb) at this year’s Alzheimer's Association International Conference (AAIC). Mon, 24 Jul 2023 06:48:45 GMT https://www.pharmadj.com/ssr/en/article/1683368604052074497 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1682219403188396033 In the first half of this year, the NMPA approved 39 new molecular entities (NMEs), a 39 percent increase from the same period last year. Fri, 21 Jul 2023 02:42:15 GMT https://www.pharmadj.com/ssr/en/article/1682219403188396033 Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1681502804382945282 Pyroptosis is a type of cell death that controls infections by stimulating strong immune responses. In the cutting-edge and unpopular field, Pyrotech Therapeutics hopes to discover and develop novel drugs against cancer and inflammatory diseases to address unmet clinical needs. Wed, 19 Jul 2023 03:14:44 GMT https://www.pharmadj.com/ssr/en/article/1681502804382945282 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1680029862545444866 Kelun Biotech IPOs at HK$6.06 billion; BeiGene and Novartis terminate their agreement on ociperlimab Sat, 15 Jul 2023 01:41:47 GMT https://www.pharmadj.com/ssr/en/article/1680029862545444866 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1679338077280129026 Funding continues to be comparatively lean as more investors are betting on drugmakers with products at the commercialization stage. Meanwhile, gene therapy companies are experiencing a surge. Thu, 13 Jul 2023 03:52:53 GMT https://www.pharmadj.com/ssr/en/article/1679338077280129026 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1678622874401837057 On May 31 of this year, RNA therapeutic start-up company SanegeneBio announced that its first siRNA drug, SGB-3403, targeting PCSK9, completed its first subject dosing in Australia, which means the company has entered into the clinical stage. We caught up with SanegeneBio's CEO to learn more. Tue, 11 Jul 2023 04:30:55 GMT https://www.pharmadj.com/ssr/en/article/1678622874401837057 Sarina Yang Interview https://www.pharmadj.com/ssr/en/article/1677153178334867457 Sinotau Pharmaceuticals announced that it raised RMB1.1 billion ,the largest sum raised by Chinese drugmaker this year. Mabwell Therapeutics announced that it has entered into a licensing agreement with Pakistan-based drugmaker Searle for its denosumab biosimilar. Fri, 07 Jul 2023 03:10:52 GMT https://www.pharmadj.com/ssr/en/article/1677153178334867457 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1676789967265804290 Oncologist and former FDA regulator Dr. Patricia Keegan brings her 30 years of expertise to Junshi Biosciences and its U.S.-based subsidiary TopAlliance, where she is developing processes and infrastructure systems. We caught up with Dr. Keegan to learn more about toripalimab, Junshi’s anti-PD-1 antibody which is currently undergoing approval in the U.S. Thu, 06 Jul 2023 03:07:36 GMT https://www.pharmadj.com/ssr/en/article/1676789967265804290 Minhua Chu Interview https://www.pharmadj.com/ssr/en/article/1675066662565527554 Genrix Biopharma went public with its IPO and was listed on Shanghai's STAR Market on June 20. Just nine days later, Laekna Therapeutics went public on the Hong Kong Stock Exchange (HKSE). Sat, 01 Jul 2023 08:59:48 GMT https://www.pharmadj.com/ssr/en/article/1675066662565527554 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1674269847679221761 In May, the number of venture financing deals in China's drugmakers grew from 12 to 22. Most deals, however, were relatively small, bringing the total amount of capital raised down from $489 million to $389 million. Thu, 29 Jun 2023 04:13:33 GMT https://www.pharmadj.com/ssr/en/article/1674269847679221761 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1673185468571795458 The Chinese pharma industry saw a surge in cross-border deals last month, with nine international deals and one domestic deal valued at a total of $4.7 billion, up 68% month on month. Mon, 26 Jun 2023 04:24:37 GMT https://www.pharmadj.com/ssr/en/article/1673185468571795458 PharmaDJ China Deals Tracker https://www.pharmadj.com/ssr/en/article/1671005490967076865 At this year’s annual meeting of the American Society of Clinical Oncology (ASCO), 19 China-based drugmakers gave presentations highlighting advancements in areas such as ADC, CAR-T, PD-1, and small molecule drugs. Tue, 20 Jun 2023 04:02:09 GMT https://www.pharmadj.com/ssr/en/article/1671005490967076865 Sarina Yang Feature https://www.pharmadj.com/ssr/en/article/1670777687382286338 Dermatology treatment specialist gets an IPO on the HSKSE Mon, 19 Jun 2023 12:56:57 GMT https://www.pharmadj.com/ssr/en/article/1670777687382286338 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1669553894672424961 Biokin Pharmaceutical is an example of how a generic drugmaker can successfully transition to an innovative biological drugmaker. Fri, 16 Jun 2023 03:54:02 GMT https://www.pharmadj.com/ssr/en/article/1669553894672424961 Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/1669149063923130369 Bliss Biopharmaceuticals signed a deal with Japanese drugmaker Eisai worth $2 billion in May, the month’s largest. With this partnership, the two companies plan to collaborate on the development of ADC treatments for a variety of cancers. Thu, 15 Jun 2023 01:05:23 GMT https://www.pharmadj.com/ssr/en/article/1669149063923130369 Sarina Yang Feature https://www.pharmadj.com/ssr/en/article/1668443002131996673 Last week, Eikon Therapeutics signed in-licensing deals with two Chinese drugmakers. Meanwhile, Betta Pharma is moving forward with two NMPA approvals. Tue, 13 Jun 2023 02:19:45 GMT https://www.pharmadj.com/ssr/en/article/1668443002131996673 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1667023184531054593 The NMPA approved nine new molecular entities (NMEs) last month. Five of them were developed by Chinese drugmakers. Fri, 09 Jun 2023 04:17:54 GMT https://www.pharmadj.com/ssr/en/article/1667023184531054593 Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1666304222495338498 Spurred by the meteoric sales of semaglutide injection (Wegovy), a growing number of domestic drugmakers are pursuing glucagon-like peptide-1 (GLP-1) with plans to market them as weight loss treatments in China. Wed, 07 Jun 2023 04:41:00 GMT https://www.pharmadj.com/ssr/en/article/1666304222495338498 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1665657756076568577 The month of June kicked off with several Chinese biotech companies making big strides in fundraising and clinical trials. Mon, 05 Jun 2023 09:52:10 GMT https://www.pharmadj.com/ssr/en/article/1665657756076568577 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1663105379876212738 China’s NMPA has just approved a marketing application for Aliqopa (copanlisib), Bayer’s PI3K inhibitor developed for treating refractory follicular lymphoma (FL) in adults. Mon, 29 May 2023 08:49:56 GMT https://www.pharmadj.com/ssr/en/article/1663105379876212738 PharmaDJ News https://www.pharmadj.com/ssr/en/article/1661925583154581505 Drugmakers sealed five overseas and three domestic deals in April. Once again, oncology drugs accounted for the overwhelming majority of transactions. Fri, 26 May 2023 02:41:51 GMT https://www.pharmadj.com/ssr/en/article/1661925583154581505 China Deals Tracker https://www.pharmadj.com/ssr/en/article/1660853070777651202 Radiopharmaceutical therapy (RPT) is proving to be a growth industry in China, but short shelf lives, low manufacturing capacity and a strict regulatory environment make the barrier to entry high. Tue, 23 May 2023 03:40:04 GMT https://www.pharmadj.com/ssr/en/article/1660853070777651202 Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/1660619284316000258 On May 12, LaNova Medicines announced an out-licensing agreement with AstraZeneca for its antibody-drug conjugate (ADC) LM-305. Mon, 22 May 2023 12:11:05 GMT https://www.pharmadj.com/ssr/en/article/1660619284316000258 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1659045517701775361 13 Chinese drugmakers announced raised a total of $864 million in April. Three raised more than $100 million each. Hasten Biopharma, a privately owned company that focuses on commercial promotion led the pack. Thu, 18 May 2023 03:59:57 GMT https://www.pharmadj.com/ssr/en/article/1659045517701775361 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1658345852022878210 After a thorough examination of annual reports and sample hospital sales figures from China's key drugmakers, we have ranked the country's top 10 homegrown novel drugs in 2022. Vaccines and cancer treatments dominate the list. Tue, 16 May 2023 05:40:57 GMT https://www.pharmadj.com/ssr/en/article/1658345852022878210 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1657970316297711617 Luzhu Biotech was listed on the Hong Kong Stock Exchange (HKSE) on May 8 with an initial offering price of HK$32.80, raising net proceeds of HK$242 million (US$30.85 million). Mon, 15 May 2023 04:45:57 GMT https://www.pharmadj.com/ssr/en/article/1657970316297711617 Sophia Shi News https://www.pharmadj.com/ssr/en/article/1656871820647804930 April saw two homegrown drugs gain new indications. They were cancer drugs from InnoCare Pharma and Hengrui Pharma. Fri, 12 May 2023 04:40:57 GMT https://www.pharmadj.com/ssr/en/article/1656871820647804930 Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1655798404880609282 PharmaDJ Report: China Biopharma Ventures, IPOs and Deals Q1 2023 Tue, 09 May 2023 04:54:57 GMT https://www.pharmadj.com/ssr/en/article/1655798404880609282 Minhua Chu Reports https://www.pharmadj.com/ssr/en/article/1655556012634099714 Cellular Biomedicine announced a global collaboration with Johnson & Johnson subsidiary Janssen Pharmaceuticals to develop and commercialize the next generation of novel CAR-T cell therapy products, C-CAR039 and C-CAR066, to non-Hodgkins lymphoma. Mon, 08 May 2023 12:51:57 GMT https://www.pharmadj.com/ssr/en/article/1655556012634099714 PharmaDJ News https://www.pharmadj.com/ssr/en/article/1653985142132183042 China-based Highlightll Pharmaceutical and U.S.-based Biohaven are taking a new dual TYK2/JAK1 inhibitor to global clinical trials with their recent out-licensing agreement. Thu, 04 May 2023 04:50:57 GMT https://www.pharmadj.com/ssr/en/article/1653985142132183042 Sarina Yang Interview https://www.pharmadj.com/ssr/en/article/1651783688449429505 Holiday Notice Fri, 28 Apr 2023 03:40:57 GMT https://www.pharmadj.com/ssr/en/article/1651783688449429505 PharmaDJ News https://www.pharmadj.com/ssr/en/article/1651499625406795778 Chinese drugmakers Junshi Biosciences and Akeso have entered partnerships that will bring their homegrown anti-PD-1 monoclonal antibodies to Southeast Asia. The region is fast becoming an important market for Chinese biopharmaceutical products. Thu, 27 Apr 2023 08:12:57 GMT https://www.pharmadj.com/ssr/en/article/1651499625406795778 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1650696840281153537 Drug asset deals slowed down significantly in March, with only nine deals amounting to $1.3 billion. Tue, 25 Apr 2023 03:40:57 GMT https://www.pharmadj.com/ssr/en/article/1650696840281153537 PharmaDJ China Deals Tracker https://www.pharmadj.com/ssr/en/article/1650329856439857153 At the 2023 AACR Annual Meeting, unofficial statistics revealed that over 98 Chinese pharmaceutical companies, such as BeiGene, InnoCare, and Innovent Biologics, showcased more than 119 new drug clinical and preclinical studies. Mon, 24 Apr 2023 02:50:57 GMT https://www.pharmadj.com/ssr/en/article/1650329856439857153 PharmaDJ News https://www.pharmadj.com/ssr/en/article/1648885368261554177 In March, Hengrui Pharma’s anti-PD-L1 antibody adebrelimab got the green light from the NMPA as a first-line treatment for extensive stage small cell lung cancer (ES-SCLC). Thu, 20 Apr 2023 03:40:57 GMT https://www.pharmadj.com/ssr/en/article/1648885368261554177 Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1648227708151361538 February 23, 2023, KYM Biosciences agreed to out-license its claudin 18.2 antibody drug conjugate (project code: CMG901) with AstraZeneca, the biggest deal of the month. Tue, 18 Apr 2023 07:40:57 GMT https://www.pharmadj.com/ssr/en/article/1648227708151361538 Sarina Yang Interview https://www.pharmadj.com/ssr/en/article/1647804277178052609 CTTQ-Akeso have signed a cooperation and licensing agreement to grant Specialised Therapeutics exclusive sales rights to penpulimab in 11 countries. Mon, 17 Apr 2023 03:28:57 GMT https://www.pharmadj.com/ssr/en/article/1647804277178052609 PharmaDJ News https://www.pharmadj.com/ssr/en/article/1646353290752008194 19 companies reported funds raised to the tune of only $489 million, a month-on-month decrease of more than 50%. Thu, 13 Apr 2023 03:23:57 GMT https://www.pharmadj.com/ssr/en/article/1646353290752008194 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1645639809916575746 China-based drugmaker CANbridge Pharmaceuticals just reported long-term follow-up data from its Phase I/II study of CAN008 plus temozolomide/radiotherapy (TMZ/RT) in newly diagnosed glioblastoma multiform (GBM) showing a five-year survival rate of 67% compared to 8.2% in the institutional database. Tue, 11 Apr 2023 04:08:00 GMT https://www.pharmadj.com/ssr/en/article/1645639809916575746 Minhua Chu Interview https://www.pharmadj.com/ssr/en/article/1645300046709653505 Chinese clinical-stage drugmaker Duality Biologics (DualityBio) and BioNTech announced an exclusive worldwide (excluding Greater China) licensing agreement for antibody-drug conjugates (ADCs) DB-1303 and DB-1311. Mon, 10 Apr 2023 05:41:26 GMT https://www.pharmadj.com/ssr/en/article/1645300046709653505 Minhua Chu News https://www.pharmadj.com/ssr/en/article/1643885713782034433 On February 21, Biosenic announced that it will regain worldwide rights to its allogeneic, off-the-shelf bone cell therapy platform ALLOB after receiving a unilateral termination notice from its Chinese partner Shenzhen Pregene Biopharma. Thu, 06 Apr 2023 07:57:51 GMT https://www.pharmadj.com/ssr/en/article/1643885713782034433 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1643125038654799874 February saw 12 innovative drug asset deals in China. Out-licensing agreements were the most lucrative, with six deals totaling $3.2 billion. Tue, 04 Apr 2023 05:35:12 GMT https://www.pharmadj.com/ssr/en/article/1643125038654799874 Sarina Yang China Deals Tracker https://www.pharmadj.com/ssr/en/article/1642748683014488065 The bidding results of the eighth batch of China's national centralized drug procurement were announced. 252 products from 174 companies won the tender, roughly 70%. Mon, 03 Apr 2023 04:39:41 GMT https://www.pharmadj.com/ssr/en/article/1642748683014488065 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1641282918033735682 Co-founders Liu Yang and Zheng Pan have big ambitions for their company OncoC4. It’s even in the name. "Onco", they explain, is the abbreviation for "tumor", while "C4" signifies the company’s two targets, CTLA-4 and CD24. But C4 is also the name of a highly explosive material. This should tell you all you need to know about what they have in store for tumors. Thu, 30 Mar 2023 03:35:16 GMT https://www.pharmadj.com/ssr/en/article/1641282918033735682 Minhua Chu Interview https://www.pharmadj.com/ssr/en/article/1640578379374751746 In February, the most talked-about drug was, by far, AstraZeneca and Daiichi Sankyo’s HER2 antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan). Tue, 28 Mar 2023 04:55:41 GMT https://www.pharmadj.com/ssr/en/article/1640578379374751746 Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1640196958432882690 Chinese biotech companies announced three out-licensing deals in one week Mon, 27 Mar 2023 03:49:51 GMT https://www.pharmadj.com/ssr/en/article/1640196958432882690 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1638775391370964994 On March 13, the expansion of eligible stocks under the Hong Kong Stock Exchange (HKSE) Stock Connect program officially took effect. Thu, 23 Mar 2023 05:31:15 GMT https://www.pharmadj.com/ssr/en/article/1638775391370964994 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1638019988232196097 Even in an unfavorable environment, in 2022 Chinese biotech companies closed 20 out-licensing deals worth $21.5 billion, thus doubling the value of 2021 deals. Tue, 21 Mar 2023 03:29:33 GMT https://www.pharmadj.com/ssr/en/article/1638019988232196097 PharmaDJ China Deals Tracker https://www.pharmadj.com/ssr/en/article/1637764797264154625 Akeso Bio’s 2022 numbers are in, and the drugmaker reports RMB1,104.4 million ($160.2 million) in sales, a year-on-year increase of 422%. Mon, 20 Mar 2023 10:35:31 GMT https://www.pharmadj.com/ssr/en/article/1637764797264154625 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1636235256469196801 China drugmakers completed 31 fundraising deals in February, 28 of which were disclosed at a total value of $1.05 billion. This is a dramatic increase from January. Thu, 16 Mar 2023 05:17:40 GMT https://www.pharmadj.com/ssr/en/article/1636235256469196801 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1635502314881101825 With its patented base editor ceBE and prime editor ePE, Base Therapeutics’ co-founder Xu Tianhong believes that its Super-NK cell products offer greater safety and more efficiency in treating cancer. Tue, 14 Mar 2023 04:45:13 GMT https://www.pharmadj.com/ssr/en/article/1635502314881101825 Minhua Chu Interview https://www.pharmadj.com/ssr/en/article/1635225159332823041 invoX Pharma, a U.K.-based wholly owned subsidiary of Sino Biopharmaceutical, announced that it has acquired F-star Therapeutics for an aggregate cash consideration of approximately $161 million (or $7.12 per share). Mon, 13 Mar 2023 10:23:54 GMT https://www.pharmadj.com/ssr/en/article/1635225159332823041 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1633672203005362177 Last month, HUTCHMED agreed to out-license its core product fruquitinib with Japanese drugmaker Takeda. Will this move help accelerate the Chinese drugmaker to profitability? Thu, 09 Mar 2023 03:33:00 GMT https://www.pharmadj.com/ssr/en/article/1633672203005362177 Minhua Chu Interview https://www.pharmadj.com/ssr/en/article/1632631066614386689 Oricell Therapeutics announced that it has closed a $45 million Series B1 investment round. This follows a $125M Series B round from July 2022. Mon, 06 Mar 2023 06:35:54 GMT https://www.pharmadj.com/ssr/en/article/1632631066614386689 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1631173868566695938 China's annual National Reimbursement Drugs List (NRDL) 2023 entry negotiations were completed in January of this year. The National Healthcare Security Administration (NHSA) successfully negotiated 121 out of 147 products to be on the list. That’s a success rate of 82.3%, the second highest since negotiations started in 2017. Thu, 02 Mar 2023 06:05:31 GMT https://www.pharmadj.com/ssr/en/article/1631173868566695938 Sarina Yang Feature https://www.pharmadj.com/ssr/en/article/1630061922303946753 Kelun has more than 10 projects in the clinical research stage. Key among them is KL-A167, an anti-PD-L1 mab that has a pending NDA application. Tue, 28 Feb 2023 03:00:25 GMT https://www.pharmadj.com/ssr/en/article/1630061922303946753 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1630401660428849153 With its new CD3 and WuXiBody® platforms, WuXi Biologics can now collaborate with world-class companies to develop potential best-in-class bispecific antibodies. Tue, 28 Feb 2023 02:57:02 GMT https://www.pharmadj.com/ssr/en/article/1630401660428849153 Danni.Yin Interview https://www.pharmadj.com/ssr/en/article/1628582181663272961 2023 kicked off with 11 licensing deals for innovative drugs. Out-licensing agreements generated the most cash, with six deals totaling an astounding $3.9 billion. January also saw three in-licensing and two domestic deals. Thu, 23 Feb 2023 02:27:04 GMT https://www.pharmadj.com/ssr/en/article/1628582181663272961 Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/1627872866547535874 In January, the NMPA granted its first marketing approvals for seven new molecular entities (NMEs) and gave the green light for two homegrown oral COVID-19 drugs, Simcere’s Xiannuoxin (simnotrelvir/ritonavir) and Junshi Biosciences’s VV116 (deuremidevir hydrobromide). Tue, 21 Feb 2023 03:28:30 GMT https://www.pharmadj.com/ssr/en/article/1627872866547535874 Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1627674323585146881 Biogen announced in its Q4 financial report that it has terminated its agreement with InnoCare Pharma regarding BTK inhibitor Orelabrutinib. Mon, 20 Feb 2023 14:19:34 GMT https://www.pharmadj.com/ssr/en/article/1627674323585146881 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1626137647670894593 Investor Insights: How Chinese drugmakers are surviving the market downturn Thu, 16 Feb 2023 08:33:22 GMT https://www.pharmadj.com/ssr/en/article/1626137647670894593 PharmaDJ Feature https://www.pharmadj.com/ssr/en/article/1625382667162873857 Following a slump that bottomed out last October, Chinese drugmakers are seeing a growing influx of investment with the new year. In January 2023 alone, companies disclosed $805 million in funds raised, a month-on-month increase of roughly 32% and almost $100 million shy of January 2022’s figures. Tue, 14 Feb 2023 06:33:21 GMT https://www.pharmadj.com/ssr/en/article/1625382667162873857 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1625007376401780737 Former Legend Biotech co-founder and CSO Fan Xiaohu has founded a new venture called Wondercel Therapeutics. Tue, 14 Feb 2023 05:55:44 GMT https://www.pharmadj.com/ssr/en/article/1625007376401780737 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1623524012784164865 PharmaDJ, L.E.K. Consulting and CHINATRIALS jointly released a report titled “Pivoting to a High-Quality Growth of Clinical Trials in China” during 2022 CHINATRIALS14 in Shanghai on November 9-11. It surveys China’s clinical development space, identifying challenges and summarizing strategic trends. Thu, 09 Feb 2023 03:27:43 GMT https://www.pharmadj.com/ssr/en/article/1623524012784164865 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1622793006573703169 Jintrolong (PEGylated hGH) by GeneScience Pharmaceuticals is the first and currently only long-acting growth hormone (LAGH) therapy in China to get market approval. Tue, 07 Feb 2023 03:02:57 GMT https://www.pharmadj.com/ssr/en/article/1622793006573703169 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1622536774889869313 Feburary began with an out-licensing deal between GSK and Zhimeng Biopharma. The two drugmakers entered an exclusive global exclusive for the TLR8 agonist CB06. Mon, 06 Feb 2023 10:04:47 GMT https://www.pharmadj.com/ssr/en/article/1622536774889869313 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1621381145517199361 In 2022, Chinese regulators approved 42 new molecular entities (NMEs, including small molecules and biological drugs), a significant slowdown from 64 in 2021. Oncology continues to be the most important therapeutic field with 23 approved innovative drugs (55% of the total), followed by rheumatology and drugs for infectious diseases. Fri, 03 Feb 2023 05:32:44 GMT https://www.pharmadj.com/ssr/en/article/1621381145517199361 Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1620626213772050433 One of the most significant changes in China's biopharmaceutical licensing space in 2022 was a sharp decline in enthusiasm for introducing new products from overseas. Meanwhile, the number of out-licensing deals, especially with US drugmakers, skyrocketed. Wed, 01 Feb 2023 03:32:54 GMT https://www.pharmadj.com/ssr/en/article/1620626213772050433 Danni.Yin China Deals Tracker https://www.pharmadj.com/ssr/en/article/1619963029721530370 Henlius Biotech's serplulimab was approved for a new indication in China as the first-line therapy for ES-SCLC. Tocilizumab is now included in China's "Treatment Protocol for Severe Cases of COVID-19 Infection". Mon, 30 Jan 2023 07:37:38 GMT https://www.pharmadj.com/ssr/en/article/1619963029721530370 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1616271404025544706 Financing for Chinese biopharmaceutical companies dropped by a staggering 44% in 2022 as next-generation treatments like cell and gene therapy (CGT) attracted more investor attention with a total 88 of deals, 30 more than in 2021. Additionally, 12 iPSC companies received funding, doubling 2021’s numbers. Fri, 20 Jan 2023 03:08:26 GMT https://www.pharmadj.com/ssr/en/article/1616271404025544706 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1615589570568552449 On Jan 10, 2023, Insilico Medicine announced positive Phase I data for its idiopathic pumonary fibrosis (IPF) candidate INS018_055. The company discover and develop a novel target for IPF by leveraging its AI powered drug development platforms. Wed, 18 Jan 2023 05:59:04 GMT https://www.pharmadj.com/ssr/en/article/1615589570568552449 Catherine Wang Interview https://www.pharmadj.com/ssr/en/article/1614877037591265282 Sinovent Pharmaceuticals entered two out-licensing transactions in January 2023. Paxlovid failed to make it onto the NRDL due to the high price offered by Pfizer. Wed, 18 Jan 2023 04:42:14 GMT https://www.pharmadj.com/ssr/en/article/1614877037591265282 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1613365177062793217 In recent years, several multinational corporations (MNCs) have established incubation hubs to incubate startups in China. These hubs offer seed funding, scientific coaching, operational support as well as office and laboratory spaces for early-stage companies. Thu, 12 Jan 2023 02:40:08 GMT https://www.pharmadj.com/ssr/en/article/1613365177062793217 Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/1612275631705300993 On December 27, 2022, Shanghai Henlius Biotech announced an exclusive licensing agreement with its holding parent company, Fosun Pharma, for the commercialization of Henlius’ anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab) in the US. Mon, 09 Jan 2023 02:30:40 GMT https://www.pharmadj.com/ssr/en/article/1612275631705300993 Sarina Yang Feature https://www.pharmadj.com/ssr/en/article/1611364372151541762 Immune-Onc Therapeutics announced the close of an extended Series B round of financing with an additional $25 million, bringing the total Series B financing to $131 million. More news from Rhegen Bio, Simnova, Orna Therapeutics. Fri, 06 Jan 2023 14:09:39 GMT https://www.pharmadj.com/ssr/en/article/1611364372151541762 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1610932003439484930 HighTide Therapeutics announced the completion of Series C/C+ financing worth $107 million. Thu, 05 Jan 2023 09:31:34 GMT https://www.pharmadj.com/ssr/en/article/1610932003439484930 Danni.Yin News https://www.pharmadj.com/ssr/en/article/1610827896607318017 The recently released phase III clinical trial results for the amyloid beta (Aβ) protein-targeting Alzheimer’s disease (AD) drugs lecanemab and donanemab may relieve the fierce debate caused by the FDA's approval of aducanumab in 2021. During the 2022 CHINATRIALS14 held by PharmaDJ in Shanghai, former FDA official Dr. Wang Yaning noted that last year’s FDA's decision was correct, and this has been further confirmed by the phase III clinical trial results of several AD products this year. Thu, 05 Jan 2023 02:37:53 GMT https://www.pharmadj.com/ssr/en/article/1610827896607318017 Yingzi.Shi Feature https://www.pharmadj.com/ssr/en/article/1610617025503240193 JGene Biotechnology has completed a round of angel funding worth tens of millions of RMB, led by EFung Capital. More news from Hengrui Pharma, Zai Lab, Leto Laboratories, Reju Therapeutics. Wed, 04 Jan 2023 12:39:57 GMT https://www.pharmadj.com/ssr/en/article/1610617025503240193 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1610245726553579521 Carrier BioMed, a specialist in exosome technology, announced that it has completed a Series A+ round of funding worth tens of millions of RMB, with investments from Heng Yuan Capital and Tsintel Technology. More news from Merck, Immunofoco, Kelun Biotech, Henlius, Sungening, MagicRNA. Tue, 03 Jan 2023 12:04:33 GMT https://www.pharmadj.com/ssr/en/article/1610245726553579521 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1606225435678568450 Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, has licensed out seven investigational preclinical antibody drug conjugates (ADC) to Merck(known as MSD) outside of the United States and Canada) for exclusive global rights. Fri, 23 Dec 2022 09:49:21 GMT https://www.pharmadj.com/ssr/en/article/1606225435678568450 Danni.Yin News https://www.pharmadj.com/ssr/en/article/1606112585089904641 Wishing you happy and healthy holidays! Fri, 23 Dec 2022 02:20:55 GMT https://www.pharmadj.com/ssr/en/article/1606112585089904641 PharmaDJ News https://www.pharmadj.com/ssr/en/article/1605865134697312257 The financing amounted to approximately RMB70 million ($10.03 million) and will be used to advance late-stage clinical development of key products. More news from BHGB, Fosun Pharma, Eisai. Thu, 22 Dec 2022 09:57:38 GMT https://www.pharmadj.com/ssr/en/article/1605865134697312257 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1605758443930533889 In November, 14 licensing deals were announced among drugmakers in China, a number that is only second to January’s 16 deals. That may be an indication of revived enthusiasm in the market. Thu, 22 Dec 2022 02:53:41 GMT https://www.pharmadj.com/ssr/en/article/1605758443930533889 Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/1605490737171939329 Salubris announced that its IND application for SAL0133 tablets, an oral 3CL protease inhibitor, has been accepted by the CDE for the treatment of adults with mild/generic COVID-19 infection. More news from RemeGen, Takeda. Wed, 21 Dec 2022 09:09:55 GMT https://www.pharmadj.com/ssr/en/article/1605490737171939329 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1605134295747371009 LianBio will receive an upfront payment totaling $20 million and will be eligible to receive potential development and commercial milestone payments of up to $135 million, more news from Biocytogen, Simcere, CStone, HUTCHMED. Tue, 20 Dec 2022 09:33:33 GMT https://www.pharmadj.com/ssr/en/article/1605134295747371009 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1605056639500656642 The positive results of ReCOV in the head-to-head study proves that the synergy of our three technology platforms - novel adjuvant, protein engineering and immune evaluation Tue, 20 Dec 2022 04:24:58 GMT https://www.pharmadj.com/ssr/en/article/1605056639500656642 Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1604811539524714497 Roche will sponsor and conduct a phase Ib/II multinational trial to evaluate ADG126 in combination with bevacizumab and atezolizumab, versus atezolizumab and bevacizumab alone, in 60 patients initially. More news from Neurophth, GenFleet, PersonGen and Merck KGaA. Mon, 19 Dec 2022 12:13:49 GMT https://www.pharmadj.com/ssr/en/article/1604811539524714497 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1603692429143269377 Ascentage Pharma presented positive results from its global phase II study of lisaftoclax (APG-2575) as a monotherapy or in combination with acalabrutinib or rituximab in patients with primary, relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL). Fri, 16 Dec 2022 10:04:05 GMT https://www.pharmadj.com/ssr/en/article/1603692429143269377 Danni.Yin News https://www.pharmadj.com/ssr/en/article/1603335831455621122 Alternative Bio (ABio) announced the completion of a seed-financing round worth $15 million co-led by Eight Roads Ventures, F-Prime Capital and Sequoia China Seed Fund. Thu, 15 Dec 2022 10:27:05 GMT https://www.pharmadj.com/ssr/en/article/1603335831455621122 Danni.Yin News https://www.pharmadj.com/ssr/en/article/1603264835860127746 Several Chinese companies are currently conducting clinical trials of AKT inhibitors in multiple solid tumors including ovarian, prostate, breast and renal cell cancers and hepatocellular carcinoma. Thu, 15 Dec 2022 05:44:59 GMT https://www.pharmadj.com/ssr/en/article/1603264835860127746 Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/1602966913457184769 Juventas Cell Therapy announced that its NDA application for CD19 CAR-T therapy CNCT19 (inaticabtagene autoleucel) has been accepted by the NMPA for the treatment of adult relapsed and refractory acute lymphoblastic lymphoma (r/r B-ALL). Wed, 14 Dec 2022 10:01:09 GMT https://www.pharmadj.com/ssr/en/article/1602966913457184769 Danni.Yin News https://www.pharmadj.com/ssr/en/article/1602591746105098241 4B Technologies has completed a round Series Pre-B financing led by Fortune Capital, raising over RMB100 million ($14.3 million). The funding will be used for the promotion of clinical programs and its R&D pipeline. Tue, 13 Dec 2022 09:10:22 GMT https://www.pharmadj.com/ssr/en/article/1602591746105098241 Danni.Yin News https://www.pharmadj.com/ssr/en/article/1602521462698237954 After a two-month slump, China's biopharmaceutical financing rebounded in November. 19 fundraising deals were announced with 17 disclosed values totalling $466 million. Tue, 13 Dec 2022 04:31:05 GMT https://www.pharmadj.com/ssr/en/article/1602521462698237954 Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/1602210926064312322 Bio-Thera Solutions and Biogen Biologics jointly announced the abbreviated biologics license application (aBLA) for their tocilizumab biosimilar BAT1806/BIIB800. In September, the companies submitted the drug’s marketing authorization application (MAA) to the European Medicines Agency (EMA) as well. Mon, 12 Dec 2022 07:57:07 GMT https://www.pharmadj.com/ssr/en/article/1602210926064312322 Danni.Yin News https://www.pharmadj.com/ssr/en/article/1601162602620182529 YZY Biopharma and Cutia Therapeutics recently submitted their listing applications to the Hong Kong Stock Exchange’s main board. Sat, 10 Dec 2022 02:52:45 GMT https://www.pharmadj.com/ssr/en/article/1601162602620182529 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1600843818519949314 GenAssist was founded in July 2020 and develops gene-editing drugs for a variety of genetic diseases. More news from ExoNeuglia, WestGene, Macera Therapeutics. Thu, 08 Dec 2022 13:24:43 GMT https://www.pharmadj.com/ssr/en/article/1600843818519949314 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1600752687211802625 November saw several NMPA approvals for several drugs developed by Chinese companies. Thu, 08 Dec 2022 07:22:36 GMT https://www.pharmadj.com/ssr/en/article/1600752687211802625 Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1600446870633746433 Oralead Pharma, a specialty pharmaceutical company dedicated to oral delivery technology of biological drugs, has completed a round of angel financing worth RMB 10 million ($1.43 million). Wed, 07 Dec 2022 11:07:23 GMT https://www.pharmadj.com/ssr/en/article/1600446870633746433 Sarina Yang News https://www.pharmadj.com/ssr/en/article/1600318780389625858 The NMPA’s Center of Drug Evaluation (CDE) has published a paper explaining condtional approvals in China, and comparing it with similar pathways in the US and Europe. Wed, 07 Dec 2022 01:25:54 GMT https://www.pharmadj.com/ssr/en/article/1600318780389625858 Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/1600057292865290242 Several Chinese companies announced that their COVID-19 vaccines received emergency use approval, including Clover Biopharmaceuticals, SinoCellTech, Wantai Biological and Westvac Biopharma. Tue, 06 Dec 2022 14:16:26 GMT https://www.pharmadj.com/ssr/en/article/1600057292865290242 Danni.Yin News https://www.pharmadj.com/ssr/en/article/7475edcc748211edaf35fa163e42049a Hansoh Pharma announced that its partner, EQRx, has submitted a marketing application in the European Union for Ameile (aumolertinib). More news from Qilu Pharma, Everlife Biomed, SinoCellTech, Clover Biopharmaceuticals, Eli Lilly, Incyte, CMS Aesthetics. Mon, 05 Dec 2022 09:52:41 GMT https://www.pharmadj.com/ssr/en/article/7475edcc748211edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/0974efb9723c11edaf35fa163e42049a Kintor Pharma announced the results of a phase II clinical trial of pyrilutamide (KX-826) for treating adult female androgenetic alopecia (AGA). More news from Innovent Biologics, InnoBM Pharmaceuticals. Fri, 02 Dec 2022 12:23:15 GMT https://www.pharmadj.com/ssr/en/article/0974efb9723c11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/baf98295715a11edaf35fa163e42049a The Hong Kong Stock Exchange (HKEX) announced that it has accepted an IPO application from Boan Biotech. Thu, 01 Dec 2022 09:30:26 GMT https://www.pharmadj.com/ssr/en/article/baf98295715a11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/f99fec5f711c11edaf35fa163e42049a Currently, 30 potential NASH drugs are in clinical studies in China, another eight candidates have submitted IND applications while six have already been greenlighted. Thu, 01 Dec 2022 02:08:23 GMT https://www.pharmadj.com/ssr/en/article/f99fec5f711c11edaf35fa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/7aa40ccf708811edaf35fa163e42049a Fosun Pharma announced yesterday that its subsidiary Gland Pharma intend to acquire Cenexi Group, a European CDMO company, for a consideration not exceeding EUR 210 million. Wed, 30 Nov 2022 08:25:24 GMT https://www.pharmadj.com/ssr/en/article/7aa40ccf708811edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/d6886f996fc011edaf35fa163e42049a Full-Life Technologies announced that it has signed an agreement to acquire Focus-X Therapeutics to expand its radiopharmaceuticals pipeline. Tue, 29 Nov 2022 08:39:00 GMT https://www.pharmadj.com/ssr/en/article/d6886f996fc011edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/012929dc6ef011edaf35fa163e42049a Sirona Biochem announced that it has signed an expanded international agreement with Wanbang Biopharmaceuticals to collaborate on licensing TFC-039, Sirona’s SGLT2 inhibitor, for treating both animals and humans. More news from Fosun Kite. Mon, 28 Nov 2022 07:41:26 GMT https://www.pharmadj.com/ssr/en/article/012929dc6ef011edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/c0d2c4896ec711edaf35fa163e42049a ​October was another slow month for licensing deals in China, with a total, once again, of only seven. Three of them were in-licensing deals with overseas companies. Mon, 28 Nov 2022 02:53:16 GMT https://www.pharmadj.com/ssr/en/article/c0d2c4896ec711edaf35fa163e42049a Yingzi.Shi China Deals Tracker https://www.pharmadj.com/ssr/en/article/cd0a09456ca311edaf35fa163e42049a PrimeLink and Xiling Lab, two ADC drug discovery companies, have just closed financing rounds. More news from Hengrui Pharma, Blueprint Medicines, CStone. Fri, 25 Nov 2022 09:30:34 GMT https://www.pharmadj.com/ssr/en/article/cd0a09456ca311edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/aa69ef1e6c7111edaf35fa163e42049a On November 14, FibroGen filed a federal lawsuit in California alleging that two of its former employees stole its anemia treatment work and established company in China to develop me-too drugs and apply for patents. Fri, 25 Nov 2022 03:31:41 GMT https://www.pharmadj.com/ssr/en/article/aa69ef1e6c7111edaf35fa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/d57716666bce11edaf35fa163e42049a ViroTech Pharmaceutical has received a strategic investment of RMB 100 million from NKY Medical. NKY will hold 10.42% of ViroTech’s shares after the investment is completed. Thu, 24 Nov 2022 08:06:06 GMT https://www.pharmadj.com/ssr/en/article/d57716666bce11edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/58eff2fb6b2211edaf35fa163e42049a JS InnoPharm announced today that it inked an agreement with Strategia Holdings to found JSI Ventures (JSV), a Boston-based company that will integrate the companies’ R&D efforts. More news from NOVAST Laboratories. Wed, 23 Nov 2022 11:31:23 GMT https://www.pharmadj.com/ssr/en/article/58eff2fb6b2211edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/beaa75f26a4511edaf35fa163e42049a Umoja Biopharma and IASO Biotherapeutics announced that they have entered a research agreement to evaluate Umoja’s iCIL platform with IASO’s chimeric antigen receptors (CARs). More news from Harbour BioMed, Dragonfly Therapeutics. Tue, 22 Nov 2022 09:12:15 GMT https://www.pharmadj.com/ssr/en/article/beaa75f26a4511edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/f2ef5e80697911edaf35fa163e42049a According to a pre-IND meeting with the FDA, the company will submit an NDA for the drug via the 505(b)(2) pathway. More news from Chase Sun, Hua Medicine, AscendRare, Triastek, VISEN Pharmaceuticals, RemeGen. Tue, 22 Nov 2022 09:10:55 GMT https://www.pharmadj.com/ssr/en/article/f2ef5e80697911edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/6e156967696d11edaf35fa163e42049a This October, Chinese drug regulators granted the first marketing approvals to three new molecular entities (NMEs) while they expanded the labels of 12 launched drugs. Mon, 21 Nov 2022 07:23:49 GMT https://www.pharmadj.com/ssr/en/article/6e156967696d11edaf35fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/bb3864f9671c11edaf35fa163e42049a VISEN Pharmaceuticals announced that its phase III study of lonapegsomatropin, a long-acting prodrug of unmodified somatropin, met its primary endpoints for the treatment of pediatric growth hormone deficiency (PGHD) in China. Fri, 18 Nov 2022 08:40:47 GMT https://www.pharmadj.com/ssr/en/article/bb3864f9671c11edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/cf5a9bb0665111edaf35fa163e42049a SynRx Therapeutics has completed a Series Pre-A financing round, raising over RMB 100 million. The company focuses on DNA damage repair pathways and uses synthetic lethality strategies to develop anti-cancer agents. Thu, 17 Nov 2022 08:33:44 GMT https://www.pharmadj.com/ssr/en/article/cf5a9bb0665111edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/b5824ecb662011edaf35fa163e42049a Nearly 20 products have undergone IPF clinical research in China. Roche's RG6354, FibroGen’s pamrevlumab, and Boehringer Ingelheim’s BI 1015550 have entered phase III clinical trials. Thu, 17 Nov 2022 02:36:44 GMT https://www.pharmadj.com/ssr/en/article/b5824ecb662011edaf35fa163e42049a Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/8d15ff8e658a11edaf35fa163e42049a On November 15, Harbour BioMed announced the establishment of its wholly-owned subsidiary Nona Biosciences. Wed, 16 Nov 2022 08:41:52 GMT https://www.pharmadj.com/ssr/en/article/8d15ff8e658a11edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/5bbd23a264c111edaf35fa163e42049a Keyi Pharmaceutical announced that it has raised nearly RMB 500 million in its first round of financing from Kequan Fund. Capital raised will be deployed for IND filings and clinical trials of core products and GMP plant construction. Tue, 15 Nov 2022 08:41:40 GMT https://www.pharmadj.com/ssr/en/article/5bbd23a264c111edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/8cdead5363ea11edaf35fa163e42049a Lupeng Pharmaceutical has completed the second tranche of its Series Pre-B financing round, raising $35 million. The tranche was led by Kaitai Capital and Temasek. The funding will be used for clinical studies of its leading drug candidates LP-108, LP-168 and LP-118. Mon, 14 Nov 2022 07:04:01 GMT https://www.pharmadj.com/ssr/en/article/8cdead5363ea11edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/f95014f061bd11edaf35fa163e42049a The strategic collaboration will focus on discovering and developing nucleic acid-based immunotherapies for select oncology targets using the Harbour’s proprietary antibody discovery platform. More news from Lundbeck, iMBIORAY, Luye Pharma, CStone. Fri, 11 Nov 2022 12:39:33 GMT https://www.pharmadj.com/ssr/en/article/f95014f061bd11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/0ed82dab616e11edaf35fa163e42049a Chunlin Xin, Vice President of External Collaboration at CanSino Biologics, told PharmaDJ that “using the adenovirus type 5 vector may be the reason why we succeeded with making the world first inhaled COVID-19 vaccine.” Fri, 11 Nov 2022 03:07:29 GMT https://www.pharmadj.com/ssr/en/article/0ed82dab616e11edaf35fa163e42049a Minhua Chu Interview https://www.pharmadj.com/ssr/en/article/f1f68a4360e811edaf35fa163e42049a YL Pharma recently received conditional marketing approval in China for its Class 1 innovative drug linperlisib tablets. More news from Huahui Health, Zhifei Longcom, BeiGene, Ark Biopharmaceutical. Thu, 10 Nov 2022 11:14:38 GMT https://www.pharmadj.com/ssr/en/article/f1f68a4360e811edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/f0455311600511edaf35fa163e42049a ChainGen Bio has completed an angel round of funding of RMB 45 million ($6.2 million) co-led by Matrix Partners China and FREESFUND. More news from Insilico Medicine, Mainline Biosciences, Recbio, BioRay Pharm, Chimagen Biosciences. Wed, 09 Nov 2022 08:09:39 GMT https://www.pharmadj.com/ssr/en/article/f0455311600511edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/73024df15f4d11edaf35fa163e42049a XellSmart Biomedical announced that it has raised over RMB 200 million ($27.64 million) in Series A1 financing. The round was co-led by Qiming Venture, Lilly Asia Ventures, FIG and CSSD. More news from HEC, Ascentage Pharma, Innovent Biologics, Merck, SIMR Biotechnology, Genevector. Tue, 08 Nov 2022 10:09:02 GMT https://www.pharmadj.com/ssr/en/article/73024df15f4d11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/e2dcefd35e6911edaf35fa163e42049a RecoRNA has completed a round of angel financing worth tens of millions of RMB. This Guangzhou-based biotech firm focuses on RNA editing therapy and has established a proprietary RNA editing platform called MIMIC by leveraging its intellectual property. Mon, 07 Nov 2022 07:02:01 GMT https://www.pharmadj.com/ssr/en/article/e2dcefd35e6911edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/b1d263d45e5011edaf35fa163e42049a In September, the China National Intellectual Property Administration (CNIPA) once again ruled against HEC group in a recent patent infringement case with Boehringer Ingelheim over Boehringer’s self-developed drug Trajenta (linagliptin). The ruling has further affirmed Boehringer’s patent rights. Mon, 07 Nov 2022 03:59:44 GMT https://www.pharmadj.com/ssr/en/article/b1d263d45e5011edaf35fa163e42049a Feature https://www.pharmadj.com/ssr/en/article/3db94a795c4311edaf35fa163e42049a KP104 is a first-in-class bifunctional biologic engineered to selectively target alternative and terminal complement pathways. More news from Tavotek, SINOVAC BIOTECH, Zhongsheng Pharma. Fri, 04 Nov 2022 13:18:05 GMT https://www.pharmadj.com/ssr/en/article/3db94a795c4311edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/4c83b48f5b5a11edaf35fa163e42049a The approval applies to all 27 member states of the European Union as well as Iceland and Norway. More news from Abbisko Therapeutics, Hexaell Biotech, Grand Pharma, Luye Pharma, Synnocare Pharmaceutical. Thu, 03 Nov 2022 09:30:37 GMT https://www.pharmadj.com/ssr/en/article/4c83b48f5b5a11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/6a4853425b2111edaf35fa163e42049a A new regulation now brings greater clarity to regulations around online prescription drug sales in China, bringing new opportunities and challenges to drugmakers. Thu, 03 Nov 2022 03:07:06 GMT https://www.pharmadj.com/ssr/en/article/6a4853425b2111edaf35fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/eb668a6c5a8f11edaf35fa163e42049a The drug is developed for the treatment of primary hypercholesterolemia and mixed hyperlipidemia. More news from CHIRAL-TECH, Sanofi. Wed, 02 Nov 2022 09:21:56 GMT https://www.pharmadj.com/ssr/en/article/eb668a6c5a8f11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/f33c0e2259c511edaf35fa163e42049a On October 31, the National Organization for Pharmaceutical Joint Procurement Office (hereinafter referred to as "Joint Procurement Office") announced that it has disqualified GlaxoSmithKline’s (GSK) Avodart (dutasteride) from the national centralized drug-procurement program and added GSK to its "Violation List". Tue, 01 Nov 2022 09:16:10 GMT https://www.pharmadj.com/ssr/en/article/f33c0e2259c511edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/939f3b9a590e11edaf35fa163e42049a Beijing CorreGene Biotechnology has completed an RMB 100 million Pre-A+ round of financing co-led by Riverhead Capital and Xinrui Investment and followed by Longmen Capital. More news from Novartis, Akeso, Fosun Pharma, Lilly, Beihai Biotech. Mon, 31 Oct 2022 11:23:32 GMT https://www.pharmadj.com/ssr/en/article/939f3b9a590e11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/05837f2358d111edaf35fa163e42049a September was a slow month in pharmaceutical licensing deals, only seven. But, despite low volume, the five deals that were disclosed amounted to a total of $2.083 billion, ranking September third below March and May in terms of deal value. Mon, 31 Oct 2022 04:02:51 GMT https://www.pharmadj.com/ssr/en/article/05837f2358d111edaf35fa163e42049a Yingzi.Shi China Deals Tracker https://www.pharmadj.com/ssr/en/article/a6c1e08756c211edaf35fa163e42049a Sciwind Biosciences announced positive interim analysis results from its ongoing Phase IIb clinical trial of XW003 (Ecnoglutide), a novel, long-acting GLP-1 analog under development for treating type 2 diabetes and obesity. More news from Ascletis Pharma, Pfizer. Fri, 28 Oct 2022 13:14:40 GMT https://www.pharmadj.com/ssr/en/article/a6c1e08756c211edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/7cd5bf6455e411edaf35fa163e42049a China biotech firm JW Therapeutics and 2seventy bio announced a strategic alliance to build a translational and clinical cell therapy development platform that will accelerate T cell-based immunotherapy products in mainland of China, Hong Kong, and Macao. Thu, 27 Oct 2022 10:44:21 GMT https://www.pharmadj.com/ssr/en/article/7cd5bf6455e411edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/ccea0c2255bf11edaf35fa163e42049a Salubris Pharmaceuticals announced that it signed a co-development agreement with Anlong Bio. The two drugmakers will collaborate in the development of small nucleic acid drugs to treat hypertension. Thu, 27 Oct 2022 06:21:44 GMT https://www.pharmadj.com/ssr/en/article/ccea0c2255bf11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/440cbdad55ae11edaf35fa163e42049a In September, two COVID-19 vaccines received NMPA approval for emergency use: CanSino’s Convidecia Air and Livzon Pharma’s V-01. Foreign companies gained several new indications as well, including AstraZeneca’s Forxiga (dapagliflozin), Bayer’s Xarelto (rivaroxaban), Novartis’s Xolair (omalizumab) and AstraZeneca/MSD’s Lynparza (olaparib). Thu, 27 Oct 2022 04:16:13 GMT https://www.pharmadj.com/ssr/en/article/440cbdad55ae11edaf35fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1095a613544911edaf35fa163e42049a The funds will be used to advance the research and development of the company's next-generation generic off-the-shelf cellular immuno-oncology therapeutic products. More news from Angal Bio, Neurovision Pharma GmbH, Vertex Ventures. Tue, 25 Oct 2022 09:39:16 GMT https://www.pharmadj.com/ssr/en/article/1095a613544911edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/23ce0500537311edaf35fa163e42049a The data show that MRX-1 and MRX-4 have similar clinical efficacy and safety profiles across subgroups of the population and demonstrate a hematologically relevant safety profile compared to similar drugs. More news from Henlius, Qurebio, Molecular Intelligence X. Mon, 24 Oct 2022 08:07:56 GMT https://www.pharmadj.com/ssr/en/article/23ce0500537311edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/e76ceb48534b11edaf35fa163e42049a Since early 2022, biopharma stocks on the Hong Kong Exchange (HKEX) have experienced a sharp tumble. We interviewed three seasoned investors who nevertheless remain optimistic about the industry’s prospects. Mon, 24 Oct 2022 03:27:05 GMT https://www.pharmadj.com/ssr/en/article/e76ceb48534b11edaf35fa163e42049a Feature https://www.pharmadj.com/ssr/en/article/f5aa6f1a513111edaf35fa163e42049a Brii Biosciences announced new data from two Phase I studies in healthy volunteers in the U.S. that evaluated long-acting BRII-732 and BRII-778. Both drug candidates are under development for the treatment of HIV. More news from More news from C4X Discovery, HitGen, GSK. Fri, 21 Oct 2022 11:16:00 GMT https://www.pharmadj.com/ssr/en/article/f5aa6f1a513111edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/97adfb5a50f311edaf35fa163e42049a Aleksandar Skuban, Brii Bio’s Head of Central Nervous System (CNS) Disease Therapy Area, believes that BRII-296 has potential to provide a more appealing, convenient and less stigama treatment option for postpartum depression (PPD) patients. Fri, 21 Oct 2022 03:49:34 GMT https://www.pharmadj.com/ssr/en/article/97adfb5a50f311edaf35fa163e42049a Minhua Chu Interview https://www.pharmadj.com/ssr/en/article/8236648b505a11edaf35fa163e42049a Maxinovel Pharmaceuticals closed an RMB 100 million ($13.84 million) Series C+ round of financing from LAPAM Capital, Zhongxin Capital and Deyi Runrong Venture Capital. More news from SEHK. Thu, 20 Oct 2022 09:33:45 GMT https://www.pharmadj.com/ssr/en/article/8236648b505a11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/09f64ce54f9111edaf35fa163e42049a Hrain Biotechnology announced the SSE STAR Market has accepted its first listing application, with a proposed capital injection of RMB 2.54 billion ($352 million). Thu, 20 Oct 2022 01:26:51 GMT https://www.pharmadj.com/ssr/en/article/09f64ce54f9111edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/73cc890f4ecc11edaf35fa163e42049a Capital raised will go to the industrialization of Beita's carbon-14 nuclear drug and the development of new technologies and products related to the carbon-14 isotope. More news from Henlius Biotech. Tue, 18 Oct 2022 10:04:21 GMT https://www.pharmadj.com/ssr/en/article/73cc890f4ecc11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/c7e2e0a24dfe11edaf35fa163e42049a Kunshi Biotechnology announced that it raised tens of millions of RMB in a round of angel funding co-invested by ASB Ventures and Riemann-Hypothesis. More news from Innovent Biologics, Essex Bio-Investment, Mitotech, Jemincare, Menovo Pharmaceutical, Liaoyuan Pharmaceutical. Mon, 17 Oct 2022 09:32:06 GMT https://www.pharmadj.com/ssr/en/article/c7e2e0a24dfe11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/a378ebe64dc911edaf35fa163e42049a Financing for Chinese drugmakers hit a 2022 low with 15 of 19 companies disclosing a total of only $346 million in funding. Mon, 17 Oct 2022 03:44:22 GMT https://www.pharmadj.com/ssr/en/article/a378ebe64dc911edaf35fa163e42049a Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/ca7dd8c14b8f11edaf35fa163e42049a According to the NMPA’s website, Kyowa Kirin's mogamulizumab injection has been approved for two common types of cutaneous T-cell lymphoma. More news from Joincare, Haisco Pharmaceutical, Simcere, Pfizer. Fri, 14 Oct 2022 07:12:12 GMT https://www.pharmadj.com/ssr/en/article/ca7dd8c14b8f11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/bb76520d4ae011edaf35fa163e42049a Ausper Bio announced the closing of a Pre-A financing round valued at roughly $16 million. Funds raised will be used for global clinical trials of a small nucleic acid drug intended to cure hepatitis B as well as the advancement of other development pipelines. More news from RemeGen, BeiGene. Thu, 13 Oct 2022 10:19:05 GMT https://www.pharmadj.com/ssr/en/article/bb76520d4ae011edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/508fe70c4ab411edaf35fa163e42049a Lower IPO requirements and a hospitable stock exchange are making Singapore a new hotspot for Chinese biotechs looking to go public. Thu, 13 Oct 2022 05:01:08 GMT https://www.pharmadj.com/ssr/en/article/508fe70c4ab411edaf35fa163e42049a Xu Weijia Feature https://www.pharmadj.com/ssr/en/article/ada8d5814a0c11edaf35fa163e42049a Chinese CAR-T cell therapies developer IASO Biotherapeutics has out-licensed its clinically validated fully human CD19 binder to Cabaletta Bio. Cabaletta now has exclusive, worldwide rights to develop, manufacture and commercialize it for use in a product designed to modify T cells for the treatment of autoimmune diseases. Wed, 12 Oct 2022 09:01:09 GMT https://www.pharmadj.com/ssr/en/article/ada8d5814a0c11edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/33c52296494711edaf35fa163e42049a Clover Biopharmaceuticals announced that SCB-2019 (CpG 1018/Alum), its lead COVID-19 vaccine candidate, has made a progress on regulatory submissions to the China NMPA, the EMA and the WHO, with completion anticipated for Q4 2022. More news from Harbour BioMed, MSD, Wantai Biopharm. Tue, 11 Oct 2022 09:27:33 GMT https://www.pharmadj.com/ssr/en/article/33c52296494711edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/41df7211488111edaf35fa163e42049a On October 6, AIM Vaccine was listed on the Main Board of the Hong Kong Stock Exchange. It was quoted at HK$16.66 ($2.12) per share by the close of trading, up 3.09% on the first day. More news from LinKr, YS Biopharma, Hua Medicine, Eli Lilly, JW Therapeutics, Roche, Bio-Thera, Connect Biopharma, Ark Biopharmaceutical, Etana. Mon, 10 Oct 2022 09:50:37 GMT https://www.pharmadj.com/ssr/en/article/41df7211488111edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/14ef7d18484811edaf35fa163e42049a Immunotherapy specialist iCamuno is looking to make big strides in cancer treatment with its three groundbreaking new platforms and a clinical-grade cell bank. Mon, 10 Oct 2022 03:01:20 GMT https://www.pharmadj.com/ssr/en/article/14ef7d18484811edaf35fa163e42049a Danni.Yin Interview https://www.pharmadj.com/ssr/en/article/f7e82cf440a511edaf35fa163e42049a NeuShen Therapeutics announced the closure of a $20 million Series pre-A financing round led by LAPAM capital. More news from MabPlex. Fri, 30 Sep 2022 09:52:35 GMT https://www.pharmadj.com/ssr/en/article/f7e82cf440a511edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/f346e063407411edaf35fa163e42049a PharmaDJ will take a brief publishing break from October 1 to 9 in observance of China’s National Day holiday. Fri, 30 Sep 2022 04:01:42 GMT https://www.pharmadj.com/ssr/en/article/f346e063407411edaf35fa163e42049a PharmaDJ News https://www.pharmadj.com/ssr/en/article/9d0e552f3fdc11edaf35fa163e42049a Almirall will be granted exclusive rights to develop and commercialize SIM0278 for all indications outside of the Greater China region. Simcere will receive a $15 million upfront payment and up to $492 million in milestone payments. More news from JHM Biopharma, Lepu Biopharma, MSD, Sinopharm, Henlius Biotech. Thu, 29 Sep 2022 09:51:13 GMT https://www.pharmadj.com/ssr/en/article/9d0e552f3fdc11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/56c4cc013fa611edaf35fa163e42049a August saw eight drug licensing deals, including five in-licensing agreements, an out-licensing deal and two partnerships between domestic companies. Thu, 29 Sep 2022 03:22:43 GMT https://www.pharmadj.com/ssr/en/article/56c4cc013fa611edaf35fa163e42049a Yingzi.Shi China Deals Tracker https://www.pharmadj.com/ssr/en/article/b9ef3bee3f0911edaf35fa163e42049a Zai Lab announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in Greater China. More news from Jiuzhou Pharma, Joincare Pharmaceutical. Wed, 28 Sep 2022 08:41:38 GMT https://www.pharmadj.com/ssr/en/article/b9ef3bee3f0911edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/852163693e5511edaf35fa163e42049a Xuanzhu Biopharmaceutical, Sihuan Pharm’s holding company, has filed for an IPO with the STAR Market to raise RMB 2.47 billion ($345.22 million). More news from SingMed, MSD, Gluetacs Therapeutics, LongBio Pharma, Hansoh Pharma, BIOHENG, Brii Biosciences. Tue, 27 Sep 2022 11:11:40 GMT https://www.pharmadj.com/ssr/en/article/852163693e5511edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/df68c8203d7111edaf35fa163e42049a Huisheng Biopharmaceutical, a non-wholly owned subsidiary of Sihuan Pharmaceutical, announced that it completed Series A financing worth RMB 500 million RMB ($70 million). The round was led by China Life Private Equity Investment, Grand Flight Investment, Yuanyi Jimao Equity Investment and Ginko Capital. Mon, 26 Sep 2022 08:02:06 GMT https://www.pharmadj.com/ssr/en/article/df68c8203d7111edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/39873cc83d4411edaf35fa163e42049a Since 2021, Induced multifunctional stem cells (iPSC) have triggered a funding boom and several Chinese companies rushing into the iPSC space. Mon, 26 Sep 2022 02:35:21 GMT https://www.pharmadj.com/ssr/en/article/39873cc83d4411edaf35fa163e42049a Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/e3a0b7713af111edaf35fa163e42049a YouJia Bio announced the completion of a Series A+ round of financing worth tens of millions of RMB. It was led exclusively by the ChengZhang Group. More news from AstraZeneca, MSD, Hepa Thera Bio, Fosun Pharma. Fri, 23 Sep 2022 03:40:35 GMT https://www.pharmadj.com/ssr/en/article/e3a0b7713af111edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/5c32a39b3a5f11edaf35fa163e42049a Chimigen Bio has closed an initial funding round worth over 100 million RMB ($14.11 million) led by Lapam Capital and followed by Puhua Capital and Kingfriend Pharma. More news from CTTQ Pharma, Inventiva Pharma, Merck. Thu, 22 Sep 2022 10:11:42 GMT https://www.pharmadj.com/ssr/en/article/5c32a39b3a5f11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/aad3c93f3a2111edaf35fa163e42049a Sirnaomics’ Executive Director and Chief Medical Officer Dr. Michael Molyneaux talks with PharmaDJ about the future of its lead siRNA candidate, STP705. Thu, 22 Sep 2022 02:50:05 GMT https://www.pharmadj.com/ssr/en/article/aad3c93f3a2111edaf35fa163e42049a Minhua Chu Interview https://www.pharmadj.com/ssr/en/article/c220bbba398611edaf35fa163e42049a InnoCare Pharma announced today that it is now listed on the Shanghai Stock Exchange’s STAR Market. This makes InnoCare the only biotech company to be listed both on the HKEX and the STAR Market. More news from Ribo Life Science, Clover Biopharmaceuticals. Wed, 21 Sep 2022 08:21:12 GMT https://www.pharmadj.com/ssr/en/article/c220bbba398611edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/bfaebd5e38bb11edaf35fa163e42049a Fosun Pharma announced that it has entered into a licensing agreement with Carephar to jointly develop KFP-H008, a potassium competitive acid blocker for all oral and generic indications available. More news from Junshi Biosciences, AstraZeneca, CDE. Tue, 20 Sep 2022 08:08:00 GMT https://www.pharmadj.com/ssr/en/article/bfaebd5e38bb11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/dc30b4af37ee11edaf35fa163e42049a Arnita Therapeutics announced the completion of a round of Seed financing worth nearly 100 million RMB led by Apricot Capital. The company will use the funds to develop its R&D platform based on antisense nucleic acid bidirectional regulation technology and to advance multiple innovative drug pipelines. Mon, 19 Sep 2022 07:41:21 GMT https://www.pharmadj.com/ssr/en/article/dc30b4af37ee11edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/32abcd3137c711edaf35fa163e42049a In August, China saw the approval of only one new molecular entity (NME), Sinocelltech’s CD20 antibody ripertamab (SCT400). Another two homegrown companies, Zelgen and Alphamab, gained new indications and dosing regimens for their self-developed products as well. Mon, 19 Sep 2022 02:57:26 GMT https://www.pharmadj.com/ssr/en/article/32abcd3137c711edaf35fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/44c5929b35af11edaf35fa163e42049a Lepu Medical made an announcement regarding the issuance of Global Depositary Receipts (GDRs) and its listing on the SWX Swiss Exchange. More news from Alphamab Oncology, Zelgen Biopharmaceuticals. Fri, 16 Sep 2022 11:00:47 GMT https://www.pharmadj.com/ssr/en/article/44c5929b35af11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/024984f834d011edaf35fa163e42049a METiS Pharmaceuticals announced that it has entered into a licensing agreement with South Korean Bio startup Voronoi. Voronoi will receive an initial payment of $1.7 million and will also be eligible for milestone payments of up to $480.5 million as well as a share of sales. More news from Apollomics. Thu, 15 Sep 2022 08:22:37 GMT https://www.pharmadj.com/ssr/en/article/024984f834d011edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/6cfcee1d34ac11edaf35fa163e42049a 38 biotech companies secured financing this August, 31 of which disclosed figures totaling $563 million. Thu, 15 Sep 2022 04:07:55 GMT https://www.pharmadj.com/ssr/en/article/6cfcee1d34ac11edaf35fa163e42049a Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/d6731ecc340611edaf35fa163e42049a Worg Pharmaceuticals announced the completion of a round of Series B financing worth 400 million RMB. Wed, 14 Sep 2022 08:24:41 GMT https://www.pharmadj.com/ssr/en/article/d6731ecc340611edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/d4183129335511edaf35fa163e42049a Nuwacell Biotechnologies announced the completion of a round of Series A financing worth several hundred million RMB. Tue, 13 Sep 2022 11:15:30 GMT https://www.pharmadj.com/ssr/en/article/d4183129335511edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/88a11ab8331a11edaf35fa163e42049a Henlius’ vice president of business development Cao Ping spoke to PharmaDJ about winning global partners, gaining commercial success overseas, and building a strong business development team. Tue, 13 Sep 2022 04:11:03 GMT https://www.pharmadj.com/ssr/en/article/88a11ab8331a11edaf35fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/6513770e302711edaf35fa163e42049a Frontier Biotechnologies disclosed a private placement with totaling RMB 200 million ($28.8 million). Funds will be used to support the research and development of Bofutrelvir (FB2001), an original novel small molecule for COVID-19. More news from Brise Pharma. Fri, 09 Sep 2022 10:05:13 GMT https://www.pharmadj.com/ssr/en/article/6513770e302711edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/1c0774792f5d11edaf35fa163e42049a Sunshine Guojian announced that it held a board meeting on September 7 to consider and approve a "Proposal on Terminating Joint Investment with Related Parties and Related Transactions" concerning its subsidiary HanBio Therapeutics. More news from Kelun Biotech. Thu, 08 Sep 2022 09:57:13 GMT https://www.pharmadj.com/ssr/en/article/1c0774792f5d11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/bd6a84b12f1d11edaf35fa163e42049a Hainan’s Medical Tourism Pilot Zone is a pioneer in the practice, with three drugs already approved for market, and seven in the pipeline. Thu, 08 Sep 2022 02:23:35 GMT https://www.pharmadj.com/ssr/en/article/bd6a84b12f1d11edaf35fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/0733f4bc2e9111edaf35fa163e42049a Dizal announced positive topline results from its first pivotal study of sunvozertinib in platinum-pretreated NSCLC Patients with EGFR exon20ins mutations. More news from Eli Lilly. Wed, 07 Sep 2022 09:36:20 GMT https://www.pharmadj.com/ssr/en/article/0733f4bc2e9111edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/4ff7c33c2dc611edaf35fa163e42049a InnoBM Pharmaceuticals raised nearly $2.88 million in series A+ financing led by Yuanbio Venture Capital to advance novel therapeutics to boost the efficacy of tumor immunotherapy. Tue, 06 Sep 2022 10:04:34 GMT https://www.pharmadj.com/ssr/en/article/4ff7c33c2dc611edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/e8e26aaa2d0111edaf35fa163e42049a CARsgen Therapeutics announced that its CGMP manufacturing facility in North Carolina’s RTP has begun GMP production of autologous CAR-T cell products and has successfully released the first GMP batch for clinical trials. More news from AstraZeneca, Bayer, Novartis, Northeast Pharma, Livzon, CanSinoBio. Mon, 05 Sep 2022 09:59:20 GMT https://www.pharmadj.com/ssr/en/article/e8e26aaa2d0111edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/f3e60b4c2cc111edaf35fa163e42049a China is seeing several very successful Chinese drugmakers rushing into the field of nucleic acid drug field, but success is far from certain. Mon, 05 Sep 2022 02:21:31 GMT https://www.pharmadj.com/ssr/en/article/f3e60b4c2cc111edaf35fa163e42049a Yingzi.Shi Feature https://www.pharmadj.com/ssr/en/article/95696aee2aa611edaf35fa163e42049a Neukio Biotherapeutics announced that it has completed a Series A-1 round of financing worth $50 million. More news from BoomRay Pharmaceuticals, MedimScience, Lepu Biopharma. Fri, 02 Sep 2022 10:00:15 GMT https://www.pharmadj.com/ssr/en/article/95696aee2aa611edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/dda94ccf29cd11edaf35fa163e42049a InnoPinnacle Fund, an early-stage RMB fund initiated and led by Innovent Bio, announced that it has raised RMB 500 million ($72.4 million). More news from Biocytogen, Clover Biopharmaceuticals, Haisco, Sirnaomics. Thu, 01 Sep 2022 08:08:55 GMT https://www.pharmadj.com/ssr/en/article/dda94ccf29cd11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/1d5493a929a211edaf35fa163e42049a Roche believes Jemincare’s novel oral androgen receptor degrader will complement its efforts to develop new treatment options for patients with advanced prostate cancer. Thu, 01 Sep 2022 02:55:44 GMT https://www.pharmadj.com/ssr/en/article/1d5493a929a211edaf35fa163e42049a Minhua Chu Interview https://www.pharmadj.com/ssr/en/article/345c2d1f290d11edaf35fa163e42049a Hangzhou-based drugmaker U-protech announced that it has completed an angel round of funding from Shanghai Biomedical Innovation and Transformation Fund along with an angel + round of funding from Zheshang Venture Capital. The company has raised nearly $2.9 million in capital. Wed, 31 Aug 2022 09:11:18 GMT https://www.pharmadj.com/ssr/en/article/345c2d1f290d11edaf35fa163e42049a Danni.Yin News https://www.pharmadj.com/ssr/en/article/6803cdc9284211edaf35fa163e42049a Novel nanoantibody drugmaker Bank Biotech has completed an angel round of funding worth over RMB 10 million ($1.45 million) led by Donghu Investment and followed by Baiying Investment. More news from Hengrui Pharma, CanSinoBio. Tue, 30 Aug 2022 08:58:07 GMT https://www.pharmadj.com/ssr/en/article/6803cdc9284211edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/b27ba819277e11edaf35fa163e42049a UniCar Therapy recently announced the completion of a Series C financing round worth tens of millions of RMB. More news from Haisco Pharmaceutical, Innovent Biologics. Mon, 29 Aug 2022 09:37:10 GMT https://www.pharmadj.com/ssr/en/article/b27ba819277e11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/cc16aaba274611edaf35fa163e42049a The 2021 Drug Review Annual Report Mon, 29 Aug 2022 02:56:59 GMT https://www.pharmadj.com/ssr/en/article/cc16aaba274611edaf35fa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/64dc8f14251d11edaf35fa163e42049a The Shanghai-based recombinant protein and antibody drug specialist said that it will use the funds to drive the commercialization of core products in development and key clinical trials for new pipelines. More news from Anovent Pharmaceuticals, Everest Medicines, CStone Pharmaceuticals. Fri, 26 Aug 2022 12:19:28 GMT https://www.pharmadj.com/ssr/en/article/64dc8f14251d11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/e8a3b56e244c11edaf35fa163e42049a Sinotherapeutics officially rang the opening bell today at the STAR Market with an official price of RMB 9.37 ($1.37) per share. As soon as trading opened, the stock price rose to RMB 15.80. More news from Trinomab. Thu, 25 Aug 2022 08:02:53 GMT https://www.pharmadj.com/ssr/en/article/e8a3b56e244c11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/a020fb61241c11edaf35fa163e42049a Gene therapy, nucleic acid drugs and radiopharmaceuticals are attracting more investor attention. Thu, 25 Aug 2022 02:17:16 GMT https://www.pharmadj.com/ssr/en/article/a020fb61241c11edaf35fa163e42049a Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/30423ce8238811edaf35fa163e42049a Lee’s and Zhaoke will receive a global license to develop and commercialize Surfaxin, its lyophilized lucinactant, and AEROSURF for any potential indications and applications. More news from TASLY Pharmaceutical, Akeso Bio. Wed, 24 Aug 2022 08:34:42 GMT https://www.pharmadj.com/ssr/en/article/30423ce8238811edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/b6948dc622b811edaf35fa163e42049a Established in Zhejiang in 2021, Juvensis Therapeutics develops gene therapy drugs with a focus on treatments for heart failure. More news from Hansoh Pharmaceuticals, CSPC Pharma. Wed, 24 Aug 2022 00:44:40 GMT https://www.pharmadj.com/ssr/en/article/b6948dc622b811edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/56400a4c21f811edaf35fa163e42049a Simcere registered a Phase II/III clinical trial for a combination of Covid-19 Oral Drug SIM0417 + Ritonavir for the treatment of mild to severe Covid-19 infections. More news from IASO Biotherapeutics, Alphamab Oncology. Mon, 22 Aug 2022 08:52:27 GMT https://www.pharmadj.com/ssr/en/article/56400a4c21f811edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/5a2da40621bd11edaf35fa163e42049a Pediatric drugs see major boom. Mon, 22 Aug 2022 01:50:11 GMT https://www.pharmadj.com/ssr/en/article/5a2da40621bd11edaf35fa163e42049a Sarina Yang Regulatory https://www.pharmadj.com/ssr/en/article/b03cadbe1f8511edaf35fa163e42049a MingMed Biotech, with a product portfolio that includes ophthalmic drugs, recombinant protein botulinum toxin, oncology immunology drugs, and pet immunology drugs, recently filed for an IPO with HKEX. More news from Jemincare, Genentech, Huahai, Pfizer. Fri, 19 Aug 2022 06:06:24 GMT https://www.pharmadj.com/ssr/en/article/b03cadbe1f8511edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/6e445c401ebc11edaf35fa163e42049a There were a total of eight drug licensing deals in China in July 2022. This includes four in-licensing agreements, two out-licensing deals and two programs between domestic companies or institutions. Thu, 18 Aug 2022 06:05:45 GMT https://www.pharmadj.com/ssr/en/article/6e445c401ebc11edaf35fa163e42049a Yingzi.Shi China Deals Tracker https://www.pharmadj.com/ssr/en/article/490b76801eb911edaf35fa163e42049a "Nature Medicine" published updated data from a clinical trial of GAVRETO. The data suggest that GAVRETO has favorable therapeutic effects in a variety of RET fusion-positive solid tumors. More news from CARsgen Therapeutics, Akeso Bio. Thu, 18 Aug 2022 05:43:14 GMT https://www.pharmadj.com/ssr/en/article/490b76801eb911edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/654e9bc21e0411edaf35fa163e42049a Wyze Biotech, founded in Guangdong in 2012, recently announced the completion of a RMB 59 million Series A+ financing round. More news from LongBio, SciClone, I-Mab. Wed, 17 Aug 2022 08:08:22 GMT https://www.pharmadj.com/ssr/en/article/654e9bc21e0411edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/cb55f4741d4111edaf35fa163e42049a SinoCellTech announced the results of its pivotal registration phase III clinical trial of its novel anti-CD20 McAb, ripertamab. More news from Healthnice Pharmaceutical, Huadong Medicine, Everest Medicines. Tue, 16 Aug 2022 09:16:19 GMT https://www.pharmadj.com/ssr/en/article/cb55f4741d4111edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/e84213441c7d11edaf35fa163e42049a BGI, focused on science and genomics, recently added capital to two of its companies, Genoimmune Therapeutics and Hemogen. More news from Bennu Biotherapeutics, Zelgen, Roche, NMPA, Pfizer, Sunshine Guojian. Mon, 15 Aug 2022 09:33:09 GMT https://www.pharmadj.com/ssr/en/article/e84213441c7d11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/0f4d79571c5811edaf35fa163e42049a China’s pursuit of innovative oncology drugs remained intense in July, as Chinese regulators granted the first marketing approval for three drugs, namely Simcere’s Cosela (trilaciclib), Lepu Biopharma’s Puyouheng (pucotenlimab) and Roche’s Rozlytrek (Entrectinib). Mon, 15 Aug 2022 05:02:13 GMT https://www.pharmadj.com/ssr/en/article/0f4d79571c5811edaf35fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/ebd302a81a1b11edaf35fa163e42049a Established in Suzhou in June 2022, nucleic acid drug delivery system R&D startup DSci Laboratory announced the completion of an angel round of funding by FosunHealth Capital. More news from Elite Pharmaceutical, Zai Lab, WuXi ATU. Fri, 12 Aug 2022 08:46:22 GMT https://www.pharmadj.com/ssr/en/article/ebd302a81a1b11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/e027176f194511edaf35fa163e42049a Singapore biotechnology startup Axcynsis Therapeutics, focusing on the development of Antibody-X Conjugate (AXC) therapies, has recently set up an R&D center in Shanghai. More news from Wuhan Bio-innovation, Insilico Medicine, Innovent Bio. Thu, 11 Aug 2022 08:53:45 GMT https://www.pharmadj.com/ssr/en/article/e027176f194511edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/89c2c558191711edaf35fa163e42049a Rona Therapeutics CEO and co-founder Stella Shi told PharmaDJ that the company has built a scalable platform that can draw talent in developing RNA therapeutics. Thu, 11 Aug 2022 01:42:28 GMT https://www.pharmadj.com/ssr/en/article/89c2c558191711edaf35fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/483e1d2b187211edaf35fa163e42049a Bivision Pharma, focuses on the development of targeted radionuclide therapy, announced the completion of an angel funding round of nearly RMB 100 million. More news from Longivitron, BeiGene, Simcere, Zai Lab, Canwell. Wed, 10 Aug 2022 06:00:59 GMT https://www.pharmadj.com/ssr/en/article/483e1d2b187211edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/0d7499f017c211edaf35fa163e42049a Constimulus Biopharma, which focuses on the development of agonistic antibodies, announced the completion of an angel funding round of tens of millions of RMB, led by Zhongshan Health Base Group and Tengye Ventures. More news from Hansoh Pharma, HUTCHMED, AnHeart Therapeutics, CSPC, Gan & Lee. Tue, 09 Aug 2022 08:58:01 GMT https://www.pharmadj.com/ssr/en/article/0d7499f017c211edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/b1fbb80e16d511edaf35fa163e42049a Epigenic Therapeutics, a biotechnology company dedicated in gene editing therapy, announced it has secured $20 million in Series Angel and Pre-A funding. More news from DDSome Lab, CSPC, Xynomic Pharma. Mon, 08 Aug 2022 04:46:07 GMT https://www.pharmadj.com/ssr/en/article/b1fbb80e16d511edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/26c292cd16c711edaf35fa163e42049a Chinese biotech companies are developing generic and innovative drugs, as well as gene therapy, for ophthalmologic diseases. Mon, 08 Aug 2022 03:05:22 GMT https://www.pharmadj.com/ssr/en/article/26c292cd16c711edaf35fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/88edc0de148e11edaf35fa163e42049a Founded in 2012 in Henan Province, Genuine Bio, which focuses on the antiviral field, filed an IPO application with HKEX. More news from MicuRx, Innovent Bio, InnoBM Pharma, Auson Pharma, BI. Fri, 05 Aug 2022 07:16:33 GMT https://www.pharmadj.com/ssr/en/article/88edc0de148e11edaf35fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/b5b8b1fd13bc11eda821fa163e42049a ConVerd, which focuses on oncolytic viruses and other cancer immunotherapies, has completed a new round of financing and strategic partner introduction with participation from Dongheng, HoFon Capital and Lanson Investment. More news from Ascletis. Thu, 04 Aug 2022 06:04:05 GMT https://www.pharmadj.com/ssr/en/article/b5b8b1fd13bc11eda821fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/37b846a213bc11eda821fa163e42049a An increase in prescription flow to retail pharmacies has become a new trend in China’s pharmaceutical market, a report by L.E.K. Consulting showed. Drugmakers are advised to adjust their sales resource allocation accordingly. Thu, 04 Aug 2022 06:01:01 GMT https://www.pharmadj.com/ssr/en/article/37b846a213bc11eda821fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/797b82a612ef11eda821fa163e42049a Sironax announced the completion of a $200 million Series B financing. With the closing of this round, the Company has raised over $300 million to date. More news from Fineimmu, Sanyou Bio, CCOA Therapeutics. Wed, 03 Aug 2022 05:34:57 GMT https://www.pharmadj.com/ssr/en/article/797b82a612ef11eda821fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/5a868cd8124011eda821fa163e42049a Coherent Biopharma, which specialises in the development of bispecific-Ligand Drug Conjugate (bi-XDC), has closed a Series B funding round. Tue, 02 Aug 2022 08:41:23 GMT https://www.pharmadj.com/ssr/en/article/5a868cd8124011eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/5919988c115611eda821fa163e42049a OriCell Therapeutics has raised over $120 million in series B financing led by Qiming Venture Partners and Quan Capital to advance cell therapies for cancer immunology. More news from Shengrui Zehua, Eli Lilly, Kira Pharma, Roche, YANYANG Bio, GluBio. Mon, 01 Aug 2022 04:46:19 GMT https://www.pharmadj.com/ssr/en/article/5919988c115611eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/2187a466114f11eda821fa163e42049a China is set to implement a strict access system for vaccine manufacturing to limit the entry of new vaccine manufacturers, according to a new rule released by the NMPA on July 11 that took effect immediately. Mon, 01 Aug 2022 03:54:39 GMT https://www.pharmadj.com/ssr/en/article/2187a466114f11eda821fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/78fcdbfe0f1a11eda821fa163e42049a Suzhou Ribo Life Science, an oligonucleotide therapeutics developer, said it closed a $40 million Series E1 on July 25 to support the global development of multiple programs. More news from RNAlfa, Sino Biological. Fri, 29 Jul 2022 08:32:20 GMT https://www.pharmadj.com/ssr/en/article/78fcdbfe0f1a11eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/f52c914a0e2e11eda821fa163e42049a Jingrui Pharma, a small molecule drug developer of Jiangsu, gained support from Heze Innovation Venture Investment to close a Series Pre-A round but the company did not disclose the amount raised. More news from CSPC Megalith Biopharmaceutical. Thu, 28 Jul 2022 04:26:27 GMT https://www.pharmadj.com/ssr/en/article/f52c914a0e2e11eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/473a40b20e2311eda821fa163e42049a In-licensing activity in China’s biotech sector has stayed weak in the second quarter of 2022, with the number of in-licensing deals dropping to a new low in June. Cash-strapped Chinese drugmakers became more prudent in buying and sought big buyers for their assets instead. Thu, 28 Jul 2022 03:02:51 GMT https://www.pharmadj.com/ssr/en/article/473a40b20e2311eda821fa163e42049a Yingzi.Shi China Deals Tracker https://www.pharmadj.com/ssr/en/article/65a0f9620d8b11eda821fa163e42049a Kelun-Biotech, a subsidiary of Sichuan Kelun Pharmaceutical, has licensed out another ADC candidate to MSD for exclusive global rights in a deal worth up to $936 million. More news from CMS Ophthalmology. Wed, 27 Jul 2022 08:55:38 GMT https://www.pharmadj.com/ssr/en/article/65a0f9620d8b11eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/a893748f0cb211eda821fa163e42049a Genuine Biotech's azvudine became the first China-developed oral drug approved to treat COVID-19 and Fosun Pharma is expected to exclusively commercialize azvudine. More news from Danatlas, Rona, Henlius, YUNNAN BAIYAO, Zelgen. Tue, 26 Jul 2022 07:04:10 GMT https://www.pharmadj.com/ssr/en/article/a893748f0cb211eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b7feae980bef11eda821fa163e42049a InvestisBio raised RMB2.084 billion ($296 million) by issuing 11,500 shares at RMB18.12 apiece on Shanghai's STAR market on July 25. More news from AstaThera, 3D Medicines. Mon, 25 Jul 2022 07:48:44 GMT https://www.pharmadj.com/ssr/en/article/b7feae980bef11eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/867e89950bcb11eda821fa163e42049a After a ‘biotech winter’, it seems the first signs of spring has arrived for the industry. Biotech fundraising trends showed more positive signs in June, with funds raised by Chinese players rising 42% from a month ago to reach $554 million. Mon, 25 Jul 2022 03:29:39 GMT https://www.pharmadj.com/ssr/en/article/867e89950bcb11eda821fa163e42049a Elise Mak China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/bea61e76097a11eda821fa163e42049a InxMed, of Nanjing, secured funding from SPD Silicon Valley Bank to push its war chest to over $100 million since its establishment in 2018. More news from NeuroFront, Junion, Genscript, Lepu, Humanwell. Fri, 22 Jul 2022 04:46:02 GMT https://www.pharmadj.com/ssr/en/article/bea61e76097a11eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d47f418308d711eda821fa163e42049a I-Mab says AbbVie’s decision to terminate an exploratory study of its CD47 antibody, lemzoparlimab, in multiple myeloma (MM) has nothing to do with the drug’s safety. The Chinese firm is also preparing a registrational trial for lemzoparlimab. Thu, 21 Jul 2022 09:19:51 GMT https://www.pharmadj.com/ssr/en/article/d47f418308d711eda821fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/04f6bb3a08cf11eda821fa163e42049a Minova Pharma, of Nanjing, has raised over RMB 100 million ($14.8 million) in a Series A round from Huagai Capital, Lize Investment and existing investors such as Oriza Holdings and Wenzhou Capital. More news from Yulu Qianxing, Gan & Lee. Thu, 21 Jul 2022 08:16:47 GMT https://www.pharmadj.com/ssr/en/article/04f6bb3a08cf11eda821fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/00ea685e080e11eda821fa163e42049a Maxvax​, of Chengdu, has raised RMB500 million ($74 million) in a Series B round and plans to use the proceeds to support the clinical trials of its multiple vaccine candidates. More news from Innovent, Wuxi Apptec, Triastek, Peplib, Uncycive. Wed, 20 Jul 2022 09:15:07 GMT https://www.pharmadj.com/ssr/en/article/00ea685e080e11eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/7076edab073d11eda821fa163e42049a Frontera Therapeutics has raised $160 million in a Series B round to support its lead program, FT-001, in clinical trials. More news from Norroy Bioscience. Tue, 19 Jul 2022 08:22:09 GMT https://www.pharmadj.com/ssr/en/article/7076edab073d11eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/7b697426066411eda821fa163e42049a Henan-based Genuine Biotech said on July 15 that the NMPA has accepted the NDA of its HIV-1 drug azvudine for the treatment of COVID-19. More news from Fermion, Attec, Linno, China Immunotech, Haisco, Sihuan, Kingfriend. Mon, 18 Jul 2022 06:29:07 GMT https://www.pharmadj.com/ssr/en/article/7b697426066411eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/11248f39064d11eda821fa163e42049a The approval of OcuMension Therapeutics’ YUTIQ was based on RWD collected in Hainan province and the phase III clinical trials that have been completed outside of China. Mon, 18 Jul 2022 03:41:30 GMT https://www.pharmadj.com/ssr/en/article/11248f39064d11eda821fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/90e8cf69041b11eda821fa163e42049a Suzhou-based startup Hepa Thera, a developer of antibody drugs that treat liver disease such as hepatitis B, said its IND for its core program, HT-101, has been accepted by the NMPA. More news from BeiGene, Lilly, CStone. Fri, 15 Jul 2022 08:41:48 GMT https://www.pharmadj.com/ssr/en/article/90e8cf69041b11eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/bb35bec8035711eda821fa163e42049a Ark Biopharmaceutical said it has completed a Series D round but did not disclose how much it has raised. More news from Biosotop, Convalife, HUTCHMED. Thu, 14 Jul 2022 09:19:57 GMT https://www.pharmadj.com/ssr/en/article/bb35bec8035711eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/eb2d5e62031e11eda821fa163e42049a Compared to last year, funding has gone down 40% but out-licensing deals almost double in the first half of 2022 Thu, 14 Jul 2022 02:41:24 GMT https://www.pharmadj.com/ssr/en/article/eb2d5e62031e11eda821fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/a1ad5670028c11eda821fa163e42049a Denovo Biopharma has formed a partnership with Canada's Nurosene Health to use its NetraPlacebo technology to optimize clinical trials for DB104 (liafensine) for depression. More news from Chipscreen, Simcere. Wed, 13 Jul 2022 09:06:07 GMT https://www.pharmadj.com/ssr/en/article/a1ad5670028c11eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/db34e93001bf11eda821fa163e42049a Qiming Venture Partners said it closed its latest funds totaling $3.2 billion. More news from Forlong, Qilu. Tue, 12 Jul 2022 08:40:16 GMT https://www.pharmadj.com/ssr/en/article/db34e93001bf11eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/da042e5600f511eda821fa163e42049a Xiangxue Life Sciences has launched the phase II trial of TAEST16001, the first TCR-T cell therapy candidate that won IND approval in China. More news from Betta Pharma. Mon, 11 Jul 2022 08:34:16 GMT https://www.pharmadj.com/ssr/en/article/da042e5600f511eda821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/a6335b9600c211eda821fa163e42049a Deal by deal, biotech treatments made in China are reaching countries in Southeast Asia, the Middle East, Latin America and even Africa – markets that are often overlooked. Mon, 11 Jul 2022 02:34:59 GMT https://www.pharmadj.com/ssr/en/article/a6335b9600c211eda821fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/60d198a3fea411eca821fa163e42049a Shenzhen Xinyue Biotech, founded in April 2021, closed a Series Pre-A round to speed up the development of its DNA encoded library (DEL)3.0 technology platform and its oncology pipeline. More news from Legend, Ubrigene. Fri, 08 Jul 2022 09:45:40 GMT https://www.pharmadj.com/ssr/en/article/60d198a3fea411eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/c11951aafddb11eca821fa163e42049a AI drug discovery startup Phil Rivers Tech, of Beijing, has raised nearly RMB100 million in Series A round to enhance its "computational medicine" platform and advance its pipeline. More news from BeiGene, Junshi, Brii, AstraZeneca, NUCIEN, Wantai. Thu, 07 Jul 2022 09:49:33 GMT https://www.pharmadj.com/ssr/en/article/c11951aafddb11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4fdf54a3fda711eca821fa163e42049a A handful of Chinese drugmakers are developing multi-targeted GLP-1R drugs for diabetes, but Doer Biologics is taking it a step further by developing the world's first GLP-1R/GCGR/FGF21R triple-target agonist. Thu, 07 Jul 2022 03:34:09 GMT https://www.pharmadj.com/ssr/en/article/4fdf54a3fda711eca821fa163e42049a Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/570ca36afd1211eca821fa163e42049a NovoCodex Biopharmaceuticals has raised over RMB400 million in Series B funding from strategic investors such as Lilly Asia Ventures and SDIC. More news from Affinity. Wed, 06 Jul 2022 09:47:46 GMT https://www.pharmadj.com/ssr/en/article/570ca36afd1211eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/14498999fc4811eca821fa163e42049a New Beijing startup Precision Autoimmune Therapeutics that develops innovative drugs for autoimmune diseases has raised RMB140 million ($20.8 million) from angel investors. More news from Brii, TargetRx, Lilly, Ping An-Shionogi. Tue, 05 Jul 2022 09:39:56 GMT https://www.pharmadj.com/ssr/en/article/14498999fc4811eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/c56d1829fb6c11eca821fa163e42049a YZY Biopharma, of Wuhan, raised RMB200 million ($30 million) in Series Pre-C round to advance its bispecific antibodies and COVID vaccine candidates. More news from Zhiyi Biotech, HEP Pharma. Mon, 04 Jul 2022 07:30:04 GMT https://www.pharmadj.com/ssr/en/article/c56d1829fb6c11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/ca68396bfb3f11eca821fa163e42049a After two years of a biotech frenzy in China, entrepreneurs and investors need a cool head to stay afloat and be pragmatic to survive a frosty season. Mon, 04 Jul 2022 02:08:05 GMT https://www.pharmadj.com/ssr/en/article/ca68396bfb3f11eca821fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/8c32a5def90711eca821fa163e42049a Shanghai startup NK CellTech closed a Series A round to raise over RMB100 million ($15 million) to help it advance its NK cell therapy pipeline and R&D. More news from Triastek. Fri, 01 Jul 2022 06:20:07 GMT https://www.pharmadj.com/ssr/en/article/8c32a5def90711eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/458ba42ef84811eca821fa163e42049a Vaccine developer Shanghai Rongsheng Biotech filed for an IPO with Shanghai's STAR board to raise over RMB1.25 billion ($186.7 million) with Essence Securities as its sponsor. More news from Winsunny, Allist, Akeso. Thu, 30 Jun 2022 07:30:55 GMT https://www.pharmadj.com/ssr/en/article/458ba42ef84811eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/dfc3a1c4f83311eca821fa163e42049a The biotech deal making space in May 2022 saw Chinese drugmakers licensing out their assets for as much as a billion dollars. MSD and Turning Point Therapeutics gained China-originated cancer drugs in deals worth $2.63 billion. Thu, 30 Jun 2022 05:04:54 GMT https://www.pharmadj.com/ssr/en/article/dfc3a1c4f83311eca821fa163e42049a Danni.Yin China Deals Tracker https://www.pharmadj.com/ssr/en/article/55fd9c3bf78211eca821fa163e42049a Backed by CICC, Beijing Luzhu Biotechnology filed for an IPO in Hong Kong with plans to spend 40% of the proceeds on LZ901, a herpes zoster vaccine candidate. More news from Visum, Henlius, GenFleet, Bayer, Hengrui. Wed, 29 Jun 2022 07:54:02 GMT https://www.pharmadj.com/ssr/en/article/55fd9c3bf78211eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9c1289faf6c711eca821fa163e42049a Amgen announced a partnership with Fosun Pharma to commercialize Otezla and Parsabiv in mainland China. More news from BMS, Luzhu, LaNova, ImmuneOnco, Clover. Tue, 28 Jun 2022 09:37:24 GMT https://www.pharmadj.com/ssr/en/article/9c1289faf6c711eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4da0f2bdf5eb11eca821fa163e42049a Westlake Therapeutics, an Hangzhou-based biotech company that focuses on red blood cell (RBC)-based therapy, has closed its Series A+ funding led by Efung Capital to raise over RMB100 million ($15 million). More news from Genor, Abogen, Bayer, Innovent. Mon, 27 Jun 2022 07:20:23 GMT https://www.pharmadj.com/ssr/en/article/4da0f2bdf5eb11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/fe941a6ef5c411eca821fa163e42049a Chinese regulators have shared their considerations on selecting drugs for inclusion in state medical insurance, which should give drugmakers food for thought in terms of their strategy. Mon, 27 Jun 2022 02:48:14 GMT https://www.pharmadj.com/ssr/en/article/fe941a6ef5c411eca821fa163e42049a Sarina Yang Regulatory https://www.pharmadj.com/ssr/en/article/747a2cbcf39511eca821fa163e42049a Sino Biopharmaceuticals' subsidiary invoX Pharma acquired Nasdaq-listed biotech firm F-star Therapeutics for $161 million cash at $7.12 per share, as part of the effort to help the Chinese pharma giant dive deep in bispecifics in immunotherapy. Fri, 24 Jun 2022 08:00:29 GMT https://www.pharmadj.com/ssr/en/article/747a2cbcf39511eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/8915af2df2c711eca821fa163e42049a Beijing-based startup Helixon netted nearly RMB500 million ($74 million) in Series A round to lay the groundwork for AI drug discovery. Thu, 23 Jun 2022 07:26:27 GMT https://www.pharmadj.com/ssr/en/article/8915af2df2c711eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d5e6c812f29f11eca821fa163e42049a Companies such as Henlius, OriCell, CStone, Gracell and Junshi presented clinical data from their PD-(L)1, cell therapy and other candidates. Henlius impresses with ES-SCLC data, Junshi boasts BTLA-targeted drug and OriCell flaunts GPRC5D-directed CAR-T Thu, 23 Jun 2022 02:42:16 GMT https://www.pharmadj.com/ssr/en/article/d5e6c812f29f11eca821fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/494a4176f20511eca821fa163e42049a Beijing-based startup JD Biotech said it raised dozens of millions of yuan in Series Pre-A funding to advance its first CAR-NK cell therapy JDC06 into clinical trials. More news from Neurophth, Teligene, Zelgen. Wed, 22 Jun 2022 08:15:58 GMT https://www.pharmadj.com/ssr/en/article/494a4176f20511eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/911ee06ff13d11eca821fa163e42049a Beijing biotech startup Therorna closed a $42 million Series A financing round to help advance its circRNA-based vaccines against SARS-CoV-2 and its variants. More news from Genrix, OcuMension, Innovent. Tue, 21 Jun 2022 08:26:19 GMT https://www.pharmadj.com/ssr/en/article/911ee06ff13d11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/fa3cf319f07211eca821fa163e42049a Backed by CICC, Laekna Therapeutics filed for an IPO in Hong Kong. More news from Connect Pharma. Mon, 20 Jun 2022 08:16:07 GMT https://www.pharmadj.com/ssr/en/article/fa3cf319f07211eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b181331bf04c11eca821fa163e42049a Chinese investors showed more support for young startups in May 2022 as four of them raised over RMB100 million each in early financing rounds, while late-stage drugmakers found fundraising more challenging than ever. Financing activity in May was also the weakest this year, with the least deals and lowest amount. Mon, 20 Jun 2022 03:42:04 GMT https://www.pharmadj.com/ssr/en/article/b181331bf04c11eca821fa163e42049a Yingzi.Shi China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/9efcd9daee1a11eca821fa163e42049a Sihuan Pharmaceutical's subsidiary Xuanzhu Biopharmaceutical has licensed out the rights to two anti-infection drugs, Benapenem and Plazomicin, in Greater China to New Asia Pharmaceutical in a deal worth up to RMB420 million ($62.5 million). More news from Phanes, Takeda. Fri, 17 Jun 2022 08:38:16 GMT https://www.pharmadj.com/ssr/en/article/9efcd9daee1a11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/fe9b60bded5411eca821fa163e42049a SinoMab BioScience said on June 15 that the first patient has been dosed in a phase I first-in-human trial of SM17, a humanized, IgG4-k monoclonal antibody targeting IL-17RB, in the U.S. More news from LP Pharma, WuXi ATU, Wugen. Thu, 16 Jun 2022 09:03:36 GMT https://www.pharmadj.com/ssr/en/article/fe9b60bded5411eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9cbfa810ed2411eca821fa163e42049a Chinese regulators gave their nod to more pediatric medicines in May 2022, a move in line with the country’s commitment to supporting the development of these drugs. Thu, 16 Jun 2022 03:17:16 GMT https://www.pharmadj.com/ssr/en/article/9cbfa810ed2411eca821fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/cb5af56eec9111eca821fa163e42049a Hansoh Pharmaceuticals' partner EQRx said the marketing application for aumolertinib has been accepted by the U.K.'s drug regulators. Wed, 15 Jun 2022 09:46:18 GMT https://www.pharmadj.com/ssr/en/article/cb5af56eec9111eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/7fc885ffebb111eca821fa163e42049a Shanghai Henlius Biotech has licensed out commercialization rights for biosimilar candidates referencing Perjeta and Prolia/Xgeva to Organon except for mainland China, Hong Kong, Macau and Taiwan. More news from Innovent, IASO, Ascletis. Tue, 14 Jun 2022 07:00:44 GMT https://www.pharmadj.com/ssr/en/article/7fc885ffebb111eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/27536105eaf311eca821fa163e42049a META Pharmaceuticals, founded in August 2021, has secured seed and Series Pre-A funding of nearly RMB100 million to move three small molecule drug candidates to clinical trials. More news from Hanwuzhiyuan, NEOMICS, Gracell. Mon, 13 Jun 2022 08:18:12 GMT https://www.pharmadj.com/ssr/en/article/27536105eaf311eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/da4182ffeac211eca821fa163e42049a Shanghai seems to be where pharma giants are concentrating their efforts to find the next top biotech star. Johnson & Johnson, Boehringer Ingelheim, Roche, Eli Lilly, Merck and AstraZeneca have all launched initiatives to incubate or accelerate Chinese biotech startups. Mon, 13 Jun 2022 02:32:24 GMT https://www.pharmadj.com/ssr/en/article/da4182ffeac211eca821fa163e42049a Xu Weijia Feature https://www.pharmadj.com/ssr/en/article/541f818be88611eca821fa163e42049a Aeonvital, of Beijing, has closed a Series Pre-A financing round to advance human trials of its tumor-infiltrating lymphocyte (TIL) therapy candidate and preclinical trials of its therapeutic HPV vaccine. More news from Huixinyigu, Junshi, Everest, BeiGene, BI, Lilly, Luye. Fri, 10 Jun 2022 06:13:49 GMT https://www.pharmadj.com/ssr/en/article/541f818be88611eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/de86b547e7ba11eca821fa163e42049a Degron Therapeutics, of Shanghai, has closed a $22 million Series A round to advance its pipeline and expand the molecular glue protein degradation platform. More news from OnCusp, Multitude, Youngene. Thu, 09 Jun 2022 05:57:24 GMT https://www.pharmadj.com/ssr/en/article/de86b547e7ba11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/1c4ca73ee7a911eca821fa163e42049a Elixiron aims to tackle multiple therapeutic areas by looking into pathways to identify targets that hold promise. Thu, 09 Jun 2022 05:36:47 GMT https://www.pharmadj.com/ssr/en/article/1c4ca73ee7a911eca821fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/6f93b044e6f611eca821fa163e42049a Innovent Biologics said its mazdutide, a GLP-1R/GCGR dual agonist, met the primary and all key secondary endpoints in a phase II study in Chinese participants with overweight or obesity. More news from Xynomic, Kexing. Wed, 08 Jun 2022 06:31:16 GMT https://www.pharmadj.com/ssr/en/article/6f93b044e6f611eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/90c3a4dbe63d11eca821fa163e42049a Hengrui Medicine said it will set up a joint venture with Shengdi Investment to engage in equity investment, investment management and asset management. More news from Insilico, First Condor, Henlius. Tue, 07 Jun 2022 08:27:55 GMT https://www.pharmadj.com/ssr/en/article/90c3a4dbe63d11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/dd054682e57a11eca821fa163e42049a ProfoundBio has raised $70 million in a Series A+ round led by Sequoia China to move two antibody-drug conjugate programs, PRO1184 and PRO1160, into clinical trials. More news from Evive, Lee's Pharma, CStone, Legend, CanSino. Mon, 06 Jun 2022 09:14:11 GMT https://www.pharmadj.com/ssr/en/article/dd054682e57a11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/67a0204fe53711eca821fa163e42049a Clinical trial researchers in Shanghai not only avoided clinical trial delays but also found ways to initiate new trials during a full-scale lockdown for two months. Mon, 06 Jun 2022 01:11:15 GMT https://www.pharmadj.com/ssr/en/article/67a0204fe53711eca821fa163e42049a Donglei Feature https://www.pharmadj.com/ssr/en/article/45690756e23411eca821fa163e42049a Jilin Huisheng Biopharmaceutical, which focuses on diabetes and complications, has closed the first round of financing by way of capital increase from four Series A investors to raise RMB500 million. More news from TOT BIO, Innovent, Walvax, HUTCHMED. Thu, 02 Jun 2022 05:10:59 GMT https://www.pharmadj.com/ssr/en/article/45690756e23411eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4fd9442ee22a11eca821fa163e42049a Tavotek Biotherapeutics wants to take the lead in multispecific biologic therapeutics to tackle hard-to-treat tumors through its homing concept in early drug discovery and three R&D platforms to drive discovery and development. Thu, 02 Jun 2022 03:59:41 GMT https://www.pharmadj.com/ssr/en/article/4fd9442ee22a11eca821fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/ae12f0f5e17611eca821fa163e42049a CStone Pharmaceuticals' shares resumed trading on the Hong Kong Stock Exchange (HKEX) on June 1 after finally announcing audited results and a new chairman. More news from DAC Bio, Volccine, Antengene. Wed, 01 Jun 2022 06:33:50 GMT https://www.pharmadj.com/ssr/en/article/ae12f0f5e17611eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/676fc012e0be11eca821fa163e42049a Xuanzhu Biopharmaceutical and CTTQ-Akeso have formed a partnership to develop combination therapies with Xuanzhu's AXL inhibitor and CTTQ-Akeso's PD-1 monoclonal antibody penpulimab for solid tumors. More news from Walvax, Sirnaomics. Tue, 31 May 2022 08:34:44 GMT https://www.pharmadj.com/ssr/en/article/676fc012e0be11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4858b1f8dff211eca821fa163e42049a GSK said China's NMPA has approved its HPV vaccine Cervarix to be used in girls aged nine to 14, who can receive two doses six months apart. More news from MicroCyto, InxMed. Mon, 30 May 2022 08:13:35 GMT https://www.pharmadj.com/ssr/en/article/4858b1f8dff211eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/77bacc99dfce11eca821fa163e42049a At least 11 Chinese drugmakers are known to be developing a COVID-19 oral drug, but experts believe that regulators will need to look at phase III trials differently to approve a long-awaited homegrown COVID-19 pill Mon, 30 May 2022 03:57:12 GMT https://www.pharmadj.com/ssr/en/article/77bacc99dfce11eca821fa163e42049a Donglei Feature https://www.pharmadj.com/ssr/en/article/b31d9ef5dd9d11eca821fa163e42049a Legend Biotech's Carvykti has been granted conditional marketing authorization by the European Commission for the treatment of adults with relapsed and refractory multiple myeloma. More news from HemaCell, GSK, Gracell, Adagene. Fri, 27 May 2022 09:02:44 GMT https://www.pharmadj.com/ssr/en/article/b31d9ef5dd9d11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/7663c5e6dcba11eca821fa163e42049a Junshi Biosciences has shared more Phase III data of VV116, its COVID-19 oral drug, versus Pfizer's Paxlovid and said the study reached its primary endpoint and secondary efficacy endpoint. More news from Wuxi Biologics, CASI Pharma, Hengrui. Thu, 26 May 2022 05:56:07 GMT https://www.pharmadj.com/ssr/en/article/7663c5e6dcba11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/edce2273dc9a11eca821fa163e42049a From March 2021 to April 2022, there have been seven deals in ophthalmology. Ophthalmic drugs have become an important target of in-licensing deals in China. Thu, 26 May 2022 02:10:23 GMT https://www.pharmadj.com/ssr/en/article/edce2273dc9a11eca821fa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/b06fb828dbf511eca821fa163e42049a Beijing-based GenEditBio has raised dozens of millions of U.S. dollars in angel and Series pre-A funding to develop next-generation gene-editing tools and advance its pipeline. More news from Henlius. Wed, 25 May 2022 06:27:33 GMT https://www.pharmadj.com/ssr/en/article/b06fb828dbf511eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/837a6b2fdb4011eca821fa163e42049a Shanghai Junshi Biosciences' VV116 tablet, an oral nucleoside analog anti-SARS-CoV-2 drug, reached its primary endpoint in a phase III registrational clinical study versus Pfizer's Paxlovid for early treatment of mild to moderate COVID-19. More news from Sinogen, Scindy, WayShine, StarMab Tue, 24 May 2022 08:50:39 GMT https://www.pharmadj.com/ssr/en/article/837a6b2fdb4011eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/388f90adda7b11eca821fa163e42049a The NMPA has approved an expanded use for Novartis' Promacta to treat children aged between 6 and 11 with chronic ITP who have had an insufficient response to glucocorticoids and immunoglobulins. Mon, 23 May 2022 09:18:22 GMT https://www.pharmadj.com/ssr/en/article/388f90adda7b11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4fb130f5da4811eca821fa163e42049a China’s drug regulators are accelerating the development pathway of pediatric and orphan drugs through revised regulations. Biotech companies that focus on developing these drugs will be rewarded with market exclusivity. Mon, 23 May 2022 03:13:54 GMT https://www.pharmadj.com/ssr/en/article/4fb130f5da4811eca821fa163e42049a Elise Mak Regulatory https://www.pharmadj.com/ssr/en/article/838b7bb2d81e11eca821fa163e42049a A year after its launch in Shanghai, Roche China Accelerator said it has identified nine local innovative drugmakers to join efforts with the pharma giant. More news from VerImmune, U-Synbio, Hansoh, ACEA Pharma, CANSino, Bayer. Fri, 20 May 2022 09:09:22 GMT https://www.pharmadj.com/ssr/en/article/838b7bb2d81e11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/41792b72d75411eca821fa163e42049a Chinese pharma giant Hengrui Pharma has launched a new company named Luzsana Biotechnology to co-develop medicines and commercialize them in North America, Europe and Japan. More news from Meton Pharma, CTTQ, Junshi. Thu, 19 May 2022 09:01:32 GMT https://www.pharmadj.com/ssr/en/article/41792b72d75411eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/87a28201d73511eca821fa163e42049a A drugmaker specializing in medicines for children raising nearly $15.7 million in April 2022 shows a shifting interest toward this area. Early-stage biotech companies also made up 18 of the 27 financing deals. Thu, 19 May 2022 05:21:36 GMT https://www.pharmadj.com/ssr/en/article/87a28201d73511eca821fa163e42049a Yingzi.Shi China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/e852efb8d67d11eca821fa163e42049a Laekna Therapeutics, which is developing an AKT kinase inhibitor afuresertib and a CYP17/CYP11B2 dual inhibitor, said it closed a $61 million Series D round to accelerate the clinical development of these two drug candidates. More news from Senlang, CStone, Simcere. Wed, 18 May 2022 07:27:10 GMT https://www.pharmadj.com/ssr/en/article/e852efb8d67d11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/f18a9240d5b211eca821fa163e42049a Shandong Boan Biotechnology, established in 2013 as a subsidiary of Luye Pharma Group, is seeking an IPO in Hong Kong with support from UBS and Essence International to keep advancing its biological drug candidates. More news from MingMed, Immune-Onc, Sinopharm. Tue, 17 May 2022 07:14:18 GMT https://www.pharmadj.com/ssr/en/article/f18a9240d5b211eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/ee3887afd4dd11eca821fa163e42049a Sichuan Kelun Pharmaceutical revealed a deal with MSD worth over $1.4 billion to license out a large molecule drug candidate in oncology for development and commercialization outside Greater China. More news from Starna, Junshi, Gracell, MSD, Biohealthcare, Hengrui Pharma. Mon, 16 May 2022 05:49:30 GMT https://www.pharmadj.com/ssr/en/article/ee3887afd4dd11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/52ff32e2d4c911eca821fa163e42049a April 2022 saw a number of foreign and licensed drugs approved in China, with the majority of them in oncology and rheumatology. Mon, 16 May 2022 03:21:59 GMT https://www.pharmadj.com/ssr/en/article/52ff32e2d4c911eca821fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/acbb585cd28111eca821fa163e42049a Innovo Therapeutics, established in June 2021 with funding from Chinese and U.S. investors, said it has received angel funding of nearly RMB100 million to expand its two targeted protein degradation platforms and advance multiple immuno-oncology programs. More news from Zhaoke, Hengrui. Fri, 13 May 2022 05:43:44 GMT https://www.pharmadj.com/ssr/en/article/acbb585cd28111eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/0c6801f5d1c711eca821fa163e42049a Shanghai's Henlius Biotech has made a deal worth up to $50.5 million with Brazil's Eurofarma to produce and market three of its biosimilars. More news from Greatsun, Ascletis Pharma. Thu, 12 May 2022 07:27:49 GMT https://www.pharmadj.com/ssr/en/article/0c6801f5d1c711eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/a3b8edf4d1b311eca821fa163e42049a China has laid out the pathway to resolve auditing disputes with the U.S. but some bottom lines are drawn, lawyer says Thu, 12 May 2022 05:08:52 GMT https://www.pharmadj.com/ssr/en/article/a3b8edf4d1b311eca821fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/04508c36d10711eca821fa163e42049a Qilu Pharma is seeking clearance from the NMPA to move AB-729 to clinical trials in China. More news from the NMPA. Wed, 11 May 2022 08:33:12 GMT https://www.pharmadj.com/ssr/en/article/04508c36d10711eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b6111503d03911eca821fa163e42049a Brii Biosciences said its long-acting COVID-19 neutralizing antibody therapy retains neutralizing activity against the Omicron BA.2 SARS-CoV-2 subvariant. More news from EPI Genic, CARsgen, ETERN. Tue, 10 May 2022 08:03:33 GMT https://www.pharmadj.com/ssr/en/article/b6111503d03911eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/31aa5d4dcf7511eca821fa163e42049a Shanghai-based Reistone said it has closed a Series A round to raise nearly $100 million. More news from Inxmed, Innovent, Bayer, Santen, BeiGene and GSK. Mon, 09 May 2022 08:36:50 GMT https://www.pharmadj.com/ssr/en/article/31aa5d4dcf7511eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/8786ebb1cf5111eca821fa163e42049a Lawyer says actions of drug originators in the invalidation proceedings will set precedent for patent linkage cases in Chinese courts Mon, 09 May 2022 04:21:32 GMT https://www.pharmadj.com/ssr/en/article/8786ebb1cf5111eca821fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/658b53c4ccfe11eca821fa163e42049a Shanghai's LaNova Medicines inked a $220 million deal with Turning Point Therapeutics to license out its LM-302, an antibody-drug conjugate (ADC) targeting Claudin18.2 that shows promise in gastric and pancreatic cancer. More news from Betta Pharma, CanSino. Fri, 06 May 2022 05:21:05 GMT https://www.pharmadj.com/ssr/en/article/658b53c4ccfe11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/34cbf914cc3e11eca821fa163e42049a Tianjin-based Accendatech said it has closed a Series C round to raise hundreds of millions of yuan to help it advance multiple programs, including ACT001 and ACT004, to fight brain tumor. More news from Resproly, Hansoh Pharma, Nikang Therapeutics, Sinovac Biotech, Hutchmed, Junshi Bio, Connect Bio, Recbio, Zhifei Bio, Gracell Bio, Adagene, I-MAB, Genetron Health, Burning Rock, and Concord Medical. Thu, 05 May 2022 06:25:20 GMT https://www.pharmadj.com/ssr/en/article/34cbf914cc3e11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/916e4380cc1611eca821fa163e42049a The race between Chinese companies to develop an mRNA vaccine for COVID-19 is on, with at least 18 firms in the running. Yet, R&D and mass production issues present hurdles. Thu, 05 May 2022 01:41:35 GMT https://www.pharmadj.com/ssr/en/article/916e4380cc1611eca821fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/d59af2eac78911eca821fa163e42049a The NMPA of China has approved Pfizer's lorlatinib for the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC). More news from BeiGene and Bio-Thera. Fri, 29 Apr 2022 06:43:46 GMT https://www.pharmadj.com/ssr/en/article/d59af2eac78911eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/1681e0ebc6d411eca821fa163e42049a mRNA firm RVAC Medicines said it has closed a Series B round and raised $140 million since its establishment to build an R&D center in Singapore and manufacturing facilities in both Singapore and China. Thu, 28 Apr 2022 09:02:47 GMT https://www.pharmadj.com/ssr/en/article/1681e0ebc6d411eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/fd1706d1c6b811eca821fa163e42049a Several early-stage out-licensing deals inked by Chinese biotech firms to carry their in-house technology platforms and pipelines to the global market marked the dealmaking space of March 2022. Thu, 28 Apr 2022 05:48:48 GMT https://www.pharmadj.com/ssr/en/article/fd1706d1c6b811eca821fa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/f43b368ec60d11eca821fa163e42049a Vivo Capital got RNAi therapeutics player Arrowhead Pharmaceuticals onboard to set up a joint venture called Visirna Therapeutics to develop four candidates for cardiometabolic diseases in Greater China. More news from VITRAC Therapeutics, Antengene. Wed, 27 Apr 2022 09:24:29 GMT https://www.pharmadj.com/ssr/en/article/f43b368ec60d11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/17042005c53f11eca821fa163e42049a Microbiome therapeutics specialist Xbiome has acquired a clinical-stage program from Assembly Biosciences to treat mild to moderate ulcerative colitis. More news from BioKangtai, CantonBio, Sinopharm. Tue, 26 Apr 2022 08:43:42 GMT https://www.pharmadj.com/ssr/en/article/17042005c53f11eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d6a467e4c47811eca821fa163e42049a TG ImmunoPharma, a startup specializing in immuno-oncology, closed a Series Pre-A round to raise hundreds of millions of yuan. More news from Renerval Therapeutics, CTTQ. Mon, 25 Apr 2022 09:04:33 GMT https://www.pharmadj.com/ssr/en/article/d6a467e4c47811eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/7e2704b7c45911eca821fa163e42049a The month of March saw a string of approvals handed out by the NMPA, with the most significant being two domestically developed anti-PD-1 inhibitors getting green lighted to treat MSI-H/dMMR solid tumors in China for the first time ever. Mon, 25 Apr 2022 05:20:10 GMT https://www.pharmadj.com/ssr/en/article/7e2704b7c45911eca821fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/d74251f7c1f611eca821fa163e42049a U.S.-listed I-Mab is said to be exploring options that include a sale of its business, Bloomberg reported, as the company's share price has plummeted over 80% since July 2021. More news from Lee's Pharmaceutical, BeyondSpring and JRSIS. Fri, 22 Apr 2022 04:28:37 GMT https://www.pharmadj.com/ssr/en/article/d74251f7c1f611eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9639e140c13611eca821fa163e42049a Though China still requires that foreign companies seek approval before using human genetic resources (HGR) in their clinical trials, a new regulation is relaxing the definition of ‘foreign entities’ and clarifying when approval is needed. This is intended to make it easier for biotech firms to start clinical trials. Thu, 21 Apr 2022 05:32:24 GMT https://www.pharmadj.com/ssr/en/article/9639e140c13611eca821fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/ef957823c13111eca821fa163e42049a Joseph Romanelli, former CEO of Chinese biotech firm JiXing Pharmaceuticals, will be returning to MSD to lead Human Health International and join the pharma giant’s executive team starting August. More news from Simcere, Innovent Bio, Hengrui Pharma and Junshi. Thu, 21 Apr 2022 04:59:07 GMT https://www.pharmadj.com/ssr/en/article/ef957823c13111eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/52524661c08111eca821fa163e42049a Zhongshan-based Hengsai Biotech said it has closed a Series Pre-A round to raise dozens of millions of yuan to help it develop and manufacture personalized dendritic cell vaccines for cancer treatment. More news from Hongxin. Wed, 20 Apr 2022 07:54:51 GMT https://www.pharmadj.com/ssr/en/article/52524661c08111eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/ce21db59bfb811eca821fa163e42049a Wuhan-based Binhui Bio said it secured another RMB300 million ($47 million) in Series B+ round to help it develop cancer drugs. More news from Bostal Drug, Junshi, Chugai. Tue, 19 Apr 2022 07:59:30 GMT https://www.pharmadj.com/ssr/en/article/ce21db59bfb811eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d036dedbbef311eca821fa163e42049a Jiangsu-based generic maker Vcare PharmaTech is tapping drug innovation after securing nearly $60 million in Series A funding. More news from the NMPA. Mon, 18 Apr 2022 08:29:23 GMT https://www.pharmadj.com/ssr/en/article/d036dedbbef311eca821fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/25c69ae1becf11eca821fa163e42049a As China battles its worst COVID outbreak, investors have turned their attentions to RNA-based therapies again. But this time, companies are flogging their platform technologies rather than specific programs. Mon, 18 Apr 2022 04:06:55 GMT https://www.pharmadj.com/ssr/en/article/25c69ae1becf11eca821fa163e42049a Yingzi.Shi China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/c5ed8148bc9011ecbee6fa163e42049a Beijing Baylx Biotech said it has closed Series B and B+ rounds to raise hundreds of millions of yuan to accelerate the development of stem cell therapeutics. More news from Hiwemed, Naicon, Chengdu PEIDE, Harbour Biomed, MSD, CTTQ and Roche. Fri, 15 Apr 2022 07:57:12 GMT https://www.pharmadj.com/ssr/en/article/c5ed8148bc9011ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9347d6aabbcd11ecbee6fa163e42049a Shanghai biotech JiXing inked a licensing deal with LENZ Therapeutics to gain rights to aceclidine and aceclidine plus brimonidine for presbyopia in Greater China. More news from Novartis and Hengrui Pharma. Thu, 14 Apr 2022 08:39:56 GMT https://www.pharmadj.com/ssr/en/article/9347d6aabbcd11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4e91d00fbba711ecbee6fa163e42049a Experts share their insights in the 2021 report to suggest how regulatory pathways can be streamlined to test combination therapies more efficiently in China. Thu, 14 Apr 2022 04:05:59 GMT https://www.pharmadj.com/ssr/en/article/4e91d00fbba711ecbee6fa163e42049a PharmaDJ Feature https://www.pharmadj.com/ssr/en/article/634961d2bb0711ecbee6fa163e42049a Suzhou Joekai Biotechnology said it has closed a Series B+ financing round to raise tens of millions of yuan to develop drugs for neurological and psychiatric disorders. More news from Legend Biotech, Connect Biopharma, Bayer, BeiGene, Luoxin Pharma, SmartNuclide, APRINOIA Therapeutics, Junshi Biosciences, CanSino Biologics and NanoMicro Tech. Wed, 13 Apr 2022 09:01:15 GMT https://www.pharmadj.com/ssr/en/article/634961d2bb0711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/ddbd7621ba3711ecbee6fa163e42049a China is the latest country to clear abrocitinib for AD, after it was also cleared in the U.S., EU, the U.K., Japan and South Korea. More news from Inventis Bio, BeiGene, Simcere Tue, 12 Apr 2022 08:15:45 GMT https://www.pharmadj.com/ssr/en/article/ddbd7621ba3711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d4522abcb96411ecbee6fa163e42049a Jiaxing-based biotech startup AnDiCon Bio has raised RMB100 million to help it develop an oral drug for COVID that is s improved based on Pfizer's nirmatrelvir. More news from LevoStar, Junshi, Huadong and the CDE. Mon, 11 Apr 2022 07:05:05 GMT https://www.pharmadj.com/ssr/en/article/d4522abcb96411ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/f826a54bb95611ecbee6fa163e42049a Cross-border biotech firm Lianbio believes in sound strategies to brace for the geopolitical tensions and market turmoil, CEO Wang Yizhe told PharmaDJ. Mon, 11 Apr 2022 05:25:52 GMT https://www.pharmadj.com/ssr/en/article/f826a54bb95611ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/86446ebeb71711ecbee6fa163e42049a Rona Therapeutics said it closed a $33 million Series A financing round to build a delivery platform and scalable drug discovery engine to develop modular and programmable medicines. More news from Bohui Bio, ArkBio and Carsgen. Fri, 08 Apr 2022 08:46:27 GMT https://www.pharmadj.com/ssr/en/article/86446ebeb71711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/18fb460cb65311ecbee6fa163e42049a LTZ Therapeutics, with operations in China, the U.S. and Germany, has closed a $17 million Series Pre-A round to develop immunotherapies to treat patients with cancer and other diseases. More news from Harbour BioMed, Everest Medicines, ASK Pharm, Abbvie, Antengene and BeiGene. Thu, 07 Apr 2022 09:20:23 GMT https://www.pharmadj.com/ssr/en/article/18fb460cb65311ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/8e19ebf1b62711ecbee6fa163e42049a Chinese courts suggested for the first time that paying generic makers to delay market launch could result in legal trouble for originators. Thu, 07 Apr 2022 04:08:41 GMT https://www.pharmadj.com/ssr/en/article/8e19ebf1b62711ecbee6fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/b9a281f5b57e11ecbee6fa163e42049a METiS Pharmaceuticals, which uses AI to aid drug discovery and targeted delivery, closed two financing rounds to raise a total of $150 million. More news from Kintor, Raymon, Arthur Group, Innovent, PREGENE, Fosun Pharma, Junshi Biosciences and Legend Biotech. Wed, 06 Apr 2022 08:00:10 GMT https://www.pharmadj.com/ssr/en/article/b9a281f5b57e11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/2f9a3113b17711ecbee6fa163e42049a Shenzhen startup Pleryon Therapeutics, focusing its work on drug delivery, received nearly RMB100 million in a Series Pre-A round. More news from GenFleet, Alphamab, Hengrui, CASI Pharmaceuticals, Sino Biopharm, Junshi Biosciences and CStone. Fri, 01 Apr 2022 04:55:56 GMT https://www.pharmadj.com/ssr/en/article/2f9a3113b17711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/5a584335b0c911ecbee6fa163e42049a mRNA specialist RNAimmune has gained $27 million from a Series A round to support its R&D in mRNA vaccine and drug discovery to tackle infectious diseases, cancer and rare diseases. More news from Artivila Biopharma, Biosion, REC Bio, Merck KGaA, Xynomic Pharma, Keymed Bio and Innovent. Thu, 31 Mar 2022 08:11:35 GMT https://www.pharmadj.com/ssr/en/article/5a584335b0c911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/104ef3fcb0b011ecbee6fa163e42049a China could soon see a stream of foreign and homegrown JAK inhibitors being cleared or tested for atopic dermatitis, as competition among local players is heating up. Thu, 31 Mar 2022 05:10:33 GMT https://www.pharmadj.com/ssr/en/article/104ef3fcb0b011ecbee6fa163e42049a Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/74e73877b00011ecbee6fa163e42049a Chinese biotech RemeGen, known for taking the first approval for a China-developed ADC, reported a revenue of RMB1.4 billion in 2021 thanks to the $200 million upfront payment from Seagen and the sales of two drugs. More news from ChinaGene Tech and TenNor. Wed, 30 Mar 2022 08:13:31 GMT https://www.pharmadj.com/ssr/en/article/74e73877b00011ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/91888093af3111ecbee6fa163e42049a Shanghai biotech GT Apeiron Therapeutics has secured $17.5 million in a Series A round to move its lead CDK7 inhibitor candidate to clinical trials and support a few early-stage programs. More news from CanSinoBIO and Binoji Bio. Tue, 29 Mar 2022 07:32:33 GMT https://www.pharmadj.com/ssr/en/article/91888093af3111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/50cb794aae7011ecbee6fa163e42049a Shenzhen biotech InnoRNA said it closed a $120 million Series B round to continue its research in mRNA-based drugs and explore untapped therapeutic areas. More news from Xinchuan Bio, Bris Pharma, RuoYi Bio, BeiGene, Legend Biotech and Innovent and Eli Lilly. Mon, 28 Mar 2022 08:29:11 GMT https://www.pharmadj.com/ssr/en/article/50cb794aae7011ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4c17a78eae5311ecbee6fa163e42049a China’s CDE has told drugmakers to communicate more with them and will offer guidance for breakthrough therapy applications. Mon, 28 Mar 2022 05:06:41 GMT https://www.pharmadj.com/ssr/en/article/4c17a78eae5311ecbee6fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/356b7da6ac1511ecbee6fa163e42049a Nanjing's Devola Biotech said it has submitted the pre-NDA in the U.S. for its post-surgical pain drug candidate QP001 and expects to file an NDA in the fourth quarter of 2022. More news from Regor, Henlius, Allist, Medinno, Novartis and Takeda. Fri, 25 Mar 2022 08:31:44 GMT https://www.pharmadj.com/ssr/en/article/356b7da6ac1511ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9cd1ec2dab4611ecbee6fa163e42049a Xingmou Biotech, a Hefei-based gene therapy startup specializing in eye diseases, has raised dozens of millions of yuan in a Series pre-A round to support its candidate for wet age-related macular degeneration. More news from JW Therapeutics and Fosun Pharma. Thu, 24 Mar 2022 07:52:52 GMT https://www.pharmadj.com/ssr/en/article/9cd1ec2dab4611ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/722bebf9aa8211ecbee6fa163e42049a SiRNA specialist Argo Biopharma from Shanghai closed a Series A round to secure over RMB400 million ($63 million) to aim at moving its programs to phase I studies in 2023. More news from YISHENG Bio, Atom Bioscience, Ascentage Pharma and CSPC. Wed, 23 Mar 2022 08:28:39 GMT https://www.pharmadj.com/ssr/en/article/722bebf9aa8211ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e03d6ec3aa6711ecbee6fa163e42049a The business director at Deloitte China predicts that Hong Kong would become the world’s largest fundraising hub for biotech companies in the future. However, he warns that the recently approved SPAC route for IPOs is not quite the shortcut many think it is. Wed, 23 Mar 2022 05:18:27 GMT https://www.pharmadj.com/ssr/en/article/e03d6ec3aa6711ecbee6fa163e42049a Donglei Interview https://www.pharmadj.com/ssr/en/article/7eae88d9a9b811ecbee6fa163e42049a Shanghai-based Nuance Pharma has made a $225 million deal with Denmark's Bavarian Nordic to gain the rights to develop and commercialise MVA-BN RSV against respiratory syncytial virus in adults in mainland China, Hong Kong, Macau, Taiwan, South Korea and certain Southeast Asian countries. More news from Transcenta and Daiichi Sankyo. Tue, 22 Mar 2022 08:23:02 GMT https://www.pharmadj.com/ssr/en/article/7eae88d9a9b811ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/ee7dbd4ba8f211ecbee6fa163e42049a Suzhou biotech startup Surio Therapeutics completed a Pre-A round of funding of tens of millions of yuan to advance its Active Tissue Targeting via Anchored ClicK Chemistry (ATTACK) candidate compounds. More news from Simcere, CSPC, Betta Pharma. Mon, 21 Mar 2022 08:48:49 GMT https://www.pharmadj.com/ssr/en/article/ee7dbd4ba8f211ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/ecb845cca8cb11ecbee6fa163e42049a Huadong Medicine announced a series of three in-licensing deals with a combined value of $1.667 billion, pushing the total deal value for February to $1.883 billion, edging over the $1.681 billion the previous month. Mon, 21 Mar 2022 04:09:36 GMT https://www.pharmadj.com/ssr/en/article/ecb845cca8cb11ecbee6fa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/8383b81aa69611ecbee6fa163e42049a Guangzhou biotech Canwell closed a Series A round of RMB200 million ($31.4 million) to advance CAN1012, a TLR7 agonist, in multiple tumor types. More news from Novastage, Bayer, Everest. Fri, 18 Mar 2022 08:42:02 GMT https://www.pharmadj.com/ssr/en/article/8383b81aa69611ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d8c772e8a5cb11ecbee6fa163e42049a Junshi Biosciences said the first patient was dosed in its Phase III trial of VV116 for the treatment of moderate to severe COVID-19. More news from Adagene, EdiGene, Zai Lab and Henlius. Thu, 17 Mar 2022 08:31:17 GMT https://www.pharmadj.com/ssr/en/article/d8c772e8a5cb11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/41b7142fa5b111ecbee6fa163e42049a Some 273 U.S.-listed Chinese stocks could be delisted in the near future. Disclosure regarding governmental entities is needed in their SEC filings right now and a dual listing helps cushion the blow, experts told PharmaDJ. Thu, 17 Mar 2022 05:20:57 GMT https://www.pharmadj.com/ssr/en/article/41b7142fa5b111ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/6f7ff7e6a50111ecbee6fa163e42049a In a deal without disclosing financial terms, China Resources Biopharma has licensed in U.S. firm Ab Studio's ABS-VIR-001, a trispecific antibody developed as a prophylaxis and therapeutic against SARS-CoV-2 infection. More news from 3D Medicines, SinoMab and Gloria. Wed, 16 Mar 2022 08:22:23 GMT https://www.pharmadj.com/ssr/en/article/6f7ff7e6a50111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/7837fcc7a44711ecbee6fa163e42049a Cell therapy and gene therapy companies extended a trend from the second half of 2021 by making up 11 of the 21 financing deals in February. PharmaDJ expects this trend to continue throughout the year. Tue, 15 Mar 2022 10:11:11 GMT https://www.pharmadj.com/ssr/en/article/7837fcc7a44711ecbee6fa163e42049a Yingzi.Shi China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/fac5aef1a43a11ecbee6fa163e42049a Shanghai-based biotech Impact Therapeutics, which develops anti-cancer therapeutics based on synthetic lethality, said it closed a Series D1 round but did not disclose the amount. More news from Gigaceuticals, Innocare, Henlius, Usynova and CanSino. Tue, 15 Mar 2022 08:41:46 GMT https://www.pharmadj.com/ssr/en/article/fac5aef1a43a11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e94c4f34a36c11ecbee6fa163e42049a Suzhou biotech MediLink Therapeutics has closed a $70 million Series B round to support the clinical development of new-generation ADCs. More news from Nutshell Therapeutics, Yuesai Bio, Hansoh Pharma, Sobi, CStone, the NMPA and the CDE. Mon, 14 Mar 2022 08:06:41 GMT https://www.pharmadj.com/ssr/en/article/e94c4f34a36c11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/c66c849aa10b11ecbee6fa163e42049a The SEC's warning sets the clock for BeiGene, Zai Lab and HUTCHMED to meet the U.S. regulations by 2024, prompting BeiGene and Zai Lab to say they are working on a solution. More news from TOT BIOPHARM and Genertec Meheco. Fri, 11 Mar 2022 07:26:03 GMT https://www.pharmadj.com/ssr/en/article/c66c849aa10b11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/3f41af39a0e911ecbee6fa163e42049a With Shanghai as a magnet for investment, the capital flowing into China’s healthcare sector has more than doubled since 2019. Chinese investors are making bigger bets on biotech companies, especially in their early days. Fri, 11 Mar 2022 03:18:54 GMT https://www.pharmadj.com/ssr/en/article/3f41af39a0e911ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/32128c19a04a11ecbee6fa163e42049a KAEDI said it has gained support from Longmen Capital and Kangyuan Huiying for its Series A and Series A+ rounds to accelerate the IND filings for multiple programs in China and the U.S. and initiate proof-of-concept studies. More news from Genevector and Biocytogen. Thu, 10 Mar 2022 08:20:22 GMT https://www.pharmadj.com/ssr/en/article/32128c19a04a11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/99310cc99f6b11ecbee6fa163e42049a Toll Biotech, a startup founded in Beijing in 2020, has added over RMB 100 million ($15.8 million) to its war chest after completing a Series A round to help it develop first-in-class drugs for autoimmune diseases. More news from Kati Medicine, Ascentage and Innovent. Wed, 09 Mar 2022 05:46:57 GMT https://www.pharmadj.com/ssr/en/article/99310cc99f6b11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/2a59cab09f6b11ecbee6fa163e42049a Chinese regulators approved 11 drugs in February. Uses and indications ran a wide gamut, including two drugs for atopic dermatitis and six new molecular entities that were approved for the first time. Wed, 09 Mar 2022 05:43:51 GMT https://www.pharmadj.com/ssr/en/article/2a59cab09f6b11ecbee6fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/3e084dd19eb911ecbee6fa163e42049a HUTCHMED said it is gearing up to initiate a global phase III study for savolitinib plus osimertinib in EGFR-mutated non-small cell lung cancer (NSCLC) patients with MET receptor driven tumors following progression after osimertinib. More news from Salubris and China's NHC. Tue, 08 Mar 2022 08:30:13 GMT https://www.pharmadj.com/ssr/en/article/3e084dd19eb911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/159abcb69de911ecbee6fa163e42049a Jiangsu Qyuns Therapeutics, specializing in immunological and autoimmune diseases, said it has raised hundreds of millions of yuan in a Series C financing round. More news from Betta Pharma and Chinese regulators. Mon, 07 Mar 2022 07:40:10 GMT https://www.pharmadj.com/ssr/en/article/159abcb69de911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b442daa49b8711ecbee6fa163e42049a InxMed was established in 2018 to work on therapies targeting stroma microenvironment as well as solid tumor resistance and metastasis, especially new drug development on anti-PD-1/PD-L1 treatment drug resistance. More news from HUTCHMED, RedCloud Bio and Haisco. Fri, 04 Mar 2022 06:57:51 GMT https://www.pharmadj.com/ssr/en/article/b442daa49b8711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d78489bb9b7611ecbee6fa163e42049a Peking University professor Yao Chen argued that it is wrong to blame the quality of recent clinical trial data in China based on a 2016 report that tells only one side of the story. Fri, 04 Mar 2022 04:57:09 GMT https://www.pharmadj.com/ssr/en/article/d78489bb9b7611ecbee6fa163e42049a Interview https://www.pharmadj.com/ssr/en/article/e0d255cd9abb11ecbee6fa163e42049a Suzhou biotech Adagene signed a $2.5 billion pact with Sanofi to generate masked monoclonal and bispecific antibodies for the French pharma giant to develop and commercialize. More news from Regend Therapeutics, Zhifei, OcuMension and Roche. Thu, 03 Mar 2022 06:38:49 GMT https://www.pharmadj.com/ssr/en/article/e0d255cd9abb11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e45f94699a0311ecbee6fa163e42049a Gene therapy startup Grit Science closed a Series A round that helped it raise hundreds of millions of RMB to develop a hemophilia A therapy candidate. More news from Tasly, Zai Lab, Antengene and Chinese regulators. Wed, 02 Mar 2022 08:41:47 GMT https://www.pharmadj.com/ssr/en/article/e45f94699a0311ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/a3028bfa993c11ecbee6fa163e42049a New startup LMBio said it has raised dozens of millions of dollars in a Series Pre-A round to support its efforts to develop tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. More news from Legend Biotech, CorrGene, Biocytogen, Harbour BioMed, Henlius, Genor Biopharma, Sihuan Pharm and Genevax. Tue, 01 Mar 2022 08:55:28 GMT https://www.pharmadj.com/ssr/en/article/a3028bfa993c11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e5d6167c987311ecbee6fa163e42049a New startup GluBio Pharmaceutical said it has closed a Series A round that raised nearly $50 million to take its interest in molecular glue degraders and undruggable targets further. More news from Brii Biosciences, Lingyi Med, Heidelberg Pharma, Digestome Therapeutics, Luye Pharma, JW Therapeutics, Beigene, and the NMPA. Mon, 28 Feb 2022 08:58:31 GMT https://www.pharmadj.com/ssr/en/article/e5d6167c987311ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/18cc1701985b11ecbee6fa163e42049a The CDE issued a new batch of guidelines that covers the subjects, primary endpoints and design of clinical trials for COVID-19 drugs. The move came six days after the NMPA granted conditional approval for Pfizer's Paxlovid. Mon, 28 Feb 2022 06:00:59 GMT https://www.pharmadj.com/ssr/en/article/18cc1701985b11ecbee6fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/604927b895fc11ecbee6fa163e42049a Abogen appears to be losing momentum in the race to produce a domestic mRNA COVID vaccine with ARCoV, but StemiRNA is catching up with a candidate that can induce “much higher levels” of neutralizing antibodies, co-founder Shen Haifa told PharmaDJ. Fri, 25 Feb 2022 05:37:43 GMT https://www.pharmadj.com/ssr/en/article/604927b895fc11ecbee6fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/5432475695f911ecbee6fa163e42049a Suzhou-based HemaCell raised RMB 100 million ($15.8 million) in a Series pre-A round. The startup was founded in June 2021 in Suzhou to work on stem cell therapy. More news from Haisco, Sirnaomics, Simcere and YolTech. Fri, 25 Feb 2022 05:15:54 GMT https://www.pharmadj.com/ssr/en/article/5432475695f911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/30da929d954e11ecbee6fa163e42049a Pakistani firm Getz Pharma paid Henlius half a million dollars upfront to sell the China-made adalimumab biosimilar in 11 countries in Africa, Asia and Europe. More news from BeiGene and Abbvie. Thu, 24 Feb 2022 08:50:51 GMT https://www.pharmadj.com/ssr/en/article/30da929d954e11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/353dd9c1946911ecbee6fa163e42049a Lepu Biopharma issued 126.8 million shares at HK$7.13 apiece with support from CICC and Morgan Stanley, but the stock traded at HK$6.83 in mid-morning. Its net current assets decreased by 41% to RMB 272 million as of August 2021. More news from the CDE, Huadong Medicine, Odeon Therapeutics and Abogen. Wed, 23 Feb 2022 05:31:44 GMT https://www.pharmadj.com/ssr/en/article/353dd9c1946911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/14aa935e946511ecbee6fa163e42049a To date, siRNA drugs have been approved for liver-released diseases only and Sirnaomics is among the few players that try their hand at oncology. “First things first, siRNA therapeutics is required to go beyond liver related diseases,” CEO Patrick Lu told PharmaDJ. Wed, 23 Feb 2022 05:02:11 GMT https://www.pharmadj.com/ssr/en/article/14aa935e946511ecbee6fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/ea278b8d93b911ecbee6fa163e42049a Imbioray (Hangzhou) Biomedicine said it has completed an RMB 230 million Series A round to advance its first-in-class off-the-shelf allogeneic CAR-NK and NK cell therapy programs to the clinic. More news from Innovent and Applied Pharmaceutical Science. Tue, 22 Feb 2022 08:36:56 GMT https://www.pharmadj.com/ssr/en/article/ea278b8d93b911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/538dca6c92ef11ecbee6fa163e42049a Vaccine developer Hualan Biological Bacterin raised RMB 2.28 billion ($400 million) on the ChiNext market on the Shenzhen Stock Exchange on Feb. 18. More news from Kexing, Starmab, Jigene, Haihe Pharma, Carsgen Therapeutics, Immune-Onc Therapeutics, Dizal Pharmaceutical, CDE and NHC. Mon, 21 Feb 2022 08:26:45 GMT https://www.pharmadj.com/ssr/en/article/538dca6c92ef11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/2d20d4ce92d411ecbee6fa163e42049a January 2022 saw 11 drugs get approval by Chinese drug regulators. JAK inhibitors started the year with momentum, with Eli Lilly's Olumiant, Pfizer's Xeljanz, and AbbVie's Rinvoq filing marketing applications for new indications. Mon, 21 Feb 2022 05:12:24 GMT https://www.pharmadj.com/ssr/en/article/2d20d4ce92d411ecbee6fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/3d941e42909711ecbee6fa163e42049a Innovent Biologics said its IBI306, a recombinant full-human anti-PCSK-9 monoclonal antibody, met primary endpoint in two Chinese registration studies in non-familiar hypercholesterolemia (non-FH) patients at high or very high cardiovascular risk as well as in patients with hypercholesterolemia. More news from RemeGen and the CDE. Fri, 18 Feb 2022 08:50:57 GMT https://www.pharmadj.com/ssr/en/article/3d941e42909711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/672766bb909111ecbee6fa163e42049a Chinese investors continued to show an interest in innovative drugmakers in the New Year with 41 closing a financing round in January. Companies developing cell and gene therapies were at the forefront, receiving 29% of all disclosed funding. Fri, 18 Feb 2022 08:09:10 GMT https://www.pharmadj.com/ssr/en/article/672766bb909111ecbee6fa163e42049a Yingzi.Shi China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/c69d4b3c8fc411ecbee6fa163e42049a AffaMed Therapeutics said the FDA has granted IND approval to its AM712, a bispecific biologic molecule blocking both VEGF and Ang-2 for the treatment of retinal vascular diseases. More news from Ambrx Biopharma. Thu, 17 Feb 2022 07:44:23 GMT https://www.pharmadj.com/ssr/en/article/c69d4b3c8fc411ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d98ca92f8ef911ecbee6fa163e42049a With the LEAPER technology originating from Peking University to make RNA editing safer, EdiGene is working to translate the technology into the clinic with an R&D center and partners in the U.S. as it seeks presence abroad, CEO Wei Dong told PharmaDJ. Wed, 16 Feb 2022 07:31:47 GMT https://www.pharmadj.com/ssr/en/article/d98ca92f8ef911ecbee6fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/98b0798f8ef711ecbee6fa163e42049a TCRCure said it has secured over RMB 300 million from investors to advance and expand its cell therapy pipeline, and to support the simultaneous development of its programs in the U.S. and China. More news from CellOrigin, SciNeuro, Legend Biotech, CellOrigin, SciNeuro, Legend Biotech, Signature Biotech, Neuragen and MingMed. Wed, 16 Feb 2022 07:15:39 GMT https://www.pharmadj.com/ssr/en/article/98b0798f8ef711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e2e05a948e5411ecbee6fa163e42049a Plastech, of Nanjing, said it raised tens of millions of RMB in a Series Pre-A round to advance the R&D pipeline, further upgrade the new drug discovery platform and team building. Tue, 15 Feb 2022 11:50:56 GMT https://www.pharmadj.com/ssr/en/article/e2e05a948e5411ecbee6fa163e42049a PharmaDJ News https://www.pharmadj.com/ssr/en/article/ae7a99168d7511ecbee6fa163e42049a Top news story of today:Pfizer's Covid-19 drug Paxlovid approved in ChinaChina said it gives conditional approval to Pfizer's oral Covid-19 drugs Paxlovid for emergency use based on the foreig Mon, 14 Feb 2022 09:13:10 GMT https://www.pharmadj.com/ssr/en/article/ae7a99168d7511ecbee6fa163e42049a PharmaDJ News https://www.pharmadj.com/ssr/en/article/d95984818d5411ecbee6fa163e42049a In the first month of 2022, 16 licensing deals related to innovative drugs were announced, including eight in-licensing, four out-licensing and four domestic deals. Mon, 14 Feb 2022 05:18:08 GMT https://www.pharmadj.com/ssr/en/article/d95984818d5411ecbee6fa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/16018b298b1e11ecbee6fa163e42049a Chinese drugmakers are warned to communicate more with the agency, adhere to ICH principles and weigh less on competitive pricing in the aftermath of Innovent’s setback. Fri, 11 Feb 2022 09:40:51 GMT https://www.pharmadj.com/ssr/en/article/16018b298b1e11ecbee6fa163e42049a PharmaDJ Feature https://www.pharmadj.com/ssr/en/article/146678a78b1611ecbee6fa163e42049a Innovent Biologics is requested by the FDA's Oncology Drug Advisory Committee to get more data to demonstrate its PD-1 drug sintilimab could work just as well in U.S. patients with NSCLC before the agency hands down a final ruling in March. More news from EdiGene and The National Health Commission of China. Fri, 11 Feb 2022 08:43:32 GMT https://www.pharmadj.com/ssr/en/article/146678a78b1611ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/c8c190f78a1e11ecbee6fa163e42049a As part of its efforts to tap oncology innovation, Huadong Medicine licensed the rights to AKSO Biopharmaceutical's AB002 in the Asia Pacific Ex-Japan region in a deal worth up to $75 million. More news from Grand Pharma, Ucello Therapeutics, EdiGene and Neukio Biotherapeutics. Thu, 10 Feb 2022 03:13:20 GMT https://www.pharmadj.com/ssr/en/article/c8c190f78a1e11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9b2bc800897d11ecbee6fa163e42049a Beijing-based gene editing specialist EdiGene is partnering with U.S. firm Arbor Biotechnologies to gain access to its CRISPR technology in a deal with undisclosed financial terms. More news from Centry Med, Innovent, CSPC, Zhuhai Zhifan, CStone Pharma and GSK. Wed, 09 Feb 2022 07:59:34 GMT https://www.pharmadj.com/ssr/en/article/9b2bc800897d11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4f0e090b896511ecbee6fa163e42049a Chinese authorities are encouraging the use of real-world data in clinical evaluation, easing regulations on human genetic resources, and welcoming more biotech services providers in Shenzhen, according to the policy incentives unveiled last month. Wed, 09 Feb 2022 05:05:39 GMT https://www.pharmadj.com/ssr/en/article/4f0e090b896511ecbee6fa163e42049a Elise Mak Regulatory https://www.pharmadj.com/ssr/en/article/f267578388ba11ecbee6fa163e42049a China-based CRO giant Wuxi Biologics suspended trading in Hong Kong on Tuesday after being added to the unverified list by the U.S. Commerce Department. More news from Gene Cradle, Usynova, Cascade Pharm and CANbridge Pharmaceuticals. Tue, 08 Feb 2022 08:46:09 GMT https://www.pharmadj.com/ssr/en/article/f267578388ba11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e9ffd04e87d811ecbee6fa163e42049a RNA specialist ExoRNA Bio has completed an angel round to raise dozens of millions of yuan to support its R&D and manufacturing of nucleic acid drugs for neurological disorders and anti-viral infectious diseases. More news from Everest Medicines, HanBio Therapeutics, Luzhu Biotech, Genmedicn, Chineo, Otovia Therapeutics, Kangrui Bio, Xbiome and Dizal Pharma. Mon, 07 Feb 2022 05:48:08 GMT https://www.pharmadj.com/ssr/en/article/e9ffd04e87d811ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/49f6a56487d711ecbee6fa163e42049a Raising concerns about core technologies and business continuity, STAR market regulators continued to impose a higher bar for IPOs, rejecting filings from 15 biotech players in 2021. Mon, 07 Feb 2022 05:36:30 GMT https://www.pharmadj.com/ssr/en/article/49f6a56487d711ecbee6fa163e42049a Xu Weijia Feature https://www.pharmadj.com/ssr/en/article/2aafaa4980c111ecbee6fa163e42049a Warm greetings as we move from the year of the ox into the year of the tiger! We will be taking a week off to celebrate the Chinese New Year and we will be back on Feb. 7 to continue our coverage on the biopharma world in China.  Sat, 29 Jan 2022 05:10:05 GMT https://www.pharmadj.com/ssr/en/article/2aafaa4980c111ecbee6fa163e42049a PharmaDJ News https://www.pharmadj.com/ssr/en/article/d1e9407e802211ecbee6fa163e42049a Faced with skepticism over the safety of China’s forerunning mRNA vaccine candidate for COVID-19, Abogen argued that the phase I safety results of ARCoV are comparable to other mRNA vaccines, its chief medical officer told PharmaDJ in an exclusive interview. Fri, 28 Jan 2022 10:16:36 GMT https://www.pharmadj.com/ssr/en/article/d1e9407e802211ecbee6fa163e42049a Interview https://www.pharmadj.com/ssr/en/article/3ae15be4800711ecbee6fa163e42049a Tsingke Biotechnology, of Beijing, said it raised nearly RMB200 million in a Series A round to upgrade its high-throughput, high-capacity and gene synthesis enabling technology platform. More news from Ractigen Therapeutics, Yingli Pharma and Hope Medicine. Fri, 28 Jan 2022 06:59:06 GMT https://www.pharmadj.com/ssr/en/article/3ae15be4800711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/da9ab3aa7f5b11ecbee6fa163e42049a 40 antibody deals were closed at a total value of $14.7 billion in 2021, 22 of them were in-licensing deals and 18 were out-licensing deals. Thu, 27 Jan 2022 10:32:21 GMT https://www.pharmadj.com/ssr/en/article/da9ab3aa7f5b11ecbee6fa163e42049a PharmaDJ Feature https://www.pharmadj.com/ssr/en/article/7bba0d677f3b11ecbee6fa163e42049a Cyan Vaccine has completed an RMB300 million Series A financing round to support the clinical trials of a second-generation COVID-19 vaccine. More news from Everest Medicines, Remegen and Junshi. Thu, 27 Jan 2022 06:40:38 GMT https://www.pharmadj.com/ssr/en/article/7bba0d677f3b11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/f52861017e7611ecbee6fa163e42049a Shanghai-based startup Unogen Biotech said it has raised RMB50 million ($8 million) from angel investors to fund its R&D for cancer therapies. More news from Abogen Biosciences and NCPC. Wed, 26 Jan 2022 07:13:51 GMT https://www.pharmadj.com/ssr/en/article/f52861017e7611ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/367822b27e5211ecbee6fa163e42049a Chinese drug regulators are approving more new drugs and more of them are developed by local players. Wed, 26 Jan 2022 06:08:55 GMT https://www.pharmadj.com/ssr/en/article/367822b27e5211ecbee6fa163e42049a Minhua Chu China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/0e4b0a127db911ecbee6fa163e42049a Shenzhen Tyercan Biopharm said it has raised dozens of millions of yuan to fund the preclinical studies and IND filing of its Tye-1001, a peptide-drug conjugate candidate for oncology. More news from BeiGene, Luye and Boan. Tue, 25 Jan 2022 08:34:28 GMT https://www.pharmadj.com/ssr/en/article/0e4b0a127db911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/538f18bf7cee11ecbee6fa163e42049a Clover Biopharmaceuticals is conducting trials to evaluate its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), as a universal COVID-19 booster vaccine. Mon, 24 Jan 2022 08:23:17 GMT https://www.pharmadj.com/ssr/en/article/538f18bf7cee11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/60cd8dde7cc411ecbee6fa163e42049a The release of good manufacturing practices for cell therapy this year is an important step in regulating cell therapies. Mon, 24 Jan 2022 03:23:00 GMT https://www.pharmadj.com/ssr/en/article/60cd8dde7cc411ecbee6fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/16144a287a9111ecbee6fa163e42049a Leap Therapeutics' anti-DKK1 antibody in combination with BeiGene's anti-PD-1 antibody demonstrated clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients. More news from Eluminex Bio, CTTQ, Neurophth, BeiGene and the CDE. Fri, 21 Jan 2022 08:10:22 GMT https://www.pharmadj.com/ssr/en/article/16144a287a9111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/1076eb9279b311ecbee6fa163e42049a Innovent Biologics is licensing the Greater China rights to up to three enzyme-specific inhibitors from Amagma Therapeutics to strengthen its inflammatory disease portfolio. More news from Pharbers, BioTroy, Biocytogen, Neukio and Hengrui Pharma. Thu, 20 Jan 2022 05:41:04 GMT https://www.pharmadj.com/ssr/en/article/1076eb9279b311ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/38d3dcbb790011ecbee6fa163e42049a Mabwell is the 13th pre-revenue biotech startup listed on STAR. It raised RMB3.477 billion ($547 million) with an offer price of RMB34.8 apiece. It opened at RMB32 then further dropped to RMB24.5 to end the day. Wed, 19 Jan 2022 08:20:52 GMT https://www.pharmadj.com/ssr/en/article/38d3dcbb790011ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/26a6f45c78d211ecbee6fa163e42049a The NMPA’s run of speedy approvals continued in the last month of 2021 as Chinese regulators granted the first marketing approvals to 16 new drugs and accepted NDAs for 11 more new ones. Wed, 19 Jan 2022 02:51:04 GMT https://www.pharmadj.com/ssr/en/article/26a6f45c78d211ecbee6fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/7050ca61782b11ecbee6fa163e42049a Abbisko Therapeutics has inked a pact with Eli Lilly to develop and commercialise novel molecules against an undisclosed target for cardiometabolic diseases. More news from ReviR Therapeutics, Leman and SparX Bio. Tue, 18 Jan 2022 06:57:42 GMT https://www.pharmadj.com/ssr/en/article/7050ca61782b11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/aa268033776911ecbee6fa163e42049a CStone's study provides the only anti-PD-L1 immunotherapy plus chemotherapy option for squamous NSCLC patients worldwide. More news from Junsai, Gracell, BeyondSpring, HISUN, EastChina, Shenogen and Betta. Mon, 17 Jan 2022 07:50:37 GMT https://www.pharmadj.com/ssr/en/article/aa268033776911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/eb3507db775511ecbee6fa163e42049a Several big series A financing in December warrant attention, as they speak of a wider trend for drug innovation in China. Big pharmaceutical companies are sharing risks, and scientists are creating a mRNA platform. Mon, 17 Jan 2022 05:29:16 GMT https://www.pharmadj.com/ssr/en/article/eb3507db775511ecbee6fa163e42049a Yingzi.Shi China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/e79f56b2750611ecbee6fa163e42049a After securing COVID-19 vaccines from Providence Therapeutics, Everest Medicines now gets hold of oral drugs for the coronavirus to shore up its COVID portfolio. More news from REC Bio. Fri, 14 Jan 2022 06:58:37 GMT https://www.pharmadj.com/ssr/en/article/e79f56b2750611ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/077c3fa774fe11ecbee6fa163e42049a Early-stage assets made up half of the licensing deals in 2021, up 10% from the previous year. Fri, 14 Jan 2022 05:55:05 GMT https://www.pharmadj.com/ssr/en/article/077c3fa774fe11ecbee6fa163e42049a Danni.Yin China Deals Tracker https://www.pharmadj.com/ssr/en/article/73417140745711ecbee6fa163e42049a Chinese biotech startups Belief Biomed is one of the few gene therapy players with in-house manufacturing capabilities, and Regor is able to deliver one preclinical candidate in 10 months with its rCARD platform. Thu, 13 Jan 2022 10:02:40 GMT https://www.pharmadj.com/ssr/en/article/73417140745711ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/94f02d68744611ecbee6fa163e42049a Vibrant Therapeutics, a Guangzhou-based startup founded in 2019, closed a Series pre-A round to raise RMB100 million ($15.7 million) to accelerate AI-driven large molecule drug development. More news from Smart Nuclide, Hober Biotech, CStone and the CDE. Thu, 13 Jan 2022 08:01:55 GMT https://www.pharmadj.com/ssr/en/article/94f02d68744611ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/0f5dfc31738511ecbee6fa163e42049a BeiGene aims 10 new molecules in clinic each year from 2024, Zai Lab targets 15+ marketed products across 35+ indications by 2025, RemeGen serves as Seagen’s ADC partner in China, and Legend gets ready for BCMA CAR-T launch. Wed, 12 Jan 2022 08:56:38 GMT https://www.pharmadj.com/ssr/en/article/0f5dfc31738511ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/781c2920737411ecbee6fa163e42049a Coherus and Junshi Biosciences are planning late-stage clinical development of TIGIT-targeted antibody JS006 in combination with toripalimab in North America, and more news from Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics, Fosun Pharma and Insilico Medicine, Kexing Biopharm, Yizun Biomedical, Echo Biotec, Kyowa Kirin, Hisun Pharmaceutical, Betta Pharma, Hengrui Pharma and the CDE. Wed, 12 Jan 2022 06:57:53 GMT https://www.pharmadj.com/ssr/en/article/781c2920737411ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/be23f13772c411ecbee6fa163e42049a Sinovac’s revenue soared 161 times thanks to its COVID-19 vaccine and CanSino is looking into an inhalable vaccine as booster, executives revealed at the 40th Annual J.P. Morgan Health Care Conference on Monday. Tue, 11 Jan 2022 09:59:59 GMT https://www.pharmadj.com/ssr/en/article/be23f13772c411ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/e08a694c72b311ecbee6fa163e42049a Incubated by Legend Capital, Binhu Biotech said it has raised nearly RMB200 million to develop universal cell and gene therapies for oncology, autoimmune diseases, and genetic diseases, and more news from Xellsmart, Youcare, BeiGene, CANbridge, Eli Lilly, JW Therapeutics and Chinese regulators. Tue, 11 Jan 2022 07:59:15 GMT https://www.pharmadj.com/ssr/en/article/e08a694c72b311ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/bd392fed71d911ecbee6fa163e42049a Jiangsu Asieris Pharmaceuticals debuted on the STAR market on Jan. 7, raising RMB 2.528 billion ($396.7 million) by issuing 110 million shares at RMB 22.98 apiece, and more news from Personalized Gene Therapy, CrystalO Bio, TYK Medicines, Zai Lab and the CDE. Mon, 10 Jan 2022 05:57:45 GMT https://www.pharmadj.com/ssr/en/article/bd392fed71d911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b559169b71d911ecbee6fa163e42049a This year, 33 mainland Chinese companies, ranging from drugmakers to CROs, will be addressing to investors and analysts at biotech's biggest annual conference from Jan. 10 to Jan. 13, up from 22 last year. Mon, 10 Jan 2022 05:57:32 GMT https://www.pharmadj.com/ssr/en/article/b559169b71d911ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/e58ea1ca6f8211ecbee6fa163e42049a In November and December 16 and 21 licensing deals were reached, respectively. December boasted the second highest number of deals for the year, including 18 in-licensing deals from overseas, seven out-licensed deals and 12 deals between Chinese pharmaceutical firms. Fri, 07 Jan 2022 06:30:55 GMT https://www.pharmadj.com/ssr/en/article/e58ea1ca6f8211ecbee6fa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/c8c47b416f7e11ecbee6fa163e42049a Suzhou-based startup Viva Star Biosciences has closed a Series A round to raise tens of thousands of U.S. dollars to fight age-related debilitating diseases, and more news from Beihai Biotech, the NMPA and the CDE. Fri, 07 Jan 2022 06:01:28 GMT https://www.pharmadj.com/ssr/en/article/c8c47b416f7e11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/fbcdb8f86ea411ecbee6fa163e42049a Cure Genetics, of Suzhou, said it has closed a $60 million Series B round to advance the clinical development of its cell therapy candidates for hematological and solid tumors, and more news from Accro Bioscience, Atom Bioscience, Sound Biopharmacauticals, MSD, BeiGene, RemeGen, Pfizer, Hengrui Pharma, Connect Biopharma, Eli Lilly, and the CDE. Thu, 06 Jan 2022 04:02:24 GMT https://www.pharmadj.com/ssr/en/article/fbcdb8f86ea411ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/99d90e6b6ea211ecbee6fa163e42049a The new guidelines clarify that some drugs need biomarker testing before prescriptions and listed specific biomarker requirements and recommendations for each drug. Thu, 06 Jan 2022 03:45:20 GMT https://www.pharmadj.com/ssr/en/article/99d90e6b6ea211ecbee6fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/925815b56df311ecbee6fa163e42049a In a deal worth up to hundreds of millions of US dollars, 3SBio licensed out its anti-PD-1 antibody 609A to U.S. firm Syncromune for use with syncrovax immuno-oncology combination therapy worldwide, and more news from Junshi, CytosinLab, ABM Therapeutics, Chance Pharmaceuticals, AffaMed, CStone, Sperogenix and Salubris. Wed, 05 Jan 2022 06:52:26 GMT https://www.pharmadj.com/ssr/en/article/925815b56df311ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/91f7a4596d3d11ecbee6fa163e42049a Shanghai Henlius Biotech is beginning to see strong sales from its trastuzumab biosimilar and wants to take its PD-1 drug abroad. Tue, 04 Jan 2022 09:09:37 GMT https://www.pharmadj.com/ssr/en/article/91f7a4596d3d11ecbee6fa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/1c1677226d3a11ecbee6fa163e42049a Sirnaomics became the last pre-revenue biotech company to list in Hong Kong in 2021. The RNAi player issued 7.54 million shares at HK$65.9 apiece to raise HK$395.7 million ($50.7 million) for advancing its dual TGF-ß1/COX-2 inhibitor, STP705, and more news from Ark, Tasly, Mabwell and Chinese regulators. Tue, 04 Jan 2022 08:44:50 GMT https://www.pharmadj.com/ssr/en/article/1c1677226d3a11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/1abe2390597111ecbee6fa163e42049a The Dec. 10 update of the list included 67 branded drugs with no generic versions for the first time. On average, prices were cut by 61.7% — the biggest since 2017. Tue, 04 Jan 2022 01:02:10 GMT https://www.pharmadj.com/ssr/en/article/1abe2390597111ecbee6fa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/530a229865e911ecbee6fa163e42049a Thank you for your support this year! We will be taking a break from Dec. 27 to Dec. 31 to celebrate the festive season with our family and friends. We will be back online on Jan. 3 to once again keep you informed of the biopharma world in China. Sun, 26 Dec 2021 01:18:27 GMT https://www.pharmadj.com/ssr/en/article/530a229865e911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/cfd29246648a11ecbee6fa163e42049a Shanghai Innogen Pharma has secured $120 million in a Series A round to support the global phase III study of supaglutide, a GLP-1 agonist for diabetes, and more news from Qure Bio, Kawin, Livzon, Mabwell and the CDE. Fri, 24 Dec 2021 07:29:23 GMT https://www.pharmadj.com/ssr/en/article/cfd29246648a11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4b398967647a11ecbee6fa163e42049a SIR-Spheres Y-90 resin microspheres have been used in selective internal radiation therapy in the U.S. for almost two decades. Now they have come to China to treat patients with unresectable liver cancer. Fri, 24 Dec 2021 05:31:08 GMT https://www.pharmadj.com/ssr/en/article/4b398967647a11ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/82c658c563c911ecbee6fa163e42049a Hangzhou HighField Biopharmaceutical has raised over RMB100 million ($15.7 million) in a Series B round to move its mRNA-LNP program to IND and advance its oncology pipeline, and more news from Xbiome, Pfizer, Sanofi and Jemincare. Thu, 23 Dec 2021 09:04:52 GMT https://www.pharmadj.com/ssr/en/article/82c658c563c911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/ca8056ff63a811ecbee6fa163e42049a BeiGene is now looking to support local startups to explore beyond oncology and autoimmune diseases. Its new innovation center in Guangzhou is set to foster a biotech ecosystem that it believes is long overdue. Thu, 23 Dec 2021 04:31:28 GMT https://www.pharmadj.com/ssr/en/article/ca8056ff63a811ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/a4a5397862f511ecbee6fa163e42049a FibroGen said it has exercised an exclusive license option for HiFiBiO’s preclinical anti-CCR8 monoclonal antibody program, HFB1011, and more news from Ji Xing Pharma, Neocura, Bio-Sincerity, CStone, Novartis and Sunshine Guojian and Toray Industries. Wed, 22 Dec 2021 07:09:04 GMT https://www.pharmadj.com/ssr/en/article/a4a5397862f511ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d63d029962d611ecbee6fa163e42049a After launching the first CAR-T therapy on China market, Richard Wang wants to stay on the R&D frontier to push for safer, more affordable and efficacious cell therapies for more patients with the iPSC-CAR-NK technology. To succeed, emphasizing innovation and CMC early on is key, he told PharmaDJ. Wed, 22 Dec 2021 03:28:33 GMT https://www.pharmadj.com/ssr/en/article/d63d029962d611ecbee6fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/c22e512f622911ecbee6fa163e42049a BeiGene will hand out the development and commercialization rights to ociperlimab, a TIGIT inhibitor, in the U.S., Canada and more countries to Novartis, and more news from Frontier Biotech, Bravo Bio, Shanghai Pharma, HITECK biopharma, BioShin, the Center for Food and Drug Inspection of the NMPA. Tue, 21 Dec 2021 06:49:36 GMT https://www.pharmadj.com/ssr/en/article/c22e512f622911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9264b3a1617011ecbee6fa163e42049a Tianti Biotherapeutics, a startup established in Suzhou in early 2021, said it completed an RMB100 million ($15.6 million) Series A round to accelerate the development of biological drugs and the commercialization of its antibody R&D platform, and more news from 20n Bio, Qilu Pharma and the Chinese regulators. Mon, 20 Dec 2021 08:43:59 GMT https://www.pharmadj.com/ssr/en/article/9264b3a1617011ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/6970c6f4614211ecbee6fa163e42049a Japanese pharma company Chugai has a patented drug in China. Two companies are seeking marketing approval for their generics. Now, Chugai can only sue one of them under the new patent linkage system. Mon, 20 Dec 2021 03:13:34 GMT https://www.pharmadj.com/ssr/en/article/6970c6f4614211ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/3493cda05f0d11ecbee6fa163e42049a Verge Genomics has closed a $98 million Series B financing to help advance its neurological disease portfolio into the clinic and expand its drug discovery platform, and more news from Skyline, Denovo, Antengene, Zai Lab, Hansoh, Pfizer, Numab, and Vitalgen BioPharma. Fri, 17 Dec 2021 07:47:27 GMT https://www.pharmadj.com/ssr/en/article/3493cda05f0d11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9ac8db595e4111ecbee6fa163e42049a Shanghai Circode Biomed said it has raised over $20 million from a Series Pre-A round to improve its RNA technology platform, advance its pipeline and build a R&D center in Shanghai, and more news from MindRank AI, Wuxi Biologics, Alphamab. Thu, 16 Dec 2021 07:30:01 GMT https://www.pharmadj.com/ssr/en/article/9ac8db595e4111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/721b50305d7a11ecbee6fa163e42049a Chinese biotech firm BeiGene becomes the world’s first stock to list in the U.S., Hong Kong and mainland China, and more news from Leads Biolabs, Simcere, Legend Biotech, Lupeng Pharmaceutical, Lupeng Pharmaceutical, Ascentage, Antengene and the CDE. Wed, 15 Dec 2021 08:01:54 GMT https://www.pharmadj.com/ssr/en/article/721b50305d7a11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/86fe58e85d7c11ecbee6fa163e42049a Biotech firm BeiGene returned home to mainland China for its third IPO and raised RMB22.2 billion ($3.5 billion) on Shanghai’s STAR market on Dec. 15. Despite its lackluster debut with shares opening 15% lower, its executives promised a rosy outlook by slashing clinical development time and cost by one third. Wed, 15 Dec 2021 07:59:17 GMT https://www.pharmadj.com/ssr/en/article/86fe58e85d7c11ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/d26481e95ca111ecbee6fa163e42049a Qilu Pharmaceutical has licensed in Arbutus Biopharma Corporation's AB-729 for the treatment or prevention of hepatitis B in Greater China, and more news from Hansoh, Biosion, IASO, Innovent, Junshi, Coherus and Antengene. Tue, 14 Dec 2021 05:53:44 GMT https://www.pharmadj.com/ssr/en/article/d26481e95ca111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/94074bf95c8a11ecbee6fa163e42049a Chinese regulators approved six new drugs in November, including the homegrown subcutaneous PD-L1 antibody KN035 (envafolimab) and third-generation BCR-ABL inhibitor HQP135 (olverembatinib). Tue, 14 Dec 2021 03:07:21 GMT https://www.pharmadj.com/ssr/en/article/94074bf95c8a11ecbee6fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/663e6b895bea11ecbee6fa163e42049a Shanghai-based Regor Therapeutics Group and pharma giant Eli Lilly have formed a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders, and more news from Brii Bio, BeiGene, KBP Biosciences, Junshi and the CDE. Mon, 13 Dec 2021 08:00:45 GMT https://www.pharmadj.com/ssr/en/article/663e6b895bea11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/eac2bca5599011ecbee6fa163e42049a In collaboration with the CDE and Tigermed, PharmaDJ provides an English report offering a glimpse of the new drug registration landscape of 2020. Fri, 10 Dec 2021 08:14:55 GMT https://www.pharmadj.com/ssr/en/article/eac2bca5599011ecbee6fa163e42049a PharmaDJ Regulatory https://www.pharmadj.com/ssr/en/article/83098a77598611ecbee6fa163e42049a CANbridge Pharmaceuticals launched an IPO in Hong Kong on Dec. 10 to raise HK$604 million ($77 million) in net proceeds with shares opening 20% lower than the offer price, and more news from Dizal Pharma, Denovo, Yinuoqini, I-Mab and Hengrui. Fri, 10 Dec 2021 07:00:26 GMT https://www.pharmadj.com/ssr/en/article/83098a77598611ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/5521b49958d611ecbee6fa163e42049a Brii Biosciences’ amubarvimab/romlusevimab combination became the first COVID-19 neutralizing antibody therapy approved in China to treat adults and teenagers as young as 12. The company is now testing its combination therapy against Omicron, with results expected within two weeks. Thu, 09 Dec 2021 10:06:55 GMT https://www.pharmadj.com/ssr/en/article/5521b49958d611ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/f1033ae558d511ecbee6fa163e42049a Avistone Pharmaceuticals, of Beijing, said it has received a strategic investment of more than $200 million led by Vivo Capital to support its acquisition of Pearl Biotech to create a fully-integrated targeted oncology platform, and more news from Hengrui, Biosion, Mabwell. Thu, 09 Dec 2021 09:56:30 GMT https://www.pharmadj.com/ssr/en/article/f1033ae558d511ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/3f93661f580611ecbee6fa163e42049a Innovent said improvements in waist circumference, body mass index, blood pressure and lipid levels were observed in type 2 diabetes patients receiving IBI362, and more news from Simcere, Xcovery, Ascentawits, Henlius and Legend Biotech. Wed, 08 Dec 2021 09:09:46 GMT https://www.pharmadj.com/ssr/en/article/3f93661f580611ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/60f9762c57d811ecbee6fa163e42049a Chinese drugmakers raised $1.26 billion in 28 financing rounds in November, representing the third highest amount of funds raised this year. This was mainly attributed to mRNA vaccine maker Abogen Biosciences’ $300 million series C+ round and CNS specialist Ignis Therapeutics’ $180 million series A round. Wed, 08 Dec 2021 03:41:26 GMT https://www.pharmadj.com/ssr/en/article/60f9762c57d811ecbee6fa163e42049a Yingzi.Shi China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/097c47f7573111ecbee6fa163e42049a Hengrui Medicine said its SHR-8854, a MOR agonist, met primary endpoint in a phase III study for the treatment of moderate to severe pain after abdominal surgery, and more news from Brii, Innoforce and RareStone. Tue, 07 Dec 2021 07:43:33 GMT https://www.pharmadj.com/ssr/en/article/097c47f7573111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9f663696565211ecbee6fa163e42049a The expanded EUA made the Lilly/Junshi therapy the first and only authorized neutralizing antibody therapy for emergency use in COVID-19 individuals under the age of 12, and more news from China's CDE. Mon, 06 Dec 2021 05:11:27 GMT https://www.pharmadj.com/ssr/en/article/9f663696565211ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/cb8bb837541311ecbee6fa163e42049a Chinese regulators on Friday released the latest National Reimbursement Drug List (NRDL) to reveal which drugs will be reimbursed in the country’s health care system starting January next year. PD-1/L1 drugs from multinational players are excluded from the list this time. Fri, 03 Dec 2021 08:36:27 GMT https://www.pharmadj.com/ssr/en/article/cb8bb837541311ecbee6fa163e42049a Elise Mak Regulatory https://www.pharmadj.com/ssr/en/article/097637bd540a11ecbee6fa163e42049a BeiGene's siltuximab, licensed in from EUSA Pharma in January 2020, has been granted approval for the treatment of adult patients with idiopathic MCD, and more news from Henlius and Asieris. Fri, 03 Dec 2021 07:26:36 GMT https://www.pharmadj.com/ssr/en/article/097637bd540a11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/f3f2b9b953e511ecbee6fa163e42049a As current tests are not sophisticated enough to measure minimal residual disease (MRD) for solid tumors, precision oncology platform firm Genetron is aiming to develop next-generation sequencing (NGS)-based tumor-informed MRD tests together with AstraZeneca to fill the void in China. Fri, 03 Dec 2021 03:08:18 GMT https://www.pharmadj.com/ssr/en/article/f3f2b9b953e511ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/08c5ea77533711ecbee6fa163e42049a Kidney disease biotech Chinook Therapeutics has set up a joint venture called SanReno Therapeutics with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners Chinam, and more news from BeyondSpring, Everest, Zai Lab and ITabMed. Thu, 02 Dec 2021 06:16:11 GMT https://www.pharmadj.com/ssr/en/article/08c5ea77533711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4bac419a529311ecbee6fa163e42049a In-licensing and going global are the two topics discussed the most in China’s biotech industry today. Zenas BioPharma wants to prove that in-licensing can be a viable strategy when carried out carefully, and a cross-border setup from day one is the key to going global quickly, CEO Mu Hua told PharmaDJ. Wed, 01 Dec 2021 10:44:06 GMT https://www.pharmadj.com/ssr/en/article/4bac419a529311ecbee6fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/94961fe8527611ecbee6fa163e42049a Shanghai Jemincare Pharmaceutical has signed a pact with HUYABIO to license out the exclusive worldwide ex-China rights to the KRAS inhibitor, JMKX1899, and more news from Hengrui, BeiGene and Neoantigen. Wed, 01 Dec 2021 07:18:33 GMT https://www.pharmadj.com/ssr/en/article/94961fe8527611ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/5d62d06451b211ecbee6fa163e42049a Suzhou Abogen Biosciences said it completed a Series C+ round to raise $300 million to accelerate the clinical development of its mRNA COVID-19 vaccine candidate and take it abroad faster, and more news from Sciwind, Ranok, Ablaze, Rorna, Keymed, Simcere and Genetron. Tue, 30 Nov 2021 07:53:59 GMT https://www.pharmadj.com/ssr/en/article/5d62d06451b211ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/af80f92650e911ecbee6fa163e42049a Primary Biotech, established in 2020 in Changzhou, said it completed an angel round to expand its team, upgrade its technology platform and advance its pipeline, and more news from GSK/ViiV Healthcare and Junshi Biosciences. Mon, 29 Nov 2021 07:57:28 GMT https://www.pharmadj.com/ssr/en/article/af80f92650e911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/28bb05b950c811ecbee6fa163e42049a While Chinese regulators have been receiving more IND filings for oncology drugs, treatment targets and indications have been jammed into a few choices, such as PD-1/L1 and VEGFR. Regulators are now trying to turn things around with a top-down approach. Mon, 29 Nov 2021 03:57:28 GMT https://www.pharmadj.com/ssr/en/article/28bb05b950c811ecbee6fa163e42049a PharmaDJ Feature https://www.pharmadj.com/ssr/en/article/1fdb9f4f4e9511ecbee6fa163e42049a Nhwa Pharmaceutical has licensed the Greater China rights to Lundbeck's Lu AF35700, an investigational drug for the treatment of schizophrenia in a deal worth up to RMB114.5 million ($18 million), and more news from Corregene, Ascentage and Alphamab. Fri, 26 Nov 2021 08:46:54 GMT https://www.pharmadj.com/ssr/en/article/1fdb9f4f4e9511ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/3bd6c1fb4e5e11ecbee6fa163e42049a Chinese regulators approved three new molecular entities (NME) in October, including two innovative diabetes drugs. Fri, 26 Nov 2021 02:13:59 GMT https://www.pharmadj.com/ssr/en/article/3bd6c1fb4e5e11ecbee6fa163e42049a Danni.Yin China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/da32d86b4da811ecbee6fa163e42049a BeiGene announced plans to develop 42-acre site in New Jersey to house a new manufacturing campus and clinical R&D center, and more news from Walvax Bio, Boan Biotech and HUTCHMED. Thu, 25 Nov 2021 04:35:36 GMT https://www.pharmadj.com/ssr/en/article/da32d86b4da811ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/17a6e9ed4d9d11ecbee6fa163e42049a Chinese regulators’ recent rejection of Shanghai HaiHe Pharmaceutical’s IPO on the STAR market casts doubts on the in-licensing model. Amid a market slump in the biotech sector, Chinese drugmakers need to think about innovation differently to win back investors’ confidence. Thu, 25 Nov 2021 03:11:25 GMT https://www.pharmadj.com/ssr/en/article/17a6e9ed4d9d11ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/9f2b5a7b4cfc11ecbee6fa163e42049a TenNor Therapeutics, of Suzhou, said it has generated positive top-line results for TNP-2092 from a phase II clinical trial for the treatment of hyperammonemiaor hepatic encephalopathy in patients with liver cirrhosis, and more news from Immunochina. Wed, 24 Nov 2021 08:02:43 GMT https://www.pharmadj.com/ssr/en/article/9f2b5a7b4cfc11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/f275cd864ccf11ecbee6fa163e42049a Shortly after the government of China launched its anti-monopoly bureau, an active pharmaceutical ingredient (API) manufacturer from Nanjing was fined RMB6.58 million ($1 million) for abusing its dominant market position and inflating prices. The swift action has sent a chill down API manufacturers’ spines. Wed, 24 Nov 2021 02:42:56 GMT https://www.pharmadj.com/ssr/en/article/f275cd864ccf11ecbee6fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/2856aed24c2911ecbee6fa163e42049a Cross-border biotech startup Allorion Therapeutics said it has raised $40 million from a Series A round to support preclinical studies and IND filings in China and the U.S. for two small molecule drug programs, and more news from Baidu and Triastek. Tue, 23 Nov 2021 06:49:00 GMT https://www.pharmadj.com/ssr/en/article/2856aed24c2911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/58c6bae14b5311ecbee6fa163e42049a Zenas gained the exclusive worldwide rights from Xencor to develop, manufacture and commercialize bifunctional antibody obexelimab, and more news from CStone, Hengrui, Keymed Biosciences, CSPC, Unicet Biotech, Neurophth, Kelun, Ascletis Pharma, Innovent and Connect Biopharma. Mon, 22 Nov 2021 05:18:29 GMT https://www.pharmadj.com/ssr/en/article/58c6bae14b5311ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/207ecea24b3f11ecbee6fa163e42049a At the 2021 China Cancer Immunotherapy Workshop, Wang Tao from China’s CDE and Jia Yuxia from the U.S. FDA each shared the Chinese and U.S. regulators’ considerations when reviewing new therapies. Wang said the CDE emphasizes clinical value to address unmet medical needs, while Jia explained the FDA’s clinical assessment for cell therapy. Mon, 22 Nov 2021 02:53:45 GMT https://www.pharmadj.com/ssr/en/article/207ecea24b3f11ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/c64943f8491111ecbee6fa163e42049a Tavotek Biotherapeutics has raised $35 million in a Series B round to support the phase I studies of several antibody drugs that are expected to start in early 2022, and more news from Biokin Pharmaceutical, Sinomab, Bio-Thera, Roche and GSK. Fri, 19 Nov 2021 08:23:49 GMT https://www.pharmadj.com/ssr/en/article/c64943f8491111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/23e9da6848e811ecbee6fa163e42049a Chinese drugmakers struck 14 licensing deals in October with five of them exceeding $100 million. Hansoh Pharma announced two big deals worth nearly $2 billion in total to mark its foray into siRNA therapeutics. Fri, 19 Nov 2021 03:25:47 GMT https://www.pharmadj.com/ssr/en/article/23e9da6848e811ecbee6fa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/e13a19d7484211ecbee6fa163e42049a Livzon is the fourth Chinese drugmaker that has licensed out an internally-developed PD-1 candidate to a foreign partner, and more news from BI and Eli Lilly, Comgen Pharma, Leading Tac Pharma and Simcere. Thu, 18 Nov 2021 07:42:48 GMT https://www.pharmadj.com/ssr/en/article/e13a19d7484211ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/09fde601483111ecbee6fa163e42049a Investors from the West are buying into the China biotech story, citing a large market, regulatory reforms and rapid — if not yet genuine — innovation, but they are also aware of what risks lie ahead. Thu, 18 Nov 2021 05:35:06 GMT https://www.pharmadj.com/ssr/en/article/09fde601483111ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/d73163fb477911ecbee6fa163e42049a China's CDE released a report that showed more clinical studies of new drugs initiated by domestic startups, but regulators are concerned about slow clinical progress and inadequate care for young and old patients. Wed, 17 Nov 2021 07:43:42 GMT https://www.pharmadj.com/ssr/en/article/d73163fb477911ecbee6fa163e42049a PharmaDJ Feature https://www.pharmadj.com/ssr/en/article/b48133fc476e11ecbee6fa163e42049a Zenith Epigenetics has out-licensed to Shanghai-based Newsoara Biopharma its lead compound, ZEN-3694, for development and commercialisation rights in Asia excluding Middle East and North Africa, India, and ten Eurasian countries, and more news from AOSAIKANG Pharm, Highlight Pharma and Beigene. Wed, 17 Nov 2021 06:24:00 GMT https://www.pharmadj.com/ssr/en/article/b48133fc476e11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e3acc84c46b711ecbee6fa163e42049a HELP therapeutics has closed a Series C round to raise hundreds of millions of yuan for supporting the clinical trials of its induced pluripotent stem cell (iPSC)-based therapy for heart disease, and more news from Youjia Med, Velavigo and Gluetacs Therapeutics. Tue, 16 Nov 2021 08:35:21 GMT https://www.pharmadj.com/ssr/en/article/e3acc84c46b711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/61c03fb045dd11ecbee6fa163e42049a The NMPA has granted the third indication approval to Janssen's CD38-directed antibody, Darzalex, and more news from Cargene Biopharma. Mon, 15 Nov 2021 06:31:13 GMT https://www.pharmadj.com/ssr/en/article/61c03fb045dd11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d8b1319e438911ecbee6fa163e42049a New CNS-focused startup Ignis Therapeutics gained a strong start with initial funding of $180 million, which is said to be the biggest Series A round by a Chinese drugmaker this year, and more news from Luye Pharma and Hengrui Pharma. Fri, 12 Nov 2021 07:28:00 GMT https://www.pharmadj.com/ssr/en/article/d8b1319e438911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/a0c28dae436e11ecbee6fa163e42049a As vaccination rates continue to rise and therapeutic drugs for COVID-19 are coming to the market, vaccine makers are taking a hit, as reflected by their lackluster financing performance in October. Fri, 12 Nov 2021 05:08:26 GMT https://www.pharmadj.com/ssr/en/article/a0c28dae436e11ecbee6fa163e42049a Yingzi.Shi China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/7f0de72142cc11ecbee6fa163e42049a I-Mab has made an agreement with Jumpcan Pharmaceutical Group to develop, manufacture and commercialise its highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa (TJ101) in mainland China, and more news from EdiGene, Henlius Biotech, Astellas, and Amgen and Profex. Thu, 11 Nov 2021 08:52:35 GMT https://www.pharmadj.com/ssr/en/article/7f0de72142cc11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/c74dffee428e11ecbee6fa163e42049a The data-heavy workshop featured six sessions, ranging from the new horizon and combination strategies of cancer immunotherapy to industry perspectives and regulatory considerations. Thu, 11 Nov 2021 01:30:48 GMT https://www.pharmadj.com/ssr/en/article/c74dffee428e11ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/9b9c257e41f311ecbee6fa163e42049a Zai Lab said it has licensed in two next-generation EGFR inhibitors, BLU-945 and BLU-701, from Blueprint Medicines to develop them as non-small cell lung cancer (NSCLC) treatment in Greater China in a deal worth up to $615 million, and more news from Zai Lab, CStone Pharmaceuticals, Ascentage Pharma, Eli Lilly and Ascletis Pharma. Wed, 10 Nov 2021 07:00:02 GMT https://www.pharmadj.com/ssr/en/article/9b9c257e41f311ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/5cf26124412711ecbee6fa163e42049a Shanghai Zhimeng Biopharma said it raised RMB350 million ($55 million) from a Series B financing round to support the clinical studies of two drug candidates, and more news from Correct Sequence, Ascletis Pharma and Suzhou Alphamab, and Bio-Thera Solutions. Tue, 09 Nov 2021 06:38:00 GMT https://www.pharmadj.com/ssr/en/article/5cf26124412711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b63370de405b11ecbee6fa163e42049a Clover Biopharmaceuticals raised $240 million in Hong Kong stock market on Novermeber 5. However, its shares falled 29.12% in its second trading day after Pfizer announced its oral drug paxlovid cuts risk of hospitalisation and death from COVID-19 by 89%. Mon, 08 Nov 2021 06:20:12 GMT https://www.pharmadj.com/ssr/en/article/b63370de405b11ecbee6fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/dafcc79a3df311ecbee6fa163e42049a The supplemental NDA application is based on the interim analysis of the global randomized, double-blind, multi-center phase III ORIENT-16 clinical trial – which evaluated sintilimab in combination with chemotherapy compared to placebo in combination with chemotherapy as first-line therapy. The trial has met the primary endpoint. Fri, 05 Nov 2021 04:51:30 GMT https://www.pharmadj.com/ssr/en/article/dafcc79a3df311ecbee6fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/64a08fc83d4711ecbee6fa163e42049a China’s CDE released its first technical guidelines for the clinical development of orphan drugs, demonstrating a concrete step by Beijing towards tackling rare diseases. Thu, 04 Nov 2021 08:17:28 GMT https://www.pharmadj.com/ssr/en/article/64a08fc83d4711ecbee6fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/eb7f69983d3111ecbee6fa163e42049a Innovent's application for its PD-1 inhibitor Tyvyt (sintilimab) as the second-line treatment of squamous non-small cell lung cancer was not accepted by the NMPA. Thu, 04 Nov 2021 05:43:16 GMT https://www.pharmadj.com/ssr/en/article/eb7f69983d3111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/586457b83c7111ecbee6fa163e42049a Traditional Chinese medicine producer ZBD Pharmaceutical plans to inject RMB1.7 billion ($266 million) to build a pipeline of antibody-drug conjugates (ADCs) to fight cancer, and more news from Carcell Biopharma. Wed, 03 Nov 2021 06:44:45 GMT https://www.pharmadj.com/ssr/en/article/586457b83c7111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/8dd4c9ab3bb511ecbee6fa163e42049a Lingfang, of Shenzhen, said it completed a Series A round to raise RMB100 million ($15.6 million) to support the clinical development of multiple core programs and expand its pipeline, and more news from Allist Pharmaceuticals, Junshi Biosciences and LianBio. Tue, 02 Nov 2021 08:20:30 GMT https://www.pharmadj.com/ssr/en/article/8dd4c9ab3bb511ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/807b96e93b7f11ecbee6fa163e42049a Eyeing millions of Chinese patients, British pharma giant GSK is pursuing a “China launch first” strategy. Medical science liaisons are now becoming more crucial than ever to help the drugmaker expand its reach in this big market, Pauline Ng, Country Medical Director of GSK China Pharma, told PharmaDJ. Tue, 02 Nov 2021 01:53:34 GMT https://www.pharmadj.com/ssr/en/article/807b96e93b7f11ecbee6fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/5ac6d6b63ad811ecbee6fa163e42049a Lepu Biopharma seeks IPO in Hong Kong to advance its ADC drug candidates and PD-1/L1 inhibitors, and more news from Angitia Biopharmaceuticals and Junshi Biosciences. Mon, 01 Nov 2021 05:57:05 GMT https://www.pharmadj.com/ssr/en/article/5ac6d6b63ad811ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/984829853ac211ecbee6fa163e42049a As companies worldwide pursue innovative drugs, one company is bucking the trend by developing low-cost me-too drugs. EQRx aims to develop affordable drugs with transparent pricing as it believes drug prices matter a lot in health care. Mon, 01 Nov 2021 03:21:19 GMT https://www.pharmadj.com/ssr/en/article/984829853ac211ecbee6fa163e42049a Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/2f5aef16389211ecbee6fa163e42049a China has approved Novo Nordisk's insulin degludec/liraglutide (IDegLira) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on basal insulin, and more news from Hengrui Pharma, Chengda Biotechnology, SINE Pharm, Roche and Shanghai Pharma. Fri, 29 Oct 2021 08:29:31 GMT https://www.pharmadj.com/ssr/en/article/2f5aef16389211ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b1b1b80b37c811ecbee6fa163e42049a Among the 22 deals Chinese drugmakers closed in September, 14 were worth $2.566 billion. Everest Medicines and Innovent Biologics dominated the dealmaking space with deals worth $1.06 billion and $529 million, respectively, representing 62% of the total value of all disclosed deals. Thu, 28 Oct 2021 08:27:11 GMT https://www.pharmadj.com/ssr/en/article/b1b1b80b37c811ecbee6fa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/e9e0003837c111ecbee6fa163e42049a To enrich its vaccine pipeline, Fosun Pharma bought a majority stake in bacterial vaccine developer Chengdu Antejin Biotech for $628 million, and more news from GX Pharma and Lee's Pharm. Thu, 28 Oct 2021 07:38:39 GMT https://www.pharmadj.com/ssr/en/article/e9e0003837c111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b5bdc140370411ecbee6fa163e42049a Signet Therapeutics, of Shenzhen, said it closed an angel+ round to raise nearly $10 million. The proceeds will help move two pipelines to clinical studies and expand its disease models, and more news from I-Mab, Boehringer Ingelheim and HUIYU Pharmceutical. Wed, 27 Oct 2021 09:04:17 GMT https://www.pharmadj.com/ssr/en/article/b5bdc140370411ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/243a7754364111ecbee6fa163e42049a With a clear mind to plan every step ahead, Abbisko has built a comprehensive portfolio in immuno-oncology (IO) to maximize synergy with its precision oncology portfolio. To waste no time, its CEO Xu Yao-Chang told PharmaDJ. Tue, 26 Oct 2021 09:44:21 GMT https://www.pharmadj.com/ssr/en/article/243a7754364111ecbee6fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/6809c9a6363c11ecbee6fa163e42049a Zai Lab reported positive results from a phase 1b proof-of-concept and first-in-human study of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP), and more news from CR Double-Crane, CANbridge Pharmaceuticals, BIOKANGAI and HUAREN. Tue, 26 Oct 2021 09:10:27 GMT https://www.pharmadj.com/ssr/en/article/6809c9a6363c11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e95172b3357011ecbee6fa163e42049a Wyze Biotech raised $21.5 million to support the clinical study of its RC1012, allogenic DNT cells designed to treat relapsed and refractory acute myelogenous leukemia, and more news from Novartis. Mon, 25 Oct 2021 08:53:47 GMT https://www.pharmadj.com/ssr/en/article/e95172b3357011ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/87ba04d5330911ecbee6fa163e42049a Sinotau Pharmaceutical Group said it closed a Series D+ round to raise RMB320 million ($50 million) to support clinical research and development of radiopharmaceuticals, and more news from Luoxin Pharmaceutical, Zai Lab and Antengene. Fri, 22 Oct 2021 07:28:30 GMT https://www.pharmadj.com/ssr/en/article/87ba04d5330911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/f671228532df11ecbee6fa163e42049a Chinese regulators gave their nod to the second domestic CAR-T cell therapy in three months, raising concerns in the market about how companies will make these expensive, advanced treatments more accessible to Chinese patients. The PD-1 frenzy also continued with PD-1 biosimilars. Fri, 22 Oct 2021 02:30:57 GMT https://www.pharmadj.com/ssr/en/article/f671228532df11ecbee6fa163e42049a China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/fe1324b3324911ecbee6fa163e42049a Why was the approval decision so controversial? Has the FDA lowered its normal standards during the review? Wang clarified the questions about the review with data from the published FDA reports. Thu, 21 Oct 2021 08:37:25 GMT https://www.pharmadj.com/ssr/en/article/fe1324b3324911ecbee6fa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/e25cc084323e11ecbee6fa163e42049a After publishing preclinical data of EEDi-5273 in the Journal of Medicinal Chemistry, Ascentage Pharma hopes to move what it believes to be a best-in-class drug to the clinic soon, and more news from Huadong Medicine, Huashen Intelligent Pharma and Lianbio. Thu, 21 Oct 2021 07:17:54 GMT https://www.pharmadj.com/ssr/en/article/e25cc084323e11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/74365788317711ecbee6fa163e42049a With its HIFI screening technology, Berry Oncology has developed one single test to early screen for liver, lung, gastric, colorectal, esophageal and pancreatic cancers. Results unveiled at IBIWS last week showed an overall sensitivity of 87.6%, specificity of 99.1% and overall Tissue of Origin precision in 82% of positive cancers. Wed, 20 Oct 2021 07:30:19 GMT https://www.pharmadj.com/ssr/en/article/74365788317711ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/4b42176d317411ecbee6fa163e42049a The NMPA has approved Chipscreen Biosciences's chiglitazar as a treatment for type 2 diabetes, and more news from Legend Biotech and CTTQ. Wed, 20 Oct 2021 07:07:42 GMT https://www.pharmadj.com/ssr/en/article/4b42176d317411ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/0b268e7930a711ecbee6fa163e42049a WuXi Advanced Therapies (WuXi ATU), a WuXi AppTec subsidiary focused on cell and gene therapy, said its new process development and commercial manufacturing facility opened in Shanghai, and more news from Bio-Thera Solutions, Huahui Health and Innovent. Tue, 19 Oct 2021 06:38:28 GMT https://www.pharmadj.com/ssr/en/article/0b268e7930a711ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/14ccd3822ff211ecbee6fa163e42049a In an ongoing dispute surrounding Abraxane (paclitaxel), a drug that BeiGene licensed from BMS' subsidiary Celgene in 2017, the Chinese drugmaker said it intends to contest "vigorously" the termination proposed by its partner, and more news from GV20 Oncotherapy, HANSOH Pharma, Hengrui Pharma and Anticancer Bioscience. Mon, 18 Oct 2021 09:03:05 GMT https://www.pharmadj.com/ssr/en/article/14ccd3822ff211ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/94f380b42d9e11ecbee6fa163e42049a Takeda's Takecab (vonoprazan), an orally bioavailable potassium-competitive acid blocker (P-CAB), was approved for a new indication in China, and more news from Boan Biotech and Eubulus Biotherapeutics. Fri, 15 Oct 2021 10:00:06 GMT https://www.pharmadj.com/ssr/en/article/94f380b42d9e11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/65b8ad172d6b11ecbee6fa163e42049a Chinese drugmakers closed 33 financing rounds in September, raising over $1.05 billion. Oncolytic virus therapies developer Virogin Biotech and two CAR-T therapy developers were the biggest fundraisers. Fri, 15 Oct 2021 03:53:43 GMT https://www.pharmadj.com/ssr/en/article/65b8ad172d6b11ecbee6fa163e42049a PharmaDJ China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/9cadbc0a2ccc11ecbee6fa163e42049a BioNova Pharmaceuticals gained Sutro Biopharma's STRO-001, a phase I-stage CD74-targeting ADC, to develop and commercialize it in hematologic cancers in Greater China, and more news from Abbisko and Fosun Pharma. Thu, 14 Oct 2021 08:57:05 GMT https://www.pharmadj.com/ssr/en/article/9cadbc0a2ccc11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/1609c6932bf711ecbee6fa163e42049a For the first time, Chinese drugmakers have won more approvals for cancer drugs than their foreign peers, but drug development is too concentrated in oncology and certain targets, regulators said at two recent conferences. Wed, 13 Oct 2021 07:28:36 GMT https://www.pharmadj.com/ssr/en/article/1609c6932bf711ecbee6fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/e8b177da2bf111ecbee6fa163e42049a Hansoh Pharmaceutical Group made a partnership with South Korea's OliX Pharmaceuticals to discover, develop and commercialize siRNA therapeutics in key targeted indications in Greater China, and more news from Sciwind Biosciences and SciClone. Wed, 13 Oct 2021 06:51:33 GMT https://www.pharmadj.com/ssr/en/article/e8b177da2bf111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/8d4c1e672b3811ecbee6fa163e42049a Brii Biosciences has injected $100 million to prepare for the COVID-19 therapy’s launch and will first eye the U.S., China, Brazil, South Africa, Mexico and Argentina, its vice president and head of infectious diseases David Margolis told PharmaDJ. Tue, 12 Oct 2021 08:48:05 GMT https://www.pharmadj.com/ssr/en/article/8d4c1e672b3811ecbee6fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/2f40b6e12b3511ecbee6fa163e42049a Biocytogen taps TRACON to develop CTLA-4 antibody in North America, and more news from China Immunotech, Janssen, Sanofi and BeiGene. Tue, 12 Oct 2021 08:22:02 GMT https://www.pharmadj.com/ssr/en/article/2f40b6e12b3511ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/86e5f2a32a7211ecbee6fa163e42049a Brii seeks EUA for COVID combo therapy BRII-196/BRII-198, and more news from BeBetter Med, CStone and Jinfeng Biotech. Mon, 11 Oct 2021 09:07:12 GMT https://www.pharmadj.com/ssr/en/article/86e5f2a32a7211ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/1b65e59c280c11ecbee6fa163e42049a Chineo raised over $15.5M in an extra pre-B round to advance "super TIL" therapy. More news from Ambrx, Junshi Biosciences, Junshi Biosciences and Leads Biolabs. Fri, 08 Oct 2021 07:48:47 GMT https://www.pharmadj.com/ssr/en/article/1b65e59c280c11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/fbeb2d2b27e111ecbee6fa163e42049a Tony Ren, J.P. Morgan’s new head of Greater China Healthcare Research, predicts that Chinese drugmakers will make more out-licensing deals, generate revenue on the global market, and even start acquiring their foreign peers, he told PharmaDJ. Fri, 08 Oct 2021 05:04:02 GMT https://www.pharmadj.com/ssr/en/article/fbeb2d2b27e111ecbee6fa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/fdcc4a3621c811ecbee6fa163e42049a Cellular Biomedicine Group said it raised a total of $120 million from a Series A to advance C-CAR039 in China and the U.S. and C-CAR088, both CAR-T therapy candidates. Thu, 30 Sep 2021 08:32:59 GMT https://www.pharmadj.com/ssr/en/article/fdcc4a3621c811ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/c935bcc6219611ecbee6fa163e42049a Genelux will receive $11 million upfront and up to $160 million in milestone payments, as well as tiered royalties sales. Thu, 30 Sep 2021 02:33:36 GMT https://www.pharmadj.com/ssr/en/article/c935bcc6219611ecbee6fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/0d92a1eb219611ecbee6fa163e42049a The fund will also be used to incubate cancer pipelines. Thu, 30 Sep 2021 02:28:21 GMT https://www.pharmadj.com/ssr/en/article/0d92a1eb219611ecbee6fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/7341181120e211ecbee6fa163e42049a Chinese drug regulators are making it clear that pediatric drug development is at the top of its agenda with a slew of new regulations. Thu, 30 Sep 2021 01:00:00 GMT https://www.pharmadj.com/ssr/en/article/7341181120e211ecbee6fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/1decfe27210d11ecbee6fa163e42049a AnHeart Therapeutics and Innovent Biologics reported interim clinical data from a phase Ⅱ trial evaluating taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) at the Chinese Society of Clinical Oncology (CSCO) 2021 Annual Meeting on September 25-29, 2021. Wed, 29 Sep 2021 10:08:07 GMT https://www.pharmadj.com/ssr/en/article/1decfe27210d11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e1466dca210c11ecbee6fa163e42049a Bio-Thera Solutions made a pact with Intract Pharma to gain access to Intract’s Soteria and Phloral drug delivery technologies to develop oral monoclonal antibody treatments for chronic gastrointestinal (GI) inflammatory diseases. Wed, 29 Sep 2021 10:06:26 GMT https://www.pharmadj.com/ssr/en/article/e1466dca210c11ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/8d76af1c20e111ecbee6fa163e42049a With its PanFlex engineering technology, BiBo Pharma hopes to ramp up biologics manufacturing in half the time for half the cost to serve biotech startups, CEO told PharmaDJ in an exclusive interview. Wed, 29 Sep 2021 04:56:17 GMT https://www.pharmadj.com/ssr/en/article/8d76af1c20e111ecbee6fa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/93482bef203911ecbee6fa163e42049a The phase II study aimed to evaluate the efficacy and safety of KN046 in combination with nab-paclitaxel/gemcitabine in the first-line treatment of locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma. Tue, 28 Sep 2021 08:53:51 GMT https://www.pharmadj.com/ssr/en/article/93482bef203911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4ba2bca8203911ecbee6fa163e42049a Innovent Biologics obtained the China rights to orismilast, a next-generation PDE4 inhibitor with broad anti-inflammatory properties, from UNION therapeutics in a deal worth up to $267 million. Tue, 28 Sep 2021 08:51:51 GMT https://www.pharmadj.com/ssr/en/article/4ba2bca8203911ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/14756532200111ecbee6fa163e42049a The Series D+ round was led by China Life Equity Investment, followed by Shenzhen Capital Group, China Securities Investment and GF Qianhe. Tue, 28 Sep 2021 02:09:26 GMT https://www.pharmadj.com/ssr/en/article/14756532200111ecbee6fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/7b2409b51f8211ecbee6fa163e42049a The trial was a multi-center, randomized, double-blind, placebo-controlled phase III clinical study to assess the efficacy and safety of Lusutrombopag for the treatment of thrombocytopenia in chronic liver disease (CLD) patients who are scheduled to undergo elective invasive procedures in the Chinese population. Mon, 27 Sep 2021 11:07:12 GMT https://www.pharmadj.com/ssr/en/article/7b2409b51f8211ecbee6fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/d7b44f091f8211ecbee6fa163e42049a The data showed the survival benefit consistent with the global pivotal registration clinical trial and well-tolerated. Mon, 27 Sep 2021 11:05:48 GMT https://www.pharmadj.com/ssr/en/article/d7b44f091f8211ecbee6fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/f13f53ac1f7011ecbee6fa163e42049a ​TriArm Therapeutics said it closed three Series A rounds to raise a total of $60 million to advance next-generation cell therapy development. Mon, 27 Sep 2021 08:57:40 GMT https://www.pharmadj.com/ssr/en/article/f13f53ac1f7011ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b2ab94601f7011ecbee6fa163e42049a Sihuan's subsidiary Xuanzhu Biopharmaceutical has licensed in AXL targeting inhibitor, SLC-391, from SignalChem Lifesciences to develop and commericalise it for cancer in the Greater China region. Mon, 27 Sep 2021 08:55:55 GMT https://www.pharmadj.com/ssr/en/article/b2ab94601f7011ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/7385baca1f7011ecbee6fa163e42049a Ennovabio, of Shanghai, said it has raised tens of millions of U.S dollars in a Series B round to support an ongoing clinical study of a first-in-class anti-inflammatory drug candidate. Mon, 27 Sep 2021 08:54:09 GMT https://www.pharmadj.com/ssr/en/article/7385baca1f7011ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/afeb1f3f1f5711ecbee6fa163e42049a A string of NDA approvals and submissions for PD-1 drugs in August is setting the stage for a price war in China. Regulators approved two homegrown PD-1 antibodies and received more submissions for them Mon, 27 Sep 2021 05:56:53 GMT https://www.pharmadj.com/ssr/en/article/afeb1f3f1f5711ecbee6fa163e42049a Elise Mak China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/48ad798b1d1d11ecbee6fa163e42049a axSpA is a chronic autoimmune diseases Ixekizumab is an inhibitor targeting interleukin 17A (IL-17A) that selectively binds IL-17A and inhibits its interaction with the IL-17 receptor. Fri, 24 Sep 2021 09:53:35 GMT https://www.pharmadj.com/ssr/en/article/48ad798b1d1d11ecbee6fa163e42049a Sarina Yang News https://www.pharmadj.com/ssr/en/article/7425519b1d1611ecbee6fa163e42049a Zai Lab CEO Samantha Du said the company expects "to have more than 15 marketed products in more than 35 indications by 2025." Fri, 24 Sep 2021 09:04:41 GMT https://www.pharmadj.com/ssr/en/article/7425519b1d1611ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/495afc301d1011ecbee6fa163e42049a There were 18 new drug licensing deals in August 2021, the most in eight months. The 12 deals that were publicly disclosed reached a total value of $3.44 billion, representing another record. Fri, 24 Sep 2021 08:26:37 GMT https://www.pharmadj.com/ssr/en/article/495afc301d1011ecbee6fa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/1325a4641cde11ecbee6fa163e42049a ​Everest Medicines and AbCellera entered a multi-year collaboration to discover therapeutic antibodies for up to 10 targets selected by Everest. This is the third deal Everest disclosed in two weeks. Fri, 24 Sep 2021 02:21:07 GMT https://www.pharmadj.com/ssr/en/article/1325a4641cde11ecbee6fa163e42049a News https://www.pharmadj.com/ssr/en/article/27fcea7f1c4211ecbee6fa163e42049a SCB-2019 demonstrated 79% overall efficacy against COVID-19 of any severity caused by the globally dominant Delta variant, 92% against the Gamma variant and 59% against the Mu variant. Thu, 23 Sep 2021 07:45:00 GMT https://www.pharmadj.com/ssr/en/article/27fcea7f1c4211ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e334114f1c4111ecbee6fa163e42049a China's NMPA has accepted the supplemental NDA for Innovent's PD-1 drug sintilimab in combination with chemotherapy as the first-line treatment of esophageal squamous cell carcinoma. Thu, 23 Sep 2021 07:43:05 GMT https://www.pharmadj.com/ssr/en/article/e334114f1c4111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/a8da1b041c4111ecbee6fa163e42049a Ascentage's MDM2-p53 inhibitor alrizomadlin (APG-115) has been granted a fast track designation by the FDA for treating unresectable or metastatic melanoma, relapsed/refractory to prior immuno-oncologic agent treatments. Thu, 23 Sep 2021 07:41:27 GMT https://www.pharmadj.com/ssr/en/article/a8da1b041c4111ecbee6fa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/707ec16c1c1c11ecbee6fa163e42049a China's latest insulin volume-based procurement is poised to change the market value of insulin, paving way for domestic insulin products to enter large hospitals. Thu, 23 Sep 2021 03:25:11 GMT https://www.pharmadj.com/ssr/en/article/707ec16c1c1c11ecbee6fa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/c68d4f021b7f11ecb98afa163e42049a Sugemalimab, as a consolidation therapy, demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus placebo. Wed, 22 Sep 2021 08:39:37 GMT https://www.pharmadj.com/ssr/en/article/c68d4f021b7f11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/8565dc7b1b7f11ecb98afa163e42049a Among 30 efficacy evaluable subjects, 15 of them had confirmed response assessed by independent radiological review committee, with an objective response rate of 50% (95% CI: 31.3%, 68.7%). Wed, 22 Sep 2021 08:37:47 GMT https://www.pharmadj.com/ssr/en/article/8565dc7b1b7f11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/af777b531b7e11ecb98afa163e42049a HighTide Therapeutics has published phase II data of its HTD1801 in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes in Nature Communications. The study met its primary endpoint of reduction in liver fat content. Wed, 22 Sep 2021 08:31:48 GMT https://www.pharmadj.com/ssr/en/article/af777b531b7e11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/4c2f46231b7e11ecb98afa163e42049a Eye disease specialist Arctic Vision has expanded its exclusive license agreement with Eyenovia to develop and commercialise MydCombi in Greater China and South Korea. Wed, 22 Sep 2021 08:29:02 GMT https://www.pharmadj.com/ssr/en/article/4c2f46231b7e11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b1a587401b5511ecb98afa163e42049a China’s NHSA and NHC jointly issued a document calling on regulatory bodies at the local level to normalize NRDL negotiation drugs and to ensure that these meet their clinical needs. Wed, 22 Sep 2021 03:40:53 GMT https://www.pharmadj.com/ssr/en/article/b1a587401b5511ecb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/6270ad45179311ecb98afa163e42049a SciClone has licensed in the Greater China rights to a preclinical-stage product portfolio of miniature drug conjugates that consist of a PI3K inhibitor payload moiety, a linker, and an HSP90 binding moiety. Fri, 17 Sep 2021 08:49:41 GMT https://www.pharmadj.com/ssr/en/article/6270ad45179311ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/17e8150e179311ecb98afa163e42049a The CAR-T therapy developer has raised more than $178 million since its establishment in 2017. Fri, 17 Sep 2021 08:47:36 GMT https://www.pharmadj.com/ssr/en/article/17e8150e179311ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/726bc18e178d11ecb98afa163e42049a Chinese biotech companies raised a total of $2.64 billion from 28 disclosed deals in August. Fri, 17 Sep 2021 08:07:11 GMT https://www.pharmadj.com/ssr/en/article/726bc18e178d11ecb98afa163e42049a Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/65c87fa5178d11ecb98afa163e42049a Everest will pay Suzhou Sinovent and SinoMab BioScience up to $561 million to license the global rights to BTK inhibitor XNW1011, four days after the mRNA transaction with Providence that is worth over $500 million. Fri, 17 Sep 2021 08:06:50 GMT https://www.pharmadj.com/ssr/en/article/65c87fa5178d11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/181120c416d011ecb98afa163e42049a Everest Medicines is the latest to join the course by tapping the mRNA technology, an area that Chinese players are flocking to. Thu, 16 Sep 2021 10:55:38 GMT https://www.pharmadj.com/ssr/en/article/181120c416d011ecb98afa163e42049a Elise Mak Interview https://www.pharmadj.com/ssr/en/article/2471eb1f16cb11ecb98afa163e42049a BeiGene's BTK inhibitor Brukinsa received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (r/r) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. Thu, 16 Sep 2021 08:56:18 GMT https://www.pharmadj.com/ssr/en/article/2471eb1f16cb11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/bf1a363f16ca11ecb98afa163e42049a Cancer drug developer InnoCare, known for its BTK inhibitor Yinuokai (orelabrutinib), is now seeking to raise RMB4 billion ($621 million) on Shanghai's STAR market. Thu, 16 Sep 2021 08:53:27 GMT https://www.pharmadj.com/ssr/en/article/bf1a363f16ca11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/c6ba80a3160711ecb98afa163e42049a Representatives of these players offered their insights to Chinese biotech companies at the South Australia ∙ Clinical Trials Ecosystem – China Event Series zoom webinar on Sep. 13. Wed, 15 Sep 2021 09:37:48 GMT https://www.pharmadj.com/ssr/en/article/c6ba80a3160711ecb98afa163e42049a Elise Mak Feature https://www.pharmadj.com/ssr/en/article/3ebb3b92160411ecb98afa163e42049a Alebund Pharmaceuticals, a renal disease specialist based in Shanghai, has secured $54.5 million in a Series B+ round to support its clinical programs and construction of a manufacturing site. The pro Wed, 15 Sep 2021 09:12:32 GMT https://www.pharmadj.com/ssr/en/article/3ebb3b92160411ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/01028d1b160411ecb98afa163e42049a MingMed, which was founded in October 2019, boasts a pipeline that covers ophthalmology, small molecule immuno-oncology, gene editing-based immunotherapy, medical aesthetics, and pet medicine. Wed, 15 Sep 2021 09:10:48 GMT https://www.pharmadj.com/ssr/en/article/01028d1b160411ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/a945ecd8160311ecb98afa163e42049a Cytovia Therapeutics and its Chinese joint venture CytoLynx Therapeutics have raised $45 million to move their cell therapy candidates to IND stage and support the trials. Wed, 15 Sep 2021 09:08:21 GMT https://www.pharmadj.com/ssr/en/article/a945ecd8160311ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/3bea733a153311ecb98afa163e42049a BeiGene's anti-PD-1 antibody tislelizumab is one step closer to winning BLA approval in the U.S. as a treatment for unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy, after the FDA accepted the application on Sep. 13. Tue, 14 Sep 2021 08:16:22 GMT https://www.pharmadj.com/ssr/en/article/3bea733a153311ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/d3fc64e6153211ecb98afa163e42049a Sichuan Haisco Pharmaceutical has added SM04690 (lorecivivint) to its pipeline from a deal worth up to $140 million with Biosplice Therapeutics. Haisco will have the rights to develop and commercialise the osteoarthritis drug in China by paying $20 million upfront. Tue, 14 Sep 2021 08:13:28 GMT https://www.pharmadj.com/ssr/en/article/d3fc64e6153211ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/ba576388146911ecb98afa163e42049a YZY Biopharma, a bispecific antibody specialist of Wuhan, raised a total of over RMB250 million ($38 million) from two Series B rounds in hopes of supporting the development and manufacturing of its C Mon, 13 Sep 2021 08:13:56 GMT https://www.pharmadj.com/ssr/en/article/ba576388146911ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e34aa74b146811ecb98afa163e42049a PackGene, which specializes in virus-based gene therapy production to provide CDMO services, said its 4,000L adeno-associated virus (AAV) cGMP production base has been put into operation. This represe Mon, 13 Sep 2021 08:07:55 GMT https://www.pharmadj.com/ssr/en/article/e34aa74b146811ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/89eb86b7122e11ecb98afa163e42049a Backed by Sinolink Securities, the company issued 26.45 million shares at RMB38.1 apiece. Fri, 10 Sep 2021 12:04:59 GMT https://www.pharmadj.com/ssr/en/article/89eb86b7122e11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/2958f4fa122e11ecb98afa163e42049a This is one of the two applications that Sanofi submitted for new indication approvals. Fri, 10 Sep 2021 12:02:17 GMT https://www.pharmadj.com/ssr/en/article/2958f4fa122e11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/18f1681a122d11ecb98afa163e42049a Gavreto is Cstone’s first product approved in China and the country’s first selective RET inhibitor. Fri, 10 Sep 2021 11:56:40 GMT https://www.pharmadj.com/ssr/en/article/18f1681a122d11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/af2cd48511ef11ecb98afa163e42049a Chinese drug developers continued to close more financing deals for the fourth consecutive month. Fri, 10 Sep 2021 08:11:39 GMT https://www.pharmadj.com/ssr/en/article/af2cd48511ef11ecb98afa163e42049a PharmaDJ China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/8be103f411ee11ecb98afa163e42049a The new law, set to take effect March 1, 2022, will grant physicians the right to use off-label drugs that could benefit drugmakers. Fri, 10 Sep 2021 04:26:54 GMT https://www.pharmadj.com/ssr/en/article/8be103f411ee11ecb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/05608ebb113811ecb98afa163e42049a Following its deal with Hikma just two weeks ago, Bio-Thera Solutions is selling more rights to its biosimilar products to speed up market entry overseas. Thu, 09 Sep 2021 06:40:20 GMT https://www.pharmadj.com/ssr/en/article/05608ebb113811ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/a042ee49112c11ecb98afa163e42049a XellSmart Bio, a Shanghai-based startup established just this year, has Qiming Venture Partners and Lilly Asia Venture (LAV) on board to support its fight with degenerative diseases by developing larg Thu, 09 Sep 2021 05:18:46 GMT https://www.pharmadj.com/ssr/en/article/a042ee49112c11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/3aa9597b107a11ecb98afa163e42049a Backed by Chinese investors, Cambridge-based biotech RootPath raised nearly $50 million in a Series B round to move a personalized T cell therapy developed from its synthetic immunology platform into the clinic. Wed, 08 Sep 2021 08:01:45 GMT https://www.pharmadj.com/ssr/en/article/3aa9597b107a11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/18adf0c1107a11ecb98afa163e42049a Macao, a special administrative region in Guangdong province, is poised to see more biotech development as Beijing rolled out a new plan to bind the city closer to the mainland in all aspects of life, Wed, 08 Sep 2021 08:00:48 GMT https://www.pharmadj.com/ssr/en/article/18adf0c1107a11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/8070d5170fac11ecb98afa163e42049a Cothera Bioscience, of Beijing, has licensed from Adastra Pharmaceuticals the global rights to zotiraciclib that targets overexpression of the Myc oncogene. Financial terms were not disclosed.Zotiraci Tue, 07 Sep 2021 07:29:06 GMT https://www.pharmadj.com/ssr/en/article/8070d5170fac11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/523266140fa811ecb98afa163e42049a Lilly China said Emgality (galcanezumab), a CGRP antibody to prevent migraine, demonstrated positive results in the global multi-center phase III CGAX study in adult patients. The company is gearing u Tue, 07 Sep 2021 06:59:11 GMT https://www.pharmadj.com/ssr/en/article/523266140fa811ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/2eaf588d0fa211ecb98afa163e42049a CAR-T therapy specialist Innovative Cellular Therapeutics (ICT), of Rockville, has netted $40 million from a Series C round to develop its CoupleCAR platform technology and advance assets to tackle so Tue, 07 Sep 2021 06:15:14 GMT https://www.pharmadj.com/ssr/en/article/2eaf588d0fa211ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/adc59d1f0edb11ecb98afa163e42049a Beijing Mabworks Biotech has inked a pact with pharma giant Jiangsu Hengrui to license out the Greater China rights to its late-stage, third-generation anti-CD20 antibody MIL62.The Beijing firm, now c Mon, 06 Sep 2021 06:34:17 GMT https://www.pharmadj.com/ssr/en/article/adc59d1f0edb11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/45b5dde00edb11ecb98afa163e42049a Merck’s blockbuster drug Keytruda (pembrolizumab) became the first PD-1 drug in China approved to be the first-line therapy of esophageal or gastroesophageal junction (GEJ) cancer, as the NMPA granted Mon, 06 Sep 2021 06:31:23 GMT https://www.pharmadj.com/ssr/en/article/45b5dde00edb11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/928669cf0c8111ecb98afa163e42049a Innovent Biologics, known for its $1 billion PD-1 antibody deal with Eli Lilly and Co., is expanding its portfolio by bringing in a KRAS G12C candidate from Shanghai peer GenFleet. Fri, 03 Sep 2021 06:44:01 GMT https://www.pharmadj.com/ssr/en/article/928669cf0c8111ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/023032f40c7311ecb98afa163e42049a The new Beijing bourse that serves innovative SMEs could be good news for Chinese biotech startups. Fri, 03 Sep 2021 04:59:46 GMT https://www.pharmadj.com/ssr/en/article/023032f40c7311ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/066519100c6411ecb98afa163e42049a Chinese regulators approved JW Therapeutics’ CAR-T therapy relma-cel (relmacabtagene autoleucel) on September 3 morning, just two months after granting the country’s first approval to a CAR-T product. Fri, 03 Sep 2021 03:12:30 GMT https://www.pharmadj.com/ssr/en/article/066519100c6411ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/dca09fec0bdb11ecb98afa163e42049a firm Pegbio is one step closer to going public, as the Shanghai stock exchange has accepted its listing application on the STAR board. Thu, 02 Sep 2021 10:57:49 GMT https://www.pharmadj.com/ssr/en/article/dca09fec0bdb11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/21e1db610bc411ecb98afa163e42049a Junshi Biosciences, the first Chinese company to clear NDA for a homegrown PD-1 drug, is now on its way to score its first U.S. approval. Thu, 02 Sep 2021 08:07:57 GMT https://www.pharmadj.com/ssr/en/article/21e1db610bc411ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/0d6479e10bc111ecb98afa163e42049a The Hong Kong Stock Exchange (HKEX) now sees 38 biotech listings that have raised HK$97 billion (US$12.47 billion) with close to 30 pre-revenue players waiting to go public, the bourse’s executives said Thursday at the Biotech Summit. Thu, 02 Sep 2021 07:47:32 GMT https://www.pharmadj.com/ssr/en/article/0d6479e10bc111ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/c7f890a60b0b11ecb98afa163e42049a Jacobio’s partnership with cell therapy specialist Hebecell signals a new direction in R&D for the Beijing firm known for developing small molecule drugs. Wed, 01 Sep 2021 10:08:19 GMT https://www.pharmadj.com/ssr/en/article/c7f890a60b0b11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/a1c268890aee11ecb98afa163e42049a Xgeva (denosumab) is set to be the next biological drug that faces challenges from a Chinese biosimilar, as Qilu Pharmaceutical submitted the first NDA for its biosimilar candidate. Wed, 01 Sep 2021 06:39:39 GMT https://www.pharmadj.com/ssr/en/article/a1c268890aee11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/e96263d30ae711ecb98afa163e42049a Sinovac could be making over ¥50 billion ($7.7 billion) from its CoronaVac in the first half of this year, financial data from its investor Sino Biopharm suggested. Wed, 01 Sep 2021 05:51:33 GMT https://www.pharmadj.com/ssr/en/article/e96263d30ae711ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/11db04310ad011ecb98afa163e42049a China’s biotech industry saw a dip in deal volume and value for innovative drugs in July after a rebound in the previous month. Chinese biotech companies made a total of 10 deals, with disclosed deal value amounting to over $1.5 billion. Wed, 01 Sep 2021 03:00:53 GMT https://www.pharmadj.com/ssr/en/article/11db04310ad011ecb98afa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/a8657c4a0ace11ecb98afa163e42049a China’s pursuit of innovative oncology drugs has kept Chinese regulators busy in July, as they granted the first marketing approvals to two foreign drugs and accepted NDAs for nine more new ones. Wed, 01 Sep 2021 02:50:46 GMT https://www.pharmadj.com/ssr/en/article/a8657c4a0ace11ecb98afa163e42049a Minhua Chu China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/d41c6e5f0a4311ecb98afa163e42049a China’s PD-1 drug market gets heated up as regulators approved the sixth homegrown drug developed by Gloria Pharmaceuticals and WuXi Biologics, and BMS’s Opdivo (nivolumab) for the fifth indication. Tue, 31 Aug 2021 10:17:00 GMT https://www.pharmadj.com/ssr/en/article/d41c6e5f0a4311ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/2b7ddd7f0a2a11ecb98afa163e42049a Started as a CRO, Biocytogen now intends to be a biotech company with its own pipeline built on its gene-editing technology. Tue, 31 Aug 2021 07:13:19 GMT https://www.pharmadj.com/ssr/en/article/2b7ddd7f0a2a11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/04b8cc4e096d11ecb98afa163e42049a Bio-Thera Solutions has out-licensed the U.S. rights for a ustekinumab biosimilar to Hikma Pharma in a $150 million deal. Mon, 30 Aug 2021 08:39:19 GMT https://www.pharmadj.com/ssr/en/article/04b8cc4e096d11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9fbdf928096c11ecb98afa163e42049a Genuine Biotech raised $100 million in a Series B round to prepare for an IPO in Hong Kong in the first quarter of 2022. Mon, 30 Aug 2021 08:36:30 GMT https://www.pharmadj.com/ssr/en/article/9fbdf928096c11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/617eb4c9096c11ecb98afa163e42049a Akeso is partnering with Pfizer to test PD-1/CTLA-4-targeted cadonilimab in combination with axitinib in advanced or metastatic clear cell renal cell carcinoma (ccRCC). Mon, 30 Aug 2021 08:34:45 GMT https://www.pharmadj.com/ssr/en/article/617eb4c9096c11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/5c4aa635086e11ecb98afa163e42049a ADCs in China tracked by company,licensing,and fundraising. Sun, 29 Aug 2021 02:17:52 GMT https://www.pharmadj.com/ssr/en/article/5c4aa635086e11ecb98afa163e42049a Danni.Yin Feature https://www.pharmadj.com/ssr/en/article/3b8262cb071011ecb98afa163e42049a Innovent taps Bolt Biotherapeutics to develop three immune-stimulating antibody conjugates (ISACs) by paying $5 million upfront. Fri, 27 Aug 2021 08:29:51 GMT https://www.pharmadj.com/ssr/en/article/3b8262cb071011ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/3401e8c3070a11ecb98afa163e42049a After scoring success with zanubrutinib, tislelizumab and pamiparib, Beigene is shifting efforts to novel targets and modalities. It is looking to challenge giants such as J&J, AstraZeneca and AbbVie. Fri, 27 Aug 2021 07:46:42 GMT https://www.pharmadj.com/ssr/en/article/3401e8c3070a11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9136842806e711ecb98afa163e42049a TransThera Biosciences hopes the Hong Kong IPO will help advance its multi-kinase inhibitor TT-00420. Fri, 27 Aug 2021 03:38:46 GMT https://www.pharmadj.com/ssr/en/article/9136842806e711ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/74d17b89063a11ecb98afa163e42049a Viracta paid Salubris $4 million to take back the China rights to tap the big market on its own. Thu, 26 Aug 2021 06:59:35 GMT https://www.pharmadj.com/ssr/en/article/74d17b89063a11ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/9ad36312063711ecb98afa163e42049a Brii Biosciences' COVID-19 neutralising antibody cocktail therapy reduces risk by 78% and offers protection for up to six months. Data by variant type are to come. Thu, 26 Aug 2021 06:40:12 GMT https://www.pharmadj.com/ssr/en/article/9ad36312063711ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/1f69fdde062811ecb98afa163e42049a Fosun reported revenue of over ¥500 million ($77 million) from Comirnaty in Hong Kong and Macau while patiently waiting for China's nod. Thu, 26 Aug 2021 04:53:32 GMT https://www.pharmadj.com/ssr/en/article/1f69fdde062811ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/87c6423a058511ecb98afa163e42049a Ocumension Therapeutics has acquired the China rights of Novartis’ Emadine and Betoptic S in a $35 million deal to step up its game in the ophthalmic drug market. Thu, 26 Aug 2021 02:26:38 GMT https://www.pharmadj.com/ssr/en/article/87c6423a058511ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/b15a86c3058611ecb98afa163e42049a Founded in early 2019, the Suzhou startup has already advanced its COVID-19 vaccine to Phase III trials. Wed, 25 Aug 2021 09:33:16 GMT https://www.pharmadj.com/ssr/en/article/b15a86c3058611ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/66fbad51054a11ecb98afa163e42049a Both events marks the official implementation of China's drug patent linkage system. Wed, 25 Aug 2021 02:21:13 GMT https://www.pharmadj.com/ssr/en/article/66fbad51054a11ecb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/e5d43107054611ecb98afa163e42049a The phase II pivotal clinical trial has reached endpoint. Wed, 25 Aug 2021 01:56:08 GMT https://www.pharmadj.com/ssr/en/article/e5d43107054611ecb98afa163e42049a Elise Mak News https://www.pharmadj.com/ssr/en/article/ed4c675dfeee11ebb98afa163e42049a In the first half of 2021, nine Chinese drug developers completed initial public offerings (IPOs), raising an average of $243.4 million. Mon, 23 Aug 2021 01:04:02 GMT https://www.pharmadj.com/ssr/en/article/ed4c675dfeee11ebb98afa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/cc9dd7e4fbd411ebb98afa163e42049a China Regulation Tracker: Jun 2021. Fri, 13 Aug 2021 01:26:15 GMT https://www.pharmadj.com/ssr/en/article/cc9dd7e4fbd411ebb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/9f961440f64b11ebb98afa163e42049a Three ADCs have been approved by NMPA. Fri, 06 Aug 2021 00:21:31 GMT https://www.pharmadj.com/ssr/en/article/9f961440f64b11ebb98afa163e42049a Feature https://www.pharmadj.com/ssr/en/article/70f2085aeb6611ebb98afa163e42049a three fourths of stocks to rise on the day of approval. Thu, 29 Jul 2021 06:16:34 GMT https://www.pharmadj.com/ssr/en/article/70f2085aeb6611ebb98afa163e42049a Yingzi.Shi Feature https://www.pharmadj.com/ssr/en/article/e70b9d5ef03111ebb98afa163e42049a Nineteen antibody deals were closed in H1 2021. Thu, 29 Jul 2021 06:02:02 GMT https://www.pharmadj.com/ssr/en/article/e70b9d5ef03111ebb98afa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/a6bec51beb7811ebb98afa163e42049a China Market Approval Tracker: Jun 2021 Fri, 23 Jul 2021 06:05:48 GMT https://www.pharmadj.com/ssr/en/article/a6bec51beb7811ebb98afa163e42049a Minhua Chu China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/675b7033eb7b11ebb98afa163e42049a China Biotech Fundraising Tracker: Jun 2021 Fri, 23 Jul 2021 06:05:22 GMT https://www.pharmadj.com/ssr/en/article/675b7033eb7b11ebb98afa163e42049a Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/0df8df52eb7a11ebb98afa163e42049a China Licensing Deals Tracker: Jun 2021 Fri, 23 Jul 2021 05:55:42 GMT https://www.pharmadj.com/ssr/en/article/0df8df52eb7a11ebb98afa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/0f7ead92e85211ebb98afa163e42049a On June 22, NMPA green-lighted Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B cell lymphoma. Mon, 19 Jul 2021 05:31:51 GMT https://www.pharmadj.com/ssr/en/article/0f7ead92e85211ebb98afa163e42049a News https://www.pharmadj.com/ssr/en/article/d850caece85011ebb98afa163e42049a "The NMPA stands in the international arena with clear goals and intentions and will actively participate in the ICH’s international affairs in the future." Mon, 19 Jul 2021 05:23:09 GMT https://www.pharmadj.com/ssr/en/article/d850caece85011ebb98afa163e42049a Minhua Chu News https://www.pharmadj.com/ssr/en/article/17c6aaade85011ebb98afa163e42049a Improve the system of laws and regulations. Speed up their formulation and revision and advance technical guidelines in an orderly manner. Mon, 19 Jul 2021 05:16:44 GMT https://www.pharmadj.com/ssr/en/article/17c6aaade85011ebb98afa163e42049a Feature https://www.pharmadj.com/ssr/en/article/b7a34138e84f11ebb98afa163e42049a On July 1, 2020, the latest Drug Registration Regulations were enacted. This new set of regulations introduced four accelerated procedures for BTDs therapy, conditional approval, priority review and approval, and special approval. Mon, 19 Jul 2021 05:14:28 GMT https://www.pharmadj.com/ssr/en/article/b7a34138e84f11ebb98afa163e42049a Feature https://www.pharmadj.com/ssr/en/article/d061dfa3e84e11ebb98afa163e42049a Recently, the National Medical Products Administration issued regulations for post-approval changes in medicinal products (for pilot implementation). Mon, 19 Jul 2021 05:07:35 GMT https://www.pharmadj.com/ssr/en/article/d061dfa3e84e11ebb98afa163e42049a News https://www.pharmadj.com/ssr/en/article/33dae8b4e84e11ebb98afa163e42049a As a weathervane of China Biotech, CES HK Biotechnology Index (CES HK Biotech) roseby 9.51% in January, By comparison, A-shares of the China Securities Medicine Index has been rising at 5.02%, the Shanghai and Shenzhen 300 Index had a growth rate at 2.7% and the Hang Seng Index (HSI) had a 3.87% growth. Mon, 19 Jul 2021 05:04:14 GMT https://www.pharmadj.com/ssr/en/article/33dae8b4e84e11ebb98afa163e42049a Feature https://www.pharmadj.com/ssr/en/article/6a69cb78e84b11ebb98afa163e42049a China Biotech Fundraising Tracker: May 2021 Mon, 19 Jul 2021 04:44:17 GMT https://www.pharmadj.com/ssr/en/article/6a69cb78e84b11ebb98afa163e42049a Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/2d228e16e84b11ebb98afa163e42049a China Regulation Tracker: May 2021. Mon, 19 Jul 2021 04:42:35 GMT https://www.pharmadj.com/ssr/en/article/2d228e16e84b11ebb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/abd3b0e9e84a11ebb98afa163e42049a Now, oncology is the hot field in drug development. Therefore, the CDE wants to guide clincial development through the document, emphasis the concept of clincial value-oriented, and implement the ICH PFDD guidelines through the document. Mon, 19 Jul 2021 04:38:58 GMT https://www.pharmadj.com/ssr/en/article/abd3b0e9e84a11ebb98afa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/5919946fe84a11ebb98afa163e42049a LianBio Acquires Three Potential FIC Therapies for Cancer and IBD. Mon, 19 Jul 2021 04:36:39 GMT https://www.pharmadj.com/ssr/en/article/5919946fe84a11ebb98afa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/c4917bcee84911ebb98afa163e42049a The NMPA Grants Three Orphan Drugs Market Approval. Mon, 19 Jul 2021 04:32:30 GMT https://www.pharmadj.com/ssr/en/article/c4917bcee84911ebb98afa163e42049a Minhua Chu China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/75431a71e84911ebb98afa163e42049a The amounts to a total increase of 32.67% from 2019 despite the pandemic. Mon, 19 Jul 2021 04:30:17 GMT https://www.pharmadj.com/ssr/en/article/75431a71e84911ebb98afa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/e711cb1fe84811ebb98afa163e42049a Investors Pursuing More Opportunities With mRNA Technology. Mon, 19 Jul 2021 04:26:18 GMT https://www.pharmadj.com/ssr/en/article/e711cb1fe84811ebb98afa163e42049a Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/9c57f07fe84811ebb98afa163e42049a The COVID-19 Pandemic Sparks New Healthcare Reform Measures in China. Mon, 19 Jul 2021 04:24:13 GMT https://www.pharmadj.com/ssr/en/article/9c57f07fe84811ebb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/4be103eee84811ebb98afa163e42049a CANbridge Secures Two In-Licensing Deals for Rare Disease Therapies. Mon, 19 Jul 2021 04:21:58 GMT https://www.pharmadj.com/ssr/en/article/4be103eee84811ebb98afa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/f7a320a5e84711ebb98afa163e42049a NMPA Expands Three PD-1(L1) Antibodies to Key Patient Populations in China. Mon, 19 Jul 2021 04:19:36 GMT https://www.pharmadj.com/ssr/en/article/f7a320a5e84711ebb98afa163e42049a Minhua Chu China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/9f9dcf0be84711ebb98afa163e42049a AffaMed and Brii Bio Rake in Massive Series B and Series C Investments. Mon, 19 Jul 2021 04:17:09 GMT https://www.pharmadj.com/ssr/en/article/9f9dcf0be84711ebb98afa163e42049a Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/25090c29e84711ebb98afa163e42049a Leaders Endorse Volume-Based Procurement at China's Annual "Two Sessions" Mon, 19 Jul 2021 04:13:43 GMT https://www.pharmadj.com/ssr/en/article/25090c29e84711ebb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/d8111923e84411ebb98afa163e42049a In-Licensing Deals Bring New Acid Reflux and Ophthalmic Treatments in to China Mon, 19 Jul 2021 03:57:15 GMT https://www.pharmadj.com/ssr/en/article/d8111923e84411ebb98afa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/73c715d9e84411ebb98afa163e42049a New Cancer & SLE Drugs Gain Market Approval in China Mon, 19 Jul 2021 03:54:27 GMT https://www.pharmadj.com/ssr/en/article/73c715d9e84411ebb98afa163e42049a Minhua Chu China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/1db508b3e84411ebb98afa163e42049a China's Fourth Batchs of VBP Sees Massive Drug Price Reductions Mon, 19 Jul 2021 03:52:02 GMT https://www.pharmadj.com/ssr/en/article/1db508b3e84411ebb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/0417f5afe84311ebb98afa163e42049a Junshi, Coherus Sign Deal Bringing New Cancer Drug to North America. Mon, 19 Jul 2021 03:44:10 GMT https://www.pharmadj.com/ssr/en/article/0417f5afe84311ebb98afa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/944f6a12e84211ebb98afa163e42049a Six NMEs Get Market Approval in China. Mon, 19 Jul 2021 03:41:02 GMT https://www.pharmadj.com/ssr/en/article/944f6a12e84211ebb98afa163e42049a Minhua Chu China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/2392476ae84211ebb98afa163e42049a Its nonsteroidal antiandrogen candidate proxalutamide reduced mortality risk by 92% and shortened the median length of hospital stays by nine days, according to an investigator-initiated trial conducted in Brazil. Mon, 19 Jul 2021 03:37:53 GMT https://www.pharmadj.com/ssr/en/article/2392476ae84211ebb98afa163e42049a Minhua Chu Feature https://www.pharmadj.com/ssr/en/article/484e8140e84111ebb98afa163e42049a Together, 18 of them reported deals that totaled more than $683 million USD. Two companies raised over $100 million USD alone: VISEN Pharmaceuticals and Abbisko Therapeutics. Mon, 19 Jul 2021 03:31:45 GMT https://www.pharmadj.com/ssr/en/article/484e8140e84111ebb98afa163e42049a Minhua Chu China Biotech Fundraising Tracker https://www.pharmadj.com/ssr/en/article/aaf97b0ce84011ebb98afa163e42049a Biosimiars will be included in VBP. Mon, 19 Jul 2021 03:27:21 GMT https://www.pharmadj.com/ssr/en/article/aaf97b0ce84011ebb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/f0b1e281e83f11ebb98afa163e42049a China's biopharmaceutical industry completed a dozen licensing deals in the first month of 2021, continuing its 2020 trend of cross-the-border hot licensing deals. Mon, 19 Jul 2021 03:22:09 GMT https://www.pharmadj.com/ssr/en/article/f0b1e281e83f11ebb98afa163e42049a Minhua Chu China Deals Tracker https://www.pharmadj.com/ssr/en/article/91c09dfce83f11ebb98afa163e42049a Takeda、Beigene、Antengene Mon, 19 Jul 2021 03:19:29 GMT https://www.pharmadj.com/ssr/en/article/91c09dfce83f11ebb98afa163e42049a Minhua Chu China NMPA Approval Tracker https://www.pharmadj.com/ssr/en/article/cef9314ae83c11ebb98afa163e42049a MAH has the main responsibilities Pharmaceutical Sales Representative. Mon, 19 Jul 2021 02:59:44 GMT https://www.pharmadj.com/ssr/en/article/cef9314ae83c11ebb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/e4af3f7be83911ebb98afa163e42049a Benefit-People Insurance is the hottest health insurance in China this year. Mon, 19 Jul 2021 02:38:52 GMT https://www.pharmadj.com/ssr/en/article/e4af3f7be83911ebb98afa163e42049a Minhua Chu Regulatory https://www.pharmadj.com/ssr/en/article/3d8bd75ce83811ebb98afa163e42049a To shake up cancer SOC. Mon, 19 Jul 2021 02:27:02 GMT https://www.pharmadj.com/ssr/en/article/3d8bd75ce83811ebb98afa163e42049a Jialing.Dai Feature https://www.pharmadj.com/ssr/en/article/b4013ea4e83711ebb98afa163e42049a In the case of Verseau, we are a global biotechnology company. It was very important for us to address the two major markets, the U.S. and China, right away. Mon, 19 Jul 2021 02:23:11 GMT https://www.pharmadj.com/ssr/en/article/b4013ea4e83711ebb98afa163e42049a Interview https://www.pharmadj.com/ssr/en/article/b27dfbbae82f11ebb98afa163e42049a T3011 is a single therapeutic agent of three distinct cancer therapies: the targeting of cancer cells by oncolytic viruses, the stimulation of the immune system by IL12 and the production of immunotherapeutic antibodies against PD-1. Mon, 19 Jul 2021 01:25:52 GMT https://www.pharmadj.com/ssr/en/article/b27dfbbae82f11ebb98afa163e42049a Interview https://www.pharmadj.com/ssr/en/article/296b35ade82f11ebb98afa163e42049a “The genetic and racial diversity of our region is very much welcomed nowadays in multinational clinical trials because you have a lot of variety in the population sample,” explained Dr. Cheaib. Mon, 19 Jul 2021 01:08:55 GMT https://www.pharmadj.com/ssr/en/article/296b35ade82f11ebb98afa163e42049a Feature https://www.pharmadj.com/ssr/en/article/6d22406be82c11ebb98afa163e42049a Sanofi is doubling down on its bet in China by forming a new business unit for China and Emerging Markets. Mon, 19 Jul 2021 01:02:28 GMT https://www.pharmadj.com/ssr/en/article/6d22406be82c11ebb98afa163e42049a Jialing.Dai Interview https://www.pharmadj.com/ssr/en/article/7a4da0a2d8cf11ebb98afa163e42049a "The NMPA stands in the international arena with clear goals and intentions and will actively participate in the ICH’s international affairs in the future." Tue, 29 Jun 2021 11:48:39 GMT https://www.pharmadj.com/ssr/en/article/7a4da0a2d8cf11ebb98afa163e42049a PharmaDJ Regulatory https://www.pharmadj.com/ssr/en/article/82f4ba7fceb211ebb98afa163e42049a Improve the system of laws and regulations. Speed up their formulation and revision and advance technical guidelines in an orderly manner. Wed, 16 Jun 2021 14:56:45 GMT https://www.pharmadj.com/ssr/en/article/82f4ba7fceb211ebb98afa163e42049a PharmaDJ Regulatory https://www.pharmadj.com/ssr/en/article/207af618b49711ebb98afa163e42049a On July 1, 2020, the latest Drug Registration Regulations were enacted. This new set of regulations introduced four accelerated procedures for BTDs therapy, conditional approval, priority review and approval, and special approval. Fri, 14 May 2021 09:33:02 GMT https://www.pharmadj.com/ssr/en/article/207af618b49711ebb98afa163e42049a PharmaDJ Regulatory https://www.pharmadj.com/ssr/en/article/b8dbce82915211ebb98afa163e42049a Recently, the National Medical Products Administration issued regulations for post-approval changes in medicinal products (for pilot implementation). Tue, 30 Mar 2021 12:23:50 GMT https://www.pharmadj.com/ssr/en/article/b8dbce82915211ebb98afa163e42049a PharmaDJ Regulatory https://www.pharmadj.com/ssr/en/article/7666dd82446511eb85e2fa163e42049a The Drug R&D and Evaluation Communication Regulation. Tue, 22 Dec 2020 14:53:18 GMT https://www.pharmadj.com/ssr/en/article/7666dd82446511eb85e2fa163e42049a PharmaDJ Regulatory